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Sex steroid production needs to be maintained within the physiological set point range, 
deviations outside of the normal range can be a symptom of- and risk factor for endocrine-
related diseases (such as polycystic ovarian syndrome (PCOS), hypogonadism, breast- and 
prostate cancer). Testosterone is the dominant male sex steroid and estradiol (E2) is the most 
abundant and potent female sex steroid. Testosterone and E2 are mainly synthesised in 
gonads of both sexes. Testosterone and E2 induce a cellular response by diffusing into cells 
and binding to their respective nuclear receptor (androgen- (AR) and estrogen receptor (ER)), 
which upon activation, operate as transcription factors and regulators of gene transcription. 
It is clinically important to have an accurate measure of detection for testosterone and E2. 
The current clinical measures, which are immunoassay-based techniques, are under scrutiny 
due to their poor sensitivity and reproducibility, especially at low concentrations. 
Furthermore, although testosterone and E2 are the most prominent endogenously 
synthesised sex steroids, they are not the only molecules capable of activating their 
intracellular cognate receptor. Other endogenously synthesised androgenic and estrogenic 
precursor molecules to testosterone and E2 can also activate AR and ER, respectively. 
Furthermore, studies have shown that exogenous (anti-) estrogens and androgens sourced 
from synthetic and plant origin have potential to activate or inhibit AR and ERs.  
 
A novel technique to identify all estrogenic and androgenic molecules within a sample is 
reporter gene bioassays (RGBs). RGBs are a cell-based technique that can measure the level 
of ER or AR activation by a test substance. Cells can be transfected with an expression plasmid 
to over express AR or ERa/b and a reporter gene plasmid that harbours the response element 
specific to the receptor, which is upstream of a reporter gene. Alternatively, a cell line with 
endogenous AR or ERa/b is transfected with a reporter gene plasmid only. Upon activation 
of AR or ERa/b, the receptor binds to its response element on the reporter plasmid to initiate 
gene transcription of the reporter gene, which is translated into an enzyme, such as luciferase. 
The reporter gene is measured following addition of a substrate to quantify the level of light 
 vii 
emission, which is proportional to the level of receptor activation. Via this mechanism, all 
molecules that are capable of activating the receptor can be monitored. 
 
The overarching aim of this study was to determine if RGBs can be used to measure clinically 
relevant samples. ER- and AR-RGBs hosted in T47D and HEK293 cells, respectively, were 
optimised to measure serum and plasma samples. The net serum estrogenicity and 
androgenicity measurement was compared with the data of the clinical standard 
immunoassay to determine if additional information could be provided. A major part of this 
PhD was the establishment of a clinical study, whereby serum from post-menopausal females 
was obtained for the purpose of measuring in the ER- and AR-RGBs. All patients recruited to 
the study started letrozole treatment and the aim of this clinical study was to determine if 
changes in ER- and AR bioactivity could be measured after the onset of treatment. Letrozole 
is an aromatase inhibitor that blocks the conversion of androgens into estrogens. Therefore, 
both ER- and AR-RGBs were utilised in a clinical setting to determine their clinical efficacy by 
comparing to the results of testosterone and E2 immunoassay data.  
 
Overall, both ER- and AR-RGBs provided a readout for all serum and plasma samples tested, 
whereas only some samples had a detectable level of testosterone and/or E2 by 
immunoassay. This study shows that information to companion quantitative measures of E2 
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Maintaining physiological concentrations and secretory patterns of sex steroids, namely 
androgens and estrogens, is vital for fertility of both males and females. The homeostasis of 
sex steroid production is necessary for fertility (gamete production and sex organ maturation) 
erythropoiesis, supporting muscle- and bone mass density. Estradiol (E2) and testosterone are 
the two main sex steroids for females and males, respectively, however, both are present and 
functional in both sexes. The synthesis of E2 and testosterone is regulated by homeostatic 
negative feedback loops between the hypothalamus and primarily the gonads but also the 
adrenal glands. In terms of molecular structure, both E2 and testosterone are steroidal, 
lipophilic molecules that have 4 carbon rings (A-D) with differing side chain groups (Figure 
1.1). Testosterone has a double bond oxygen (=O) on carbon 3 (C3) while E2 has a hydroxyl 
group (-OH) instead. C10 of the testosterone molecule has a methyl (-CH3) group, which E2 
does not. The steroidal nature of sex steroids allows for the simple diffusion across the 
phospholipid bilayer membrane of all cells in the body, where they bind and activate their 
cognate receptor. Within a target cell, estrogens and androgens will bind nuclear receptors, 
which upon activation, function as transcription factors to regulate expression of estrogenic 
and androgenic genes, respectively. Androgens specifically bind and activate the androgen 
receptor (AR) and estrogens bind and activate both estrogen receptor a (ERa) and estrogen 
receptor b (ERb) isoforms.  
 
It is vital to ensure that E2 and testosterone concentrations are maintained within a set point 
range to prevent risk of disease. A normal E2 concentration for premenopausal females 
fluctuates between 110 -1500 pM (30 - 400 pg/mL) and drops to less than 11 pM (0 - 3 pg/mL) 
at menopause, which is close to the normal level in adult eugonadal males where levels will 
generally not exceed 180 pM (50 pg/mL). The normal range of testosterone in eugonadal adult 
males is between 8 - 33 nM (2 – 10 ng/mL) and up to 2 nM (0.6 ng/mL) in adult females. 
Importantly, testosterone can be converted into E2 by the enzyme P450 aromatase. Changes 
in the set point range concentrations of E2 or testosterone could be a symptom, or risk factor, 
for disease or endocrinological disorder. Therefore, the ability to accurately measure 
testosterone and E2 levels is clinically important.  
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This literature review will discuss homeostatic mechanisms that ensure the correct 
physiological secretion profiles of sex steroids, their cell signalling mechanisms and the 
importance of accurately measuring sex steroids in a clinical setting. This review also aims to 
highlight the dynamic nature of sex steroid production in health and disease, underpinning 
why accurate measures need to be implemented to provide an adequate scope of the 
endocrine profile of a patient. Current measures in clinical and research laboratories show 
that there is still need for improvement in measuring sex steroids to better understand the 
endocrine status of a patient. 
 
AR- and ER-reporter gene bioassays (RGBs) are cell-based tools that provide a read out for the 
level of receptor activity in response to a test substance, such as serum, to allow for the net 
androgenicity or estrogenicity to be determined. This enables all molecules that are estrogenic 
or androgenic to be encapsulated and measured as part of the assay rather than only 
testosterone or E2. In this study, the main focus is to elucidate whether AR- and ER-RGBs can 
provide clinically relevant information and to determine if they can companion current clinical 
measures that directly detect E2 or testosterone, specifically. 
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A. Carbon numbering of steroid molecule 
 




Figure 1.1: Molecular structure of testosterone and E2. 
 
A. The standard labelling of the carbon groups of a steroid molecule (C1-17) and the four 
carbon rings (A-D). B. The molecular structure and functional groups of E2; aromatic ring A, 
hydroxyl (-OH) on C3 (ring A) and C17 (ring D) and a methyl group (CH3) on C13 (between 
rings C and D). C. The molecular structure and functional groups of testosterone; double 
bond oxygen (=O) on C3 (ring A), two CH3 groups on C10 (between rings A and B) and C13 




1.2 The endogenous regulation of steroidogenesis 
 
There is a homeostatic feedback loop between the brain and peripheral organs to regulate 
steroid hormone production. The hypothalamus and the anterior pituitary gland are primary 
control centres for adjusting the level of endogenous steroid hormone production from the 
gonads and adrenal glands of both sexes via the hypothalamic-pituitary-gonadal (HPG) and 
hypothalamic-pituitary-adrenal (HPA) axis, respectively. The dominant male androgen, 
testosterone, is synthesized from within the testes. Whereas the ovaries synthesise the 
dominant female sex hormones, E2 and progesterone. Both sexes synthesize androgens 
(dehydroepiandrosterone (DHEA), androstenedione and testosterone) from the zona 
reticularis of the adrenal gland. The correct regulation of the HPG and HPA axes is important 
for maintaining a physiological set point range of the concentration of steroid hormones. 
Correct functioning of the HPG and HPA axes is vital for preventing endocrine-related 
disorders or increasing the risk of some cancers, such as breast (Rosenberg et al., 1994; Cauley 
et al., 1999) and prostate cancer (Gann et al., 1996; Parsons et al., 2005). Overall, the 
concentration of sex steroids in the blood is tightly controlled by the hypothalamus and 
pituitary gland to maintain the concentration of sex steroids within the physiological set point 
range and thus prevent endocrine-related diseases. 
 
1.2.1 Hypothalamic pituitary gonadal (HPG) axis 
 
The HPG axis stimulates testosterone production from the testes of males and E2 production 
from the developing ovarian follicle in females. In both sexes, the HPG axis originates at the 
base of the brain in the hypothalamus where gonadotropin-releasing hormone (GnRH) 
neurons are located. GnRH neurons project to the anterior pituitary gland to stimulate the 
release of gonadotropins (peptide hormones), luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) (Schally et al., 1971). Kisspeptin neurons are an important 
population of neurons, which are involved in regulating the HPG axis (Roseweir & Millar, 
2009). Kisspeptin neurons are located upstream of GnRH neurons in the arcuate and 
anteroventral periventricular nuclei (Smith et al., 2005). The fibers of kisspeptin neurons 
project to and release the kisspeptin neurotransmitter onto GnRH neurons. Kisspeptin 
potently stimulate GnRH neurons by binding to GPR54 (Lee et al., 1999; Kotani et al., 2001). 
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The kisspeptin neurotransmitter is derived from the Kiss1 gene (Lee et al., 1996) and its gene 
expression is responsive to sex hormones (Smith et al., 2005). The Kisspeptin neuron 
populations play a critical role in mediating the response of estrogens and is therefore 
important in the regulation of the HPG axis. 
 
In males, the steady, pulsatile secretion profile of LH and FSH (Veldhuis et al., 1987) stimulates 
intratesticular testosterone synthesis in Leydig cells (Dufau, 1988) and spermatogenesis from 
Sertoli cells (Van Alphen et al., 1988), respectively. To induce a cellular response, LH and FSH 
bind and activate cell surface G-protein coupled receptors (GPCRs) that stimulate cyclic 
adenosine monophosphate (cAMP) cell signalling to induce steroidogenesis and 
spermatogenesis (Kuehl et al., 1970; Stocco & Chaudhary, 1990), respectively (for a 
comprehensive review on the LH receptor see Dufau (1998) and for the FSH receptor see 
Simoni et al. (1997)). Testosterone synthesized by the Leydig cells supports Sertoli cell 
function by nourishing developing spermatozoa (reviewed by Walker and Cheng (2005)). 
Testosterone is released into the periphery and together with its aromatized by product, E2, 
switches off GnRH secretion from GnRH neurons in the hypothalamus and gonadotropin 
releasing cells in the anterior pituitary gland (Bagatell et al., 1994) (reviewed by Griswold 
(1998)) (Figure 1.2).  
 
The functioning of the HPG axis in females differs to males since E2 and progesterone are the 
main regulatory hormones and the secretory profile of the gonadotropins fluctuates in an 
ordered manner over a 28-day cycle (the information throughout this section to revise the 
menstrual cycle was sourced from the following review articles by Sherman and Korenman 
(1975); Knobil (1980); (Hawkins & Matzuk, 2008)).The 28-day menstrual cycle promotes the 
release of an oocyte from the ovary and subsequent shedding of the uterine wall to dispel the 
unfertilised oocyte. The first 14 days of the cycle is called the follicular phase and the later 14 
days is referred to as the luteal phase. On day 1 of the follicular phase, the uterine wall begins 
to shed and the follicle within the ovary starts to mature. The follicle consists of granulosa and 
theca cells which encapsulate the oocyte. Follicle maturation occurs as E2 and FSH stimulate 
the proliferation of granulosa and theca cells (Goldenberg et al., 1972). Theca cells synthesize 
androstenedione (a weak androgen) in response to LH stimulation, of which diffuses into 
neighbouring granulosa cells to produce E2 when stimulated by FSH (Dorrington et al., 1975). 
During the follicular phase, E2 negatively feeds back upon the hypothalamus and anterior 
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pituitary gland to downregulate the synthesis of LH and FSH. At approximately day 14, E2 
levels peak and E2 switches to positive feedback. The positive feedback of E2 is mediated by 
kisspeptin neurons located in the AVPV of the brain and stimulates GnRH and LH secretion. 
The LH surge drives ovulation, which stimulates release of the mature oocyte from the follicle 
within the ovary into the uterine tube of the uterus. During the luteal phase, E2 levels drop 
and E2 reverts to negative feedback to signal to arcuate nucleus kisspeptin neurons to inhibit 
GnRH neurons and subsequent LH and FSH secretion. The hormonal withdrawal initiates 
degeneration of the follicle in the ovary, of which forms the corpus luteum. The corpus luteum 
synthesises progesterone, which stimulates the proliferation of the endometrial lining of the 
uterus. Around day 28 of the menstrual cycle, the corpus luteum forms into corpus albicans 
and no longer produces progesterone. The drop in progesterone production stimulates the 
shedding of the endometrium and the onset of menses on day 1 again. The secretory profiles 
of the two gonadotropins and their target cells are vastly different between the sexes, 
however, regulation of sex steroid synthesis by the HPG axis is vital for fertility (Figure 1.2). 
 
The HPG axis can be manipulated or altered either as the result of disease or due to 
administration of sex steroids. The cases that are explained in this section apply to 
menopause, PCOS, testosterone replacement therapy in males and contraception for females.  
 
The onset of menopause generally occurs between the ages of 45-55 in females as a result of 
ovarian failure due to the depletion of viable oocytes. Menopause is a natural onset of 
infertility and is a result of the breakdown in the feedback mechanisms between the anterior 
pituitary gland and the ovaries. Due to the lack of maturing follicles, the ovaries stop 
synthesizing E2 and the lack of negative feedback on the hypothalamus and anterior pituitary 
gland causes an increase in FSH secretion (Burger et al., 1999). During peri-menopause (the 
years leading up to menopause), the menstrual cycle becomes shorter due to a shorter 
follicular phase or longer due to anovulatory vaginal bleeding (Sherman & Korenman, 1975). 
Elevated FSH maintains E2 levels within a normal range until the follicle supply is depleted at 
the onset of menopause. At the time of menopause, E2 and E1 concentrations drop while FSH 
levels remain elevated (Longcope et al., 1986; Rannevik et al., 1986). The concentration of 
estrone (E1), a weak estrogen, is not reduced as significantly as E2 during menopause since 
the majority of E1 synthesis predominantly occurs peripherally. Furthermore, in a study by 
Kim et al. (2017), it was shown that E1 is present in concentrations approximately 5-fold higher 
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than E2 following menopause and is therefore likely to take on more clinical importance in 
post-menopausal females. The role of E1 in the postmenopausal female is unclear but it has 
been postulated that it is important for maintaining bone mass density, which can decline in 
the years following menopause due to the associated drop in E2 (Suzuki et al., 1995).   
 
Menopause also affects the ovarian synthesis of androgens (Vermeulen, 1976). The changes 
in androgen concentration are less well defined than E2, E1 and FSH, but studies have shown 
steep decreases in testosterone and androstenedione concentration (Vermeulen, 1976; 
Rannevik et al., 1986), while other studies have shown no change (Longcope et al., 1986). It 
has been postulated that the adrenal glands slowly decline in androstenedione synthesis from 
21-51 years of age (Zumoff et al., 1995) and may contribute more significantly to the drop in 
androgens observed around the same time as menopause onset (Silberberg & Silberberg, 
1956; Rannevik et al., 1986). However, in a study conducted by Vermeulen (1976), it was 
shown that ovariectomised pre-menopausal females had no difference in E2 concentration 
but lower concentrations of androgens than postmenopausal females, which suggests the 
post-menopausal ovary is capable of synthesising androgens but not E2. In support of this, a 
study by Fogle et al. (2007) demonstrated that both testosterone and E2 are synthesized from 
the post-menopausal ovary, as detected in blood samples taken directly from the ovarian vein 
of post-menopausal females undergoing hysterectomy and bilateral oophorectomy. The post-
menopausal ovary has been shown to contribute to approximately 50% and 30% total 
testosterone and androstenedione, of which, can be converted into E2 and E1, respectively, 
by the enzyme P450-aromatase (Vermeulen, 1976). 
 
PCOS illustrates how a break down in normal HPG functioning can lead to fertility issues. PCOS 
is the most common cause of female infertility (Hull et al., 1985) and is clinically characterized 
by the presence of oligo-/anovulation and hyperandrogenism, which symptomatically 
manifests as oligo-/amenorrhea. Although the exact mechanism is still yet to be fully 
understood, women present with elevated LH (Venturoli et al., 1988) and increased levels of 
ovarian-derived testosterone and E2 (Rosenfield et al., 1972; Levrant et al., 1997). It is 
speculated that GnRH neurons are overstimulated by the hyper-production of androgens, 
which causes an increased production of gonadotropins. High levels of LH drive hyperplasia of 
the theca cells within the developing follicle in the ovary, which stimulates the overproduction 
of androstenedione, a precursor to testosterone (Levrant et al., 1997). This cycle prevents the 
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normal LH surge from occurring around day 14 of the menstrual cycle, thereby arresting 
ovulation. For a review on PCOS see Rosenfield and Ehrmann (2016). 
Testosterone replacement therapy for hypogonadal males or the doping with an androgenic 
steroid in healthy athletes will cause endogenous testosterone synthesis to cease. Exogenous 
testosterone will inhibit LH and FSH secretion from the anterior pituitary gland, which, in turn, 
causes intratesticular testosterone synthesis and spermatogenesis to cease, which can lead to 
infertility (Fujioka et al., 1987; Crosnoe et al., 2013). 
 
As a means of contraception for females, ovulation can be suppressed through the 
administration of synthetic E2 in the contraceptive pill. The oral contraceptive pill is the most 
common form of contraception prescribed to females in New Zealand (Chesang et al., 2016). 
The contraceptive pill is either a combined E2-progesterone mixture (combined pill) or 
progesterone only (P-only). The P-only pill does not arrest ovulation completely (Rudel et al., 
1965) but high doses effectively suppresses ovulation (Diczfalusy et al., 1969). In addition to 
oligo-/anovulation, the P-only and combined pills increases the viscosity of the cervical mucus 
(Elstein et al., 1976), which is a non-viable environment for sperm. Furthermore, the 
endometrial lining of the uterus becomes thinner (Grow & Iromloo, 2006) and therefore does 
not support viable implantation of the blastocyst (8-9 days post-fertilization) (Elstein et al., 
1976).These extra-ovarian effects contribute to the contraceptive action of the P-only pill. The 
combined pill suppresses the HPG axis more effectively than the P-only pill since the LH surge 
can still occur in some women taking P-only pill (reviewed by Rivera et al. (1999)). The 
mechanism of HPG axis suppression is due to negative feedback upon the GnRH neurons and 
gonadotropin releasing cells in the hypothalamus and anterior pituitary gland, respectively 
(De Leo et al., 1991). As a result, the concentration of LH, FSH and testosterone are suppressed 
(Moutos et al., 1995), thereby preventing the mid-cycle LH surge and subsequent ovulation. 
Female fertility can be synthetically modulated by interrupting HPG axis functioning through 
administration of exogenous E2 and/or progesterone. In addition to the oral contraceptive 
pill, there is a wide range of progesterone-based contraception options available to females. 
All of which operate by suppressing the HPG axis and limiting ovulation in a similar mechanism 
to the P-only pill. Such contraceptives can be administered in the format of a subdermal 
implant in the arm (Shoupe & Mishell, 1989), intrauterine device (Luukkainen et al., 1990), 
vaginal ring (Mulders & Dieben, 2001), an injection (Westhoff, 2003) or a skin patch. For a 
comprehensive review on female hormonal contraception, see Rivera et al. (1999). 
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1.2.2 Hypothalamic pituitary adrenal (HPA) axis 
 
The hypothalamic-pituitary-adrenal (HPA) axis regulates the synthesis of mineralocorticoids, 
glucocorticoids and androgenic steroid hormones from the adrenal gland to coordinate the 
water-salt balance, the physiological stress response and to provide an extra-gonadal source 
of sex steroids. The anatomical structures that comprise the HPA axis are analogous to the 
HPG axis, except the adrenal gland is the target organ. Parvocellular neurons situated in the 
paraventricular nucleus of the hypothalamus project to the anterior pituitary gland and 
release corticotropin releasing hormone (CRH), which stimulates adrenocorticotropic 
hormone (ACTH) release from corticotropic cells (reviewed by Tsigos and Chrousos (2002)). 
ACTH stimulates the adrenal gland to release aldosterone (a mineralocorticoid), cortisol (a 
glucocorticoid), DHEA (a weak androgen) and epinepherine (a catecholamine) from the zona 
glomerulus, zona fasciculata, zona reticularis of the adrenal cortex and the adrenal medulla of 
the adrenal gland, respectively. All adrenal steroids negatively feedback to the hypothalamus 
and anterior pituitary to regulate their secretion. Adrenal androgens are the primary source 
of androgens for post-menopausal females (Vermeulen, 1976). The pool of adrenal androgens 
provides a source for extra-ovarian synthesis of E1 and E2 (Grodin et al., 1973), whereby the 
adrenal androgens can be converted into E1 and E2 by the P450 aromatase enzyme in the 






 Figure 1.2: Hypothalamic-pituitary-
gonadal (HPG) axis. 
 
GnRH neurons in the hypothalamus project to 
the anterior pituitary gland and release GnRH 
to stimulate the secretion of gonadotropins, LH 
and FSH (Schally et al., 1971). LH and FSH travel 
throughout the circulatory system and 
stimulate steroidogenesis from the ovaries in 
females and testicles in males (Dufau, 1988). In 
females, gonadotropins stimulate E2 synthesis 
in the granulosa cells of the ovaries (Dorrington 
et al., 1975). E2 mostly inhibits gonadotropin 
and GnRH release at the level of the anterior 
pituitary gland and hypothalamus, 
respectively. At approximately day 14 of the 
menstrual cycle, E2 stimulates GnRH and 
gonadotropin release from the hypothalamus 
and anterior pituitary gland, respectively, to 
initiate a surge in LH secretion. The LH surge is 
necessary to stimulate ovulation (Hawkins & 
Matzuk, 2008). In males, gonadotropins 
stimulate testosterone (T) synthesis in Leydig 
cells of the testicles. T inhibits GnRH and 
gonadotropin secretion at the level of 
hypothalamus and anterior pituitary gland, 
respectively. The feedback mechanisms of E2 
and T regulate steroidogenesis at the gonads to 








1.2.3 Metabolic pathways for testosterone and E2 synthesis 
 
There are a multitude of different steroid hormones endogenously synthesized at the gonads 
and adrenal glands, including glucocorticoids, mineralocorticoids, progestogens, androgens 
and estrogens. Of these main 5 divisions of steroid hormones, each have weak precursor 
molecules and more potent metabolites, determined by their binding affinity and activation 
of, the glucocorticoid receptor (GR), mineralocorticoid receptor (MR), progesterone receptor 
(PR), AR or ERa/b, respectively. All steroid hormones are derived from cholesterol and the 
biosynthesis of steroid hormones is enzymatically regulated. 
 
The biosynthesis of sex steroids is initiated by peptide hormone stimulation downstream of 
the HPA and/or HPG axis. The first steps of steroidogenesis occurs in the mitochondria and 
the process is completed in the smooth endoplasmic reticulum. The two common and 
previously introduced peptide hormones that stimulate sex steroid synthesis in the HPG and 
HPA axis, respectively are LH/FSH and ACTH. LH/FSH and ACTH released from the anterior 
pituitary gland activate GPCRs, which comprise a 7-transmembrane domain with a and bg 
intracellular subunits that act as second messengers within the cell. Upon activation, the Ga 
subunit stimulates adenylate cyclase, which subsequently activates cAMP. cAMP activates 
steroidogenic acute regulatory protein (StAR), which facilitates the flux of cholesterol into the 
mitochondria to initiate steroidogenesis. At the inner mitochondrial membrane, cholesterol is 
cleaved by cholesterol side-chain cleavage enzyme (P450scc) to form pregnenolone. 
Pregnenolone is the universal precursor steroid hormone to all steroids and diffuses into the 
smooth endoplasmic reticulum for the final stages of steroid hormone metabolism. 
Pregnenolone can undergo two different reactions to either form progesterone or 17a-
hydroxypregnenolone. Progesterone can be further metabolised to aldosterone (a 
mineralocorticoid), whereas 17a-hydroxypregnenolone can be metabolised into cortisol (a 
glucocorticoid) or DHEA (a weak androgen), the latter is a precursor for testosterone. 
 
The pathways involved in testosterone and E2 biosynthesis will be discussed in more detail 
since they are relevant to this review (Figure 1.3, page 14). To synthesize androgens, 
pregnenolone undergoes hydroxylation (addition of -OH group) of C17 by 17a-hydroxylase to 
form 17a-hydroxypregnenolone, which then undergoes cleavage of the C17-C20 bond by the 
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enzyme 17,20 lyase to form DHEA (a weak androgen). DHEA is converted by 3b-hydroxysteroid 
dehydrogenase (3b-HSD) into androstenedione by oxidation of the hydroxyl (-OH) group on 
C3 (-OH à =O). Alternatively, the -OH group on C17 of DHEA can undergo a reduction reaction 
(=O à -OH) by 17b-hydroxysteroid dehydrogenase (17b-HSD) to form androstenediol. Both 
androstenedione and androstenediol can be converted into testosterone by 17b-HSD and 3b-
HSD, respectively. Testosterone is formed by oxidation of the -OH group on C3 of 
androstenediol by 3b-HSD or through the reduction of the =O group on C17 of 
androstenedione by 17b-HSD. Testosterone can be further metabolised into the most potent 
endogenous androgen, dihydrotestosterone (DHT) by the enzyme 5a-reductase, which 
removes the double bond carbon (C=C) between C4 and C5 of testosterone. Testosterone and 
androstendione can also be aromatised into E2 (a potent estrogen) and E1 (a weak estrogen), 
respectively, by the enzyme P450-aromatase (reviewed by Hanukoglu (1992)) (Figure 1.3, 
page 14). Importantly, the different metabolites and intermediates of testosterone and E2 can 
still bind AR and ERa/b, thus they are considered hormonally active (Sasson & Notides, 1983; 
Chen et al., 2005). However, most clinical measurements focus only on testosterone or E2 




Figure 1.3: Metabolic 
pathways involved in 
testosterone and E2 
synthesis 
 
Only the metabolic pathways 
involved in androgen and estrogen 
synthesis are depicted in the 
above figure, therefore, not all 
steroid hormone metabolic 
pathways are shown. 
Pregnenolone is the universal 
precursor to all steroid hormones, 
which is converted into a 
progestin, 17a-pregnenolone. 
17a-pregnenolone is the 
precursor molecule for all 
androgens shown in the blue box 
(DHEA, androstenediol, 
androstendione, testosterone and 
DHT). Testosterone and 
androstenedione are converted 
into estrogens, E2 and E1, 
respectively (pink box) by the 
enzyme aromatase. The 
aromatisation of testosterone and 
androstenedione into E2 and E1 is 
an important reaction to this 




1.3 AR molecular structure and cell signaling 
pathways  
 
Androgenic steroids, such as testosterone, stimulate their cellular effects through binding to 
AR. AR is expressed in many reproductive tissues in males (testis, epididymis, vas deferens, 
seminal vesicles, penis) and females (mammary glands, vagina and cervix) (Misso et al., 2005). 
AR is also expressed in extra-reproductive tissues such as skeletal muscle and bone (Wiren et 
al., 1997; Sinha-Hikim et al., 2004). AR binds androgenic ligands and coordinates a cellular 
response by activating gene transcription of genes regulated by androgen response elements 
(AREs). The AR protein has different domains, which allow for ligand-induced gene 
transcription. AR is broadly classified as a type of nuclear receptor due to its role in regulating 
gene transcription in the nucleus (Davey & Grossmann, 2016). 
 
1.3.1 AR molecular structure 
 
The human AR is structurally classified into 5 domains (A/B, C, D and E) and consists of 917 
amino acids and a molecular weight of 98 kDa (Brinkmann et al., 1989). The DNA binding 
domain (DBD) and ligand binding domains (LBD) are located in domain C and E, respectively. 
The LBD binds the androgenic ligand to induce a cascade of events that lead to receptor 
activation and subsequent gene transcription (Davey & Grossmann, 2016).Gene transcription 
occurs as a result of the DBD binding the DNA at AREs. The mechanism of AR cell signalling is 
discussed in further detail in section 1.3.3.1. 
 
The majority of phosphorylation sites of AR are located at activation function-1 (AF-1) (N-
terminal). Several phosphorylation residues of AR have been identified in Cos9 and LNCaP cells 
(Serine (Ser)-16, -81, -94, -256, -308 and - 424) in response to androgen treatment, with Ser-
94 being constitutively phosphorylated (Gioeli et al., 2002) (Figure 1.4). Phosphorylation of AR 
promotes stabilisation, expression levels within a cell (Chen et al., 2006c) and assists in gene 
transcription by mediating AR-DNA binding (Gordon et al., 2010; Chen et al., 2012).  
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Following ligand binding to the LBD, AF-1 (N-terminal) and activation function-2 (AF-2) (C-
terminal) need to be in physical contact for full AR activation. The hinge domain of AR (domain 
D) enables this interaction between N- and C-terminals. This inter-domain communication of 
AR is also mediated by cofactor proteins (discussed in further detail in section 1.3.2), which 
bind to FxxLF (F = phenylalanine, L = leucine and x = any amino acid) motifs in AF-2 (Ikonen et 
al., 1997; He et al., 2000; He et al., 2002a). Domain C is also involved in translocation of the 
activated AR into the nucleus from the cytosol and transcriptional regulation. The importance 
of domain D in the transcriptional control of the receptor was shown when residues 629-636 
located within the hinge were deleted resulting in upregulation of AR-dependent transcription 
(Haelens et al., 2007).  
 
Human ER has a low level of amino acid homology with DBD and LBD of AR with 59% and 23% 
homology, respectively (Brinkmann et al., 1989) (reviewed by Gao et al. (2005)). The low 
homology limits ligand- and DNA binding cross over between ER and AR. Interestingly, it has 
been shown that AR and ERa can dimerise with each other and form a functional 
heterodimeric complex, albeit suppressing the transcriptional efficacy relative to their 





Figure 1.4: Primary structure of the androgen receptor 
 
Domain A/B of AR is heavily phosphorylated and located at the N-terminal, within this domain is AF-1. Serine (S) residues; -16, -81, -94, -256, 
-308 and -424 are located in the A/B domain and can be phosphorylated. The C-domain is the DNA binding domain of AR. Domain D is the 
hinge of the receptor and serine-650 is a phosphorylation site. Domain E is located at the C-terminus and is where the LBD and AF-2 is located. 
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1.3.2 Cofactor proteins and the androgen receptor 
 
An important step in AR cell signalling is the binding of coregulatory proteins to AR, which 
modulate transcriptional activity. Coregulatory proteins, otherwise referred to as cofactors, 
enhance or suppress the transcriptional activity of nuclear receptors when an agonist and 
antagonist is bound, respectively.  
 
At the C-terminal end of AR, AF-2 is located and this portion of the receptor contains the 
cofactor binding consensus sites (He et al., 2002b). Upon ligand binding, AF-2 of AR 
preferentially binds cofactors with FxxLF and LxxLL motifs. Cofactors assist in the 
rearrangement of the AR protein to bind back on itself allowing for an interaction between 
the N- and C-termini. Although AR binds both FxxLF and LxxLL cofactors, there is a stronger, 
preferential binding affinity for FxxLF cofactor proteins (Ikonen et al., 1997; He et al., 2000; 
He et al., 2002a). Examples of LxxLL coactivator proteins include steroid receptor coactivator-
1 (SRC-1) and CREB-binding protein (CBP), which function to deacetylate DNA and recruit RNA 
polymerase II (Shang et al., 2002; Louie et al., 2003), thereby supporting gene transcription. 
Although ERa requires SRC-1 and CBP cofactor protein binding to realise full receptor activity, 
AR does not require the recruitment of SRC-1 and CBP proteins for full activation (Aarnisalo et 
al., 1998; Bevan et al., 1999). 
 
Cofactor proteins are also involved in mediating the potency of a ligands binding affinity for 
AR. For example, both testosterone and DHT bind AR at the LBD with the same molecular 
interactions. However, DHT has a stronger binding affinity for AR than testosterone (Tóth & 
Zakár, 1982), which makes it a  more potent activator of AR. A point of differentiation between 
the DHT- and testosterone-bound AR is the stronger binding affinity of a cofactor protein 
(melanoma antigen gene protein-11 (MAGE-11)) at AF-2 when DHT is bound. The higher 
binding affinity of MAGE-11 to AF-2 when DHT is bound is capable of mediating a stronger 
activation of AR (Askew et al., 2007). Therefore, cofactor proteins can aid in the level of AR 
activation in a ligand-dependent manner. 
 
When an antagonist is bound, the conformation recruits corepressor proteins (Nuclear 
receptor corepressor/silencing mediator retinoic - NCoR/SMRT), which prevents coactivators 
from binding to AR (Shang et al., 2002; Yoon & Wong, 2006) and therefore inhibits AR 
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mediated gene transcription. There are over 50 cofactor proteins that associate with AR. 
Overall, cofactor proteins modulate the agonist and antagonist response assist with the 





1.3.3 AR cell signaling pathways 
 
1.3.3.1 Classical AR cell signaling 
 
The circulating concentration of free testosterone is low. Indeed, ~2% of testosterone is 
considered to be free and unbound from steroid binding proteins in the serum (Pugeat et al., 
1981; Södergard et al., 1982). Testosterone binds to serum proteins (steroid hormone binding 
globulin – SHBG, albumin and corticosteroid binding globulin – CBG), which allows the 
hydrophobic molecule to be transported through the hydrophilic blood. Steroid binding 
proteins also controls the bioavailability, mediates the concentration and importantly 
increases the stability and half-life of testosterone in the blood (Dunn et al., 1981; Laurent et 
al., 2016). Approximately 45%, 50% and 4% of testosterone binds to SHBG, albumin and CBG, 
respectively (Dunn et al., 1981). The concentration of SHBG (~30 nM) is lower than albumin 
(~500 µM), however, SHBG binds testosterone with higher affinity compared with albumin 
(10-9 M versus 10-6 M) (Sedelaar & Isaacs, 2009). Due to the strong binding interactions of 
testosterone to SHBG, SHBG has a lower capacity relative to albumin. Furthermore, due to the 
lower binding affinity of testosterone to albumin, it is considered that the portion of albumin 
bound-testosterone contributes to the bioavailable pool of testosterone (Manni et al., 1985; 
Wheeler, 1995).  
 
To initiate a cellular response, the bioavailable testosterone must first diffuse into cells 
(dissociates from albumin) and bind to AR. AR regulates the transcription of DNA in the 
nucleus to induce androgenic cellular effects (reviewed by Ribeiro et al. (1995)) The cytosolic-
located ARs are in close association with heat shock proteins (HSP-56, -70 and -90) 
(Veldscholte et al., 1992) to ensure the hormone-binding region of the receptor is in an 
optimal conformation and to facilitate ligand binding (Zoubeidi et al., 2007). Once an 
androgen binds to AR, HSPs dissociate from AR to allow for homodimerization with another 
androgen-bound-AR complex (Wong et al., 1993). FxxLF motifs mediate intermolecular 
binding between the N- and C-termini of ARs to form anti-parallel dimers (Schaufele et al., 
2005). Following dimerization, the dimeric receptor translocates into the nucleus where it 
binds to AREs in the DNA. Once bound to the ARE, coactivator proteins, such as SRC-1/CBP, 
are recruited to assist AR transcriptional function (Chang & McDonnell, 2005). RNA 
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polymerase II is recruited to the enhancer region to initiate gene transcription (Louie et al., 
2003). Following gene transcription, translation of the mRNA product and protein synthesis 
occurs to exert an androgenic effect upon the cell (Figure 1.5). The mechanism of this classical 
AR cell signalling pathway is exploited in the AR-RGB technique, which is a focal technique of 
this study and will be discussed in further detail in section 1.7 of this literature review. 
 
 
Figure 1.5: Classical cell signalling of ARs 
 
(1) The bioavailable fraction of testosterone diffuses into the cell across the cell membrane, 
binds to AR to induce dissociation of the AR from HSPs (Veldscholte et al., 1992). (2) The 
activated ARs dimerise (Wong et al., 1993) and (3) recruit kinases to phosphorylate AR to 
assist receptor activity (Gordon et al., 2010; Chen et al., 2012). (4) The dimeric ARs 
translocate to the nucleus and bind to AREs upstream of the target gene (5) and cofactor 
proteins are recruited to AR to assist with gene transcription (Chang & McDonnell, 2005). 






1.3.3.2 Non-classical activation of AR 
 
AREs in the DNA can also be activated by ARs in an androgen-independent manner. Since 
prostate cancer cell proliferation relies on AR activation, many studies utilise prostate cancer 
cells (i.e. LNCaP cells) to understand AR cell signalling pathways. Non-classical pathways that 
induce autonomous activity of AR is a mechanism by which cancer cells continue to proliferate 
in the absence of an androgen. AR mediated gene transcription can be induced independent 
of an androgen by phosphorylation of the receptor, which is mediated by kinases downstream 
of growth factor receptors (Culig et al., 1994; Guo et al., 2006; Léotoing et al., 2007). Under 
androgen-free conditions, it has been shown that treatment of prostate cancer cell lines 
(LNCaP and DU-145) with epidermal growth factor (EGF), insulin-like growth factor I (IGF-1) 
and keratinocyte growth factor are capable of activating AR-mediated gene transcription in 
an AR-RGB (Culig et al., 1994). This AR-mediated gene transcription was inhibited through the 
treatment with anti-androgen treatment (bicalutamide), which shows that growth factors are 
capable of activating AR (Culig et al., 1994). Protein kinase A (PKA) has also been shown to 
activate AR-mediated gene transcription under androgen-free conditions (Sarwar et al., 2014). 
EGF works through its receptor (EGF-Rs) and other studies show an inverse relationship 
between AR and EGF-R where EGF-R activation inhibits AR activity. In mouse vas deferens 
epithelial cells that endogenously express AR, EGF co-treated with DHT downregulated AR 
expression and this effect was reversed in the presence of an anti-androgen (bicalutamide) 
(Léotoing et al., 2007). 
 
The above studies show signalling kinases, such as PKA,  can activate AR transcription 
mechanism. One way that AR could be activated by kinases is via phosphorylation. For 
example, src kinase has been shown to phosphorylate AR (Tyrosine-534) in prostate cancer 
cell lines (Guo et al., 2006). 
 
Another mechanism of alternate AR gene activation is through cell-surface mediated signalling 
by testosterone-bound SHBG. Testosterone-bound SHBG was shown to bind a cell-surface 
receptor that resulted in an increase in cAMP production and augmented prostate-specific 
antigen (PSA) secretion from human prostate explants (Rosner et al., 1999). The activation of 
the second messenger, cAMP, suggests the cell surface receptor activated is a GPCR (Sassone-
Corsi, 2012) and cAMP activates downstream kinase, PKA. 
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Furthermore, another mechanism of androgen-independent activation of AR is via 
proinflammatory cytokine (IL-6) cell signalling. Cell signalling downstream of the IL-6 receptor  
has been shown to activate mitogen activated protein kinase (MAPK), which most likely 
increases AR phosphorylation, thereby driving transcription of ARE genes in LNCaP cells. It was 
shown that ARE-mediated PSA gene transcription was activated by IL-6 and blocked by anti-




1.4 ERa and ERb structure and cell signaling pathways 
 
E2 stimulates its cellular effects through binding to both isoforms of its cognate receptors, 
ERa and -b. Upon ERa/b activation by binding an estrogenic molecule, ERs, like AR, function 
as transcription factors, which bind to estrogen response elements (ERE), to regulate the 
transcription of specific genes related to the estrogen response of the cell. The two isoforms, 
ERa and ERβ, possess different molecular structures, which translates into different cellular 
functions. ERa and ERβ are differentially expressed in tissues throughout the tissues in males 
and females and impart their most important role in reproductive tissues. For example, ERa 
is predominately expressed in the epididymis, prostate, testis (Dupont et al., 2000), pituitary 
gland, ovary, uterus, bladder and lung (Kuiper et al., 1997). ERβ expression shows some 
similarities, expressed in fallopian tubes, uterus, lung, kidney, brain, heart, prostate, thymus, 
testis, ovary and spleen (Mosselman et al., 1996). Single- and double knock out mouse models 
of ERa and/or ERβ have shown the effect on the reproductive anatomy and physiology in both 
males and females, whereby it was shown that both ERa and ERβ are necessary for female 
fertility whereas only ERa is necessary for male fertility (Dupont et al., 2000). 
 
1.4.1 ERa and ERb molecular structure 
 
The primary structures of ERa and ERb are characterised by A/B, C, D, E and F domains and 
within each domain, ERa and -b share differences and similarities in structure. The A/B 
domain is located at the N-terminus and is the least conserved domain (30% homology) 
between the two ER isoforms (Mosselman et al., 1996). The A/B domain contains AF-1 (Tora 
et al., 1989), which is involved in cofactor binding and ER gene activation at EREs (Cowley & 
Parker, 1999). AF-1 contains MAPK-targeted phosphorylation sites (Kato et al., 1995a). 
Domain C is highly conserved between ERa and ERβ (96% homology) (Mosselman et al., 1996) 
and contains the DNA binding domain (DBD), which binds to EREs within the DNA (Kumar et 
al., 1987). Conversely, the D-domain is poorly conserved between the ER subtypes and 
structurally forms a hinge to allow AF-1 (N-terminal) and AF-2 (C-terminal) to interact, 
necessary for full activation of the receptor upon ligand binding (Métivier et al., 2001). The E-
domain located in the C-terminus shows 58% homology (Mosselman et al., 1996) between 
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both ERa and ERβ and contains AF-2. The E-domain is involved in receptor dimerisation and 
ligand binding (Webster et al., 1988; Tora et al., 1989). AF-2, like AF-1, binds cofactors, 
necessary for ER-targeted gene transcription (Figure 1.6).  
 
 
Figure 1.6: Structural domains and key phosphorylation sites of ERa and 
ERβ. 
 
Both ERa and ERβ are comprised of five structural domains, A/B-F. The red coloured 
phosphorylation residues have been classified only in the murine isoform of ERβ, all other 
residues have been identified in the human isoform of ERa and ERβ. The A/B domain 
located at the N-terminus share 30% amino acid homology, contains AF-1 and is heavily 
phosphorylated (Mosselman et al., 1996). The 184 amino acid A/B domain of ERa contains 
Ser106, Ser118 and Ser176 phosphorylation sites (Le Goff et al., 1994). The A/B domain of 
ERβ is 149 amino acids and contains four phosphorylation sites, Ser87 (Sauvé et al., 2009), 
Ser94 (Tremblay et al., 1997), Ser106 and Ser124 (Tremblay et al., 1999). The C-domain 
contains the DBD and one phosphorylation site in ERa only at S236 (Chen et al., 1999). The 
hinge domain spans 39 and 34 amino acids in ERa and ERβ, respectively and shares 24% 
amino acid homology. The largest domain is the E domain, which contains the LBD and AF-
2 where ligands and cofactors bind and this domain shares 58% homology between ER 
isoforms (Mosselman et al., 1996). The E domain possesses a single phosphorylation site on 
each ERa and ERβ at Tyr537 and Tyr437, respectively (White et al., 1997). The F domain is 
located in the C-terminus and is the least conserved domain with 12% amino acid homology 
between the ER isoforms. 
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1.4.2 Cofactor proteins and the estrogen receptor 
 
Cofactor proteins interact with liganded ERa and -b to enhance or suppress gene 
transcription. ER-associated cofactor proteins can be broadly characterised into 3 main classes 
(1) AF-2 coactivators, (2) secondary coactivators and (3) corepressor proteins.  
 
AF-2 coactivators upregulate gene transcription of liganded ERs through direct interaction 
with AF-2 located in the LBD domain. The LBD consists of twelve alpha helices arranged to 
form a hydrophobic pocket for ligand and AF-2 coactivator binding. All AF-2 coactivators 
express a conserved LXXLL (L represents leucine amino acid and X represents any other amino 
acid) motif that binds to AF-2 (Heery et al., 1997) to promote histone acetylase activity. 
Histone acetylases unwind DNA from histone proteins to assist gene transcription (Spencer et 
al., 1997) at EREs. Examples of AF-2 coactivators include SRC-1, -2, -3 (Oñate et al., 1995), CBP 
(Kamei et al., 1996) (Chakravarti et al., 1996), transcriptional intermediary factor 2 (Voegel et 
al., 1996) and glutamate receptor-interacting protein 1 (Hong et al., 1996). Notably, SRC 
cofactors are necessary for full ER activation in the presence of E2 (Shang et al., 2000). E2-
bound ERa binds SRC-1 directly and SRC-1 recruits and binds CBP/p300 (Sheppard et al., 
2001). This complex enables full ERa transcriptional activity. Although most coactivator 
proteins bind to the AF-2 portion of ERs, some AF-2 coactivators, such as SRC-1 and CBP, can 
be recruited to AF-1 following MAPK dependent phosphorylation of specific serine residues in 
the A/B domain (Tremblay et al., 1999; Chen et al., 2002) (discussed in further detail in section 
1.4.3.2). 
 
Unlike AF-2 coactivators, secondary coactivators only operate in conjunction with AF-2 
coactivators to synergistically enhance gene transcription of liganded ERs (Stallcup et al., 
2000; Koh et al., 2001). Coactivator associated arginine methyltransferase 1 and protein 
arginine methyltransferase (Kim et al., 2003) are examples of secondary coactivators that 
methylate arginine residues of histone proteins (Chen et al., 1999), which upregulates the 
recruitment of RNA polymerase II to the promoter region of ER targeted genes. Coiled-coil 
coactivator is another example of a secondary coactivator that synergistically operates with 
CBP to enhance gene transcription (Kim et al., 2003).  
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Not all cofactors enhance ER function, corepressor proteins are recruited to ER by ER 
antagonists to downregulate ER gene transcription (Lavinsky et al., 1998). For example, the 
NCoR/SMRT form a corepressor complex that deacetylases histone proteins and prevents 
coactivator binding, which suppress ER-mediated gene transcription (Lavinsky et al., 1998).  
 
Differences in ER cofactor expression between tissues may be the reason why some ligands 
of ER can function as agonists in some tissues and antagonists in others. Agonists and 
antagonists of ER induce distinct conformations, which alters the type of cofactors recruited 
(Norris et al., 1999) and ultimately the level of receptor driven gene transcriptional activity. 
For example, tamoxifen, a partial agonist in the endometrium and partial antagonist in breast 
tissue competes for ER binding against E2. Tamoxifen is used in the treatment of ER+ breast 
cancer due to its ability to block ER-mediated activity in the breast and slow breast tumour 
progression. Tamoxifen exhibits antagonist effects in breast cells in two ways. Firstly, its ability 
to move helix 12 into the coactivator binding groove within the LBD and therefore prevent 
coactivator binding (Shiau et al., 1998). Secondly, tamoxifen recruits corepressor proteins, 
NCoR/SMRT, which dampens ER-mediated gene transcription (Shang et al., 2000). Cofactor 
expression is different between endometrial cell and breast cells (Thenot et al., 1999) and this 
difference is a plausible reason why tamoxifen can operate in a tissue-selective manner 
(Lavinsky et al., 1998). 
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1.4.3 ERa and ERb cell signaling pathways 
 
ERa binds E2 with higher affinity (Kuiper et al., 1997) and promotes stronger activation of 
gene transcription at ERE sites compared with ERβ (Mosselman et al., 1996; Cowley & Parker, 
1999). The reason for the enhanced transcriptional efficacy of ERa could be two-fold: (1) once 
ERa is bound to the ERE, the structure of the hinge domain enables a strong interaction 
between AF-1 and AF-2; and (2) the structure of AF-1 promotes the recruitment of SRC-1 
coactivator to ERa to bring RNA polymerase II to the transcription start site to enhance 
transcriptional efficacy. In contrast, the hinge region of ERβ does not mediate a complete 
interaction between AF-1 and -2 and AF-1 and SRC-1 is not able to bind effectively (Métivier 
et al., 2001). ERa and ERβ can form functional heterodimers and are capable of binding DNA 
(Papoutsi et al., 2009). ERβ has been shown to dominantly negatively regulate transcriptional 
efficacy of ERa/β heterodimer complex when liganded with E2 (Williams et al., 2008; 
Pettersson et al., 2000). This concept was supported in a study where ERβ homodimers and 
ERa/β heterodimers were shown to induce a slower rate of cell proliferation relative to ERa 




Quiescent ERa and ERβ are held in an inactive state in the nucleus and the cytoplasm, 
respectively (King & Greene, 1984; Ren & Wu, 2012), by HSPs (Renoir et al., 1990). Upon E2 
entering the cell, the ligand binds to the LBD domain of ERa/β and promotes the dissociation 
of HSPs. ERa/β are subjected to a number of phosphorylation events following E2 binding that 
modulate ER-targeted gene transcription. The conformational change induced by ligand-
binding of an agonist exposes serine-104, -106, -118 (Le Goff et al., 1994) and -167 (Ali et al., 
1993; Arnold et al., 1994) residues located within the AF-1 (Figure 1.6) of ERa. These residues 
are targeted by kinases, such as casein kinase II (Arnold et al., 1994), cyclin dependent kinase 
7 (Chen et al., 2000), MAPK (Kato et al., 1995a), protein kinase A (PKA) and –C (PKC) (Le Goff 
et al., 1994) (Ali et al., 1993), which add phosphate groups to augment receptor activity by 
promoting cofactor recruitment to the receptor (Webb et al., 1998). Following cofactor 
recruitment to the receptor, the liganded receptor dimerises with other liganded receptors. 
Dimerisation of receptors is dependent upon PKA phosphorylation of Ser-236 (Chen et al., 
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1999). The dimeric ERa and ERβ receptors bind with high affinity (ERβ binds with lower 
affinity) to specific promoter regions in the DNA called EREs (Kumar & Chambon, 1988) to 




ERs can also be activated by phosphorylation or point mutations alone irrespective of E2 
binding. MAPK, which is activated by downstream growth factor signalling pathways, such as 
EGF (Ignar-Trowbridge et al., 1992) and IGF-1 (Aronica & Katzenellenbogen, 1993) is capable 
of inducing E2-independent gene transcription. MAPK phosphorylates residues Ser-118 
(Tremblay et al., 1999; Chen et al., 2002) and Ser-94 (Tremblay et al., 1997), -106  and -124 
(Tremblay et al., 1999) in AF-1 domain of ERa and murine ERβ, which enables full receptor 
activation (Ignar-Trowbridge et al., 1993; Kato et al., 1995a). The phosphorylation of these 
residues promotes recruitment of SRC-1 coactivators to AF-1 (Tremblay et al., 1999; Tremblay 
& Giguère, 2001), which is responsible for full transcriptional activity of ERa and ERβ at EREs 
(Kalkhoven et al., 1998). Mutation or phosphorylation of tyrosine-537 and -437 residues (by 
src kinase) in the LBD of human ERa and –β (White et al., 1997), respectively, also 
constitutively activates both receptors in an E2-independent manner (Arnold et al., 1995) 
(Figure 1.7). Both ERa and ERβ contain phosphorylation sites targeted by MAPK and Src to 
mediate basal- and pathological ER activation. Activation of these pathways, which mediate 
constitutive ER activation are implicated in hormone-resistant breast cancer (Murphy et al., 




Figure 1.7: A general overview of ERa/b cell signalling 
 
Bioavailable E2 diffuses into the cell to initiate one of three cell signalling pathways. (1a) 
The bioavailable E2 can diffuse into the cell to induce ligand-dependent signalling. (1b) 
Ligand-dependent signalling is the classical route by which E2 diffuses into the cell and 
activates the nuclear-located ERα and/or -β (King & Greene, 1984; Ren & Wu, 2012) (1c) E2 
binds ERα and/or -β, which induces phosphorylation (Ali et al., 1993; Arnold et al., 1994; Le 
Goff et al., 1994; Kato et al., 1995a; Chen et al., 2000), cofactor recruitment (Webb et al., 
1998) and receptor dimerisaton (Chen et al., 1999). (1d) The dimeric ERs bind EREs to induce 
gene transcription. Ligand-independent signalling is the activation of ERα and/or ERβ via 
phosphorylation independent of E2 binding. (2a) EGF binds and activates its cell surface 
receptor, EGF-R. (2b) MAPKs are activated downstream of EGF-R signalling, which 
phosphorylates ERs (Ignar-Trowbridge et al., 1992). (2c) Cofactors are recruited to 
phosphorylated ERs (Tremblay et al., 1999). (2d) Phosphorylated ERs are capable of 
inducing gene transcription at EREs (Ignar-Trowbridge et al., 1993; Kalkhoven et al., 1998). 
(1,2e) Following activation of gene transcription (Kumar & Chambon, 1988) the mRNA 
transcript undergoes protein synthesis to induce an estrogenic cellular response.  
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1.5 Current methods to measure estradiol and 
testosterone 
 
The ability to accurately and sensitively measure E2 and testosterone levels clinically is 
necessary for the diagnosis and treatment of patients with a number of syndromes or 
diseases, including PCOS, disorders of sexual development, cancer, infertility and determining 
menopausal status. Currently enzyme-linked immunosorbent assay (ELISA) and 
radioimmunoassays (RIA) are the routine methods used for clinical measurements of 
testosterone and E2. However, the sensitivity of both immunoassay-based approaches is 
under scrutiny, since low concentrations of E2 and testosterone produce highly variable 
results or go undetected (Stanczyk et al., 2003; Stanczyk et al., 2010; Stanczyk & Clarke, 2014).  
 
1.5.1 Immunoassay (enzyme-linked and radiolabeled) 
 
ELISA and RIA are commonly used in clinical and research laboratories for measuring the 
concentration of testosterone and E2 (Elder & Lewis, 1985; Al-Dujaili, 2006; Caron et al., 
2010). ELISAs and RIAs are carried out in a 96-well plate and glass tube formats, respectively. 
Testosterone and E2 ELISAs are a technique used throughout this thesis to quantify the level 
of testosterone and E2 serum and plasma samples. There are different variations of the ELISA 
technique and the type used throughout this thesis is called a competitive ELISA. For a 
competitive ELISA, antibodies are coated to the base of the 96-well plate (anti-testosterone 
or anti-E2). During the procedure, conjugated antigen (testosterone/E2 bound to a 
colourmetric enzyme) and the test antigen (E2 or testosterone in test sample) are introduced 
into the wells. The labelled and conjugated antigen compete for binding to the anti-
testosterone or anti-E2 antibodies, which are adhered to the base of the wells. The unbound 
antigens are washed away and the substrate is added to each well, which enables the 
colourmetric reaction to commence. Wells with a strong colour output corresponds to a low 
level of antigen (E2 or testosterone) in the test sample since minimal enzyme-linked antigen 
is displaced. The concept is similar for RIA, instead the label is a radioactive isotope and 
following a wash step, the level of radioactive bound antibody is measured by gamma counter. 
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Overall, both ELISAs and RIAs provide a level of E2 or testosterone concentration for a test 
sample when interpolated from a standard curve, which is carried out simultaneously.  
 
1.5.2 Liquid Chromatography- Gas Chromatography-Mass 
Spectrophotometry (LC- and GC/MS) 
 
LC- and GC/MS are exquisitely sensitive measures used to quantify levels of certain molecules 
within a sample, such as serum and is used in a research laboratory. LC- and GC/MS combine 
two techniques for identification of chemical structure; gas or liquid chromatography and 
mass spectrometry. Gas and liquid chromatography are techniques that separate a sample 
based on molecular size. The key difference between gas and liquid chromatography is the 
mobile phase, which is either an inert gas (such as hydrogen, helium or nitrogen) or a liquid 
solvent (water, acetonitrile and/or methanol). Specific products from different phases of the 
chromatography technique can be isolated and subjected to mass spectrometry. Mass 
spectrometry is performed by ionisation of the molecule by a stream of high-energy electrons. 
When electrons bombard an organic molecule, it displaces the valence electrons to form 
cation radicals. The cation radicals are then separated according to mass-to-charge ratio (m/z) 
and this provides a mass spectrum of the unknown sample. The analysed molecule can be 
identified if the mass spectrum trace matches the Registry of Mass Spectral Data, which is a 
database of known chemical structures, each represented by a unique mass-spectrum trace. 
 
1.5.3 Advantages and disadvantages of above methods 
 
Currently ELISAs and RIA are the routine methods employed for clinical evaluation of 
testosterone and E2. Both RIA and ELISA are techniques that can measure biological samples 
directly and can be automated to accelerate the screening process. These high throughput 
approaches for steroid measurement are favourable in a clinical setting for fast turnaround 
results. However, LC- and GC/MS remain the gold standard for the most accurate and sensitive 
method for detecting E2 and testosterone within a sample. Despite improved accuracy, LC- 
and GC/MS is a time-consuming, which requires specialized equipment, standardization 
protocols and is expensive.  
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The sensitivity of RIA and ELISAs are under scrutiny, especially at low end levels where high 
the assays have high variability, lack specificity and the reproducibility between 
manufacturers of ELISA kits is poor (Stanczyk et al., 2003). Serum, plasma and urine contain 
conjugated steroids, which can cross react with the antibodies in ELISA and RIA. This can result 
in overestimation of the true E2 or testosterone concentration (Stanczyk & Clarke, 2014). 
Conjugated steroids are biologically inert and contain sulfate or glucuronide groups attached 
to the steroids as a result of first- and second-pass metabolism (liver and kidney metabolism). 
To overcome this, an organic solvent extraction step of the serum or urine is required to 
remove the conjugated steroids from the sample. By adding this extra step, the protocols are 
more labour intensive and require additional laboratory expertise. Due to the low specificity 
of the antibodies in ELISAs towards specifically E2, precursor metabolites can also be detected, 
which summate to a false reading of a higher interpreted concentration of E2 in a sample 
(Stanczyk & Clarke, 2014). 
 
The common denominator of the above approaches (immunoassay and LC- and GC/MS) for 
steroid measurement is that they are designed to specifically detect only E2 or testosterone 
and the net estrogenicity or androgenicity of a sample is not accounted for. This means that 
exogenous synthetic or plant-based (anti-) estrogenic or androgenic compounds go 
undetected. Furthermore, weaker precursor molecules and metabolites of E2 and 
testosterone are also not measured. However, if a molecule is capable of activating ER- or AR, 
they are of physiological importance. The ability to detect the entire net estrogenicity and 
androgenicity of a test sample also allows for all physiologically important estrogens and 
androgens to be measured. Therefore, there is a need for an alternative, less direct measure 
of androgens and estrogens, which will allow for a measurement of the overall level of 
estrogen or androgen activity in a sample. Bioassays that rely on ER and AR cell signalling 
provide a more holistic approach for measuring all steroid hormones rather than to identify 
only certain molecules within a sample.  
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1.6 Methods to measure estrogenicity and 
androgenicity 
 
Although E2 and testosterone are the most dominant endogenous ligands to ERa/b and AR, 
respectively, they are not the only molecules capable of activating these receptors. In fact, it 
is well established that estrogen mimicking molecules of synthetic (xenoestrogens) (Bonefeld-
Jørgensen et al., 2001; Matthews et al., 2001; Meerts et al., 2001; Plíšková et al., 2005; Pinto 
& Reali, 2009; Wagner & Oehlmann, 2009; Zhang et al., 2014) and plant origin 
(phytoestrogens) (Zava et al., 1998; Sotoca et al., 2010) are capable of activating or inhibiting 
ERa/b, thereby mimicking or interfering with the action of endogenous estrogens. 
Furthermore, androgens and anti-androgens have been discovered in environmental samples 
(Legler et al., 2002; Peck et al., 2004; Thomas et al., 2004; Koh et al., 2005; Houtman et al., 
2006; Grund et al., 2011; Schilirò et al., 2012; Wang et al., 2014a) and in a similar manner also 
pose a risk to the health of those exposed. Due to the persistent nature of some synthetic 
estrogens and androgens some have been detected in human serum, milk (Noren & 
Meironyte, 2000; Solomon & Weiss, 2002), adipose tissue and placenta (Lopez-Espinosa et al., 
2007). Therefore, exposure to these molecules has the potential to disrupt the endocrine 
system of an organism, potentially posing a serious health risk. A bioassay approach can be 
taken to screen novel molecules to determine the estrogenic and androgenic potential when 
the chemical structure is unknown. This chapter provides an overview of the types of 
bioassays used in research laboratories to identify both estrogenic and androgenic 
compounds. Table 1.1 provides an overview of the advantages and disadvantages for the four 
estrogen and androgen bioassays. 
 
1.6.1 Uterotrophic and Hershberger assays 
 
The uterotrophic and Hershberger assays are in vivo measures for the overall estrogenicity 
and androgenicity of a test compound, respectively. The assays both involve treating 
gonadectomised rats with a test compound orally (Hershberger assay) or intravenously 
(uterotrophic  assay) and then measuring the effect on the size and dry weight of target 
organs. In the uterotrophic assay, the dry weight of the uterus is measured (Wakeling et al., 
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1991) after 30 days treatment, whereas in the Hershberger assay, the prostate gland, seminal 
vesicles, Cowper’s glands, glans penis (Gray et al., 2005) and levator ani muscle are measured 
after 8 days of treatment (Hershberger et al., 1953). The dry weight of these target organs are 
measured due to the well-established effects of estrogen- and androgen-induced growth of 
these target tissues. The uterotrophic and Hershberger assays also provide good in vivo 
measures of the anti-estrogenic and anti-androgenic effects when the test substance is co-
administered with E2 and testosterone, respectively. Furthermore, since such assays are a 
whole-body model, the estrogenicity or androgenicity of the test substance following 
metabolism can be inferred (Odum et al., 1997; Yamasaki et al., 2003). However, whole animal 
models have drawbacks since it is time-consuming treating animals, operating, preserving and 
weighing organs. Furthermore, using an animal model has ethical implications. The inherent 
nature of animals increases variability, therefore, the outcome of the in vivo bioassays are 
poorly reproducible.  
 
1.6.2 Radioactive ligand binding assays 
 
Radioactive ligand binding (RLB) assays determine whether a pure test compound labelled 
with a radioactive isotope can bind to a particular receptor. RLB assays are straight forward to 
perform and are highly sensitive and specific to whether the ligand of interest can bind the 
receptor of interest. The RLB assay can show whether a ligand binds with strong or weak 
affinity to ERa or AR but not whether the ligand is functionally active (Rich et al., 2002; Feau 
et al., 2009). In some cases, the ligand of interest may have high binding affinity to the 
receptor but have minimal in vivo effects (Wang et al., 2014b) and therefore, no downstream 
biological effects following ligand binding of the receptor can be inferred. RLBs report 
accurately on the binding affinity of a test substance, however, agonists cannot be 
distinguished from antagonists.  
 
1.6.3 Cell proliferation assays 
 
Hyperplasia of breast cancer cells and prostate cancer cells are a hallmark effect of estrogens 
and androgens, respectively. This effect has been exploited as a measurable variable to 
determine whether a particular compound is estrogenic or androgenic. By utilising an ER-
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expressing cell line, such as MCF-7 breast cancer cells, or an AR-expressing cell line such as 
LNCaP cells, the rate of cell proliferation in response to a test compound can be measured. 
The premise of these assays is that the rate of cell proliferation is a marker of the level of AR 
or ER activation induced by the test compound. Therefore, potent estrogens and androgens 
will induce higher rates of cell proliferation compared to weak estrogens and androgens. Cell 
proliferation can be measured by a variety of different techniques.  
 
The androgen LNCaP cell proliferation assay has been carried out in vitro (Yamabe et al., 2000) 
and in vivo (Lim et al., 1993) whereby LNCaP cells are injected into mice in a matrigel and 
tumour progression is assessed in response to various compounds. However, it has been 
shown that LNCaP cells have a biphasic response to androgens, with both high and low 
concentrations of androgens suppressing cell proliferation. This can complicate the 
interpretation of results (Lim et al., 1993). 
 
The MCF-7 cell proliferation assay, otherwise referred to as the E-screen is a well-established 
technique to measure the estrogenicity and anti-estrogenicity of a test substance (Okubo et 
al., 2004). A reduced rate of cell proliferation relative to E2 alone describes a weaker estrogen 
or an anti-estrogen when co-cultured with E2. However, since MCF-7 cells express both ER 
isoforms, it cannot be determined whether the proliferative response is mediated via ERa or 
ERb (Li et al., 2009b). Importantly, the MCF-7 cell proliferation assay is a reliable measure of 
estrogenicity due to its strong correlation with the in vivo uterotrophic assay (Wang et al., 
2014b). 
 
1.6.4 Reporter gene bioassays (RGBs) 
 
RGBs measure ERa- and/or ERb- and AR-targeted gene transcription to determine the 
estrogenicity and androgenicity of a test substance, respectively (described in greater detail 
in Chapter 1.7, page 40). RGBs are an in vitro technique, whereby cells are transfected with 
both expression- and reporter gene plasmids (Legler et al., 1999; Bovee et al., 2004; Bovee et 
al., 2007). The expression plasmid ensures the steroid hormone receptor of interest is 
expressed in the cell. If the test substance is an agonist, the activated receptor will activate 
gene transcription of the reporter gene at the response element on the reporter plasmid. 
 37 
Therefore, receptor activation can be measured by the level of reporter protein expression 
from the cells. RGBs are advantageous for measuring the relative potencies of different 
molecules by comparing EC50 values derived from dose response curves (Bovee et al., 2010). 
Furthermore, plasma, serum and urine matrices can all be applied directly to cells to measure 
the absolute level of inducible gene transcription (Nielen et al., 2006; Lim et al., 2014a). 
Additionally, like cell proliferation bioassays, RGBs can also measure the anti-estrogenicity and 
anti-androgenicity of a test substance by co-culturing test substances with E2 and 
testosterone, respectively.  
 
The overall aim of a bioassay is to understand how a molecule or mixture would behave in 
vivo and to help with predictions on potential physiological and anatomical manifestations. In 
a study by Wang et al. (2014b), the MCF-7 cell proliferation assay, yeast-and human cell ERa 
and/or ERb RGBs and ligand binding assays were compared to the outcome of the 
uterotrophic assay. The results of the yeast-based ER bioassay correlated strongly with the 
outcome of the uterotrophic assay (Wang et al., 2014b), followed by the MCF-7 cell 
proliferation assay and then the human cell ERa- and/or ERb-RGBs. There are some reported 
inconsistencies between the uterotrophic bioassay and RGB measurement as it has been 
shown that some compounds that did not activate the ERa-RGB did induce estrogenic effects 





Table 1.1: The advantages and disadvantages for estrogen and androgen 
bioassays. 
Bioassay Advantages Disadvantages 
In vivo bioassay 
• Can observe whole body 
response. 
 
• Can determine agonists 
and antagonists. 
 
• Alter other homeostatic 
hormone signalling 
pathways (i.e. HPG axis). 
 
• Low throughput (time 
consuming). 
 
• Animals (high variability, 






• Can determine ligands to 
ERa, ERb and AR. 
 
• Sensitive and specific. 
 
• High throughput 
(compared with in vivo 
bioassays). 
• Cannot determine if the 
test compound is an 
agonist or antagonist. 
 
• Can only apply pure test 
molecules to the assay. 
 
• Cannot determine if the 
test compound binds fully 
or partially to the 
receptor. 
 
• Cannot infer downstream 






• Can determine cell cycle 
stage using flow 
cytometry. 
 
• The results of the MCF-7 
cell proliferation assay has 
strong predictive power 
towards the outcome of 
the uterotrophic assay 
(Wang et al., 2014b). 
 
• High throughput 
(compared with in vivo 
bioassays). 
• Alternative cell signalling 
mechanisms could be 
responsible for cell 
proliferation, therefore 
other cell signalling 
pathways could be 
activated independent of 
AR/ER signalling. 
 
• Cell culture is laborious, 
expensive and not 






• Yeast ERa-RGB has strong 
predictive power towards 
the outcome of the 
uterotrophic assay (Wang 
et al., 2014b). 
 
• A measure of net receptor 
activation from the test 
substance. 
 
• Test substance can be in 
the form of a pure 
molecule or a mixture. 
 
• High throughput 
(compared with in vivo 
bioassays). 
• Sensitivity and specificity 
issues may arise from cell 
line and reporter used. 
 
• Human cell ER-RGBs had 
moderate predictive 
power of the outcome of 
the uterotrophic assay 
(Wang et al., 2014b). 
 
• The interpretation of the 
assay is cell specific. 
 
• Cell culture is laborious, 
expensive and not 





1.7 AR- and ER reporter gene bioassays 
 
ERa/b- and AR-RGBs have been engineered to mimic classical ERa/b and AR signalling, 
respectively, for the purpose of providing a measure of the level of ERa/b and AR activation 
by a test sample. The level of ERa/b or AR activation induced by a test sample is an indication 
of how ERa/b or AR expressing cells in the human body would also respond. The main 
approaches used to create a RGB are: (1) transfection of a reporter gene plasmid into a 
mammalian cell line that endogenously expresses high levels of ERa and/or -b or AR (Figure 
1.8A), or (2) cotransfection of an ERa and/or -b or AR expression plasmid and an ERE or ARE 
reporter plasmid into a cell with no or low level endogenous ERa and/or -b or AR expression 
(Figure 1.8B). The first approach based in receptor expressing cell lines, such as certain breast 
cancer cell lines (MCF-7 or T47D cells), where only a reporter gene plasmid is stably 
transfected into the cell. Whereas, the second approach uses an ERa or -b or AR expression 
plasmid to overexpress ERa or -b or AR in non- or low ERa or -b or -AR expressing cells. Both 
approaches use a reporter gene plasmid, which contains either an ERE or ARE upstream of a 
minimal promoter that together increases expression of the reporter gene in the presence of 
an estrogenic- or androgenic molecule. 
 
Upon treatment of the cells with the test substance, the bioassay mechanism follows a 
signalling pathway analagous to classical steroid hormone receptor cell signalling. Under this 
mechanism, any molecule that can enter the cell and activate recombinant or endogenous 
ERa and/or -b or AR will promote receptor activation and subsequent dimerisation. Dimerised 
receptors bind to the reporter plasmid at the response element, which is located upstream of 
the reporter gene. Activated receptors will then recruit cellular transcriptional machinery to 
induce expression of the reporter gene that will be subsequently translated into the readout 
protein. If the reporter protein is green fluorescent protein (GFP) (Bovee et al., 2004), the cells 
can be directly measured for fluorescence within 24 hours of treatment. Alternatively, the 
reporter protein may be an enzyme that is expressed in the cells. After 18-24 hours of 
treatment, cells are treated with a specific substrate to produce a colour or light emission 
change (Akram et al., 2011). For example, transcription of the lacZ gene on the reporter 
plasmid induces expression of b-galactosidase (enzyme), which cleaves ortho-nitrophenyl-β-
galactoside (ONPG) (substrate), to produce a chromogenic product that absorbs light at a 
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wavelength of 420 nm. The fluorescence, absorbance or luminescence readout is proportional 
to the level of ERa and/or -b or AR activity induced by the test estrogen or androgen (Figure 
1.8, page 42).  
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A. Expression of recombinant receptors 
 
B. Expression of endogenous receptors 
 
Figure 1.8: General mechanisms of ER- and AR-RGBs 
 
A. Stable transfection of expression- and reporter gene plasmids (1) Stable transfection of 
ERa or -b or AR expression plasmid encodes the ERa or -b or AR gene from which the cell 
synthesizes ERa or -b or AR, (2) The test estrogen or androgen diffuses into the cell and 
binds to the recombinant receptors, (3) The activated receptors form a dimeric complex, 
which (4) translocates to the ERE or ARE on the reporter plasmid upstream of the reporter 
gene (located in nucleus – not shown) (5) This prompts the transcription of the reporter 
gene and subsequent reporter protein expression, which (6) induces the read out of the 
bioassay in the form of fluorescence, luminescence or colourmetric change. B. Stable 
transfection of the reporter gene plasmid only. (1) Estrogenic or androgenic molecules 
diffuse into the cell and binds to endogenous nucleic ERa and/or -b or cytosolic AR (sub-
cellular location of receptors not shown), (2) The activated receptors dimerise, (3) The 
dimeric receptors translocate to the ERE or ARE on the reporter plasmid upstream of the 
reporter gene, (4) This prompts the transcription of the reporter gene and subsequent 
reporter protein expression, which (5) Induces the read out of the bioassay in the form of 
fluorescence, luminescence or colourmetric change. 
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RGBs are a useful cell-based tool that exploit ER and AR cell-signalling pathways. Since E2 and 
testosterone are not the only biologically active androgens and estrogens, measuring the net 
androgenicity and estrogenicity through the use of RGBs can help to provide an alternative 
insight into hormone measurement. RGBs are yet to emerge as a clinical tool, however, the 
premise of detecting the net androgenicity or estrogenicity of samples such as serum or 
plasma could be a novel surrogate marker for endocrine-related diseases. This study optimizes 
AR- and ER-RGBs for the purpose of measuring serum and plasma from racehorses and breast 
cancer patients for the purposes of determining if there is potential clinical value in this cell-









Overall, it is hypothesized that RGBs can measure steroid hormone receptor activity in clinical 
samples and will provide companion information beyond immunoassay data that may be 
useful to the clinician. 
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2.0 General Methods 
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2.1 RNA Applications 
 
2.1.1 RNA extraction 
 
The following protocol was carried out to extract RNA from cells. The volumes of each reagent 
required for harvesting from a 6-well plate and T75 flask are stated in the table on the next 
page (Table 2.1, top of page 46). Cell culture media was aspirated from the flask (T75) or plate 
(6-well) of confluent cells followed by two 1X phosphate-buffered saline (PBS) washes to 
remove residual media and cellular debris. To lyse the cells, TriZol reagent (Ambion, Cat 
#15596-018) was incubated with cells at room temperature for 2 minutes and then scraped 
to lift the cells. The cell lysate was then transferred into a 1.7 mL Eppendorf tube and 
incubated for a further 5 minutes at room temperature. Chloroform was then added to each 
tube and shaken vigorously for 15 seconds to dissociate the nucleoprotein complex. The tubes 
were left to incubate at room temperature for 3 minutes and then centrifuged at 12,000 x g 
for 15 minutes at 4°C to allow the RNA to separate into the upper clear aqueous phase. The 
clear aqueous phase was transferred into a clean 1.7 mL Eppendorf tube and mixed with 
isopropanol to precipitate the RNA. Following a 10 minute incubation at room temperature, 
the samples were centrifuged at 12,000 x g for another 10 minutes at 4°C. The supernatant 
was carefully removed from the gel-like pellet on the side of the Eppendorf tube. Next, the 
RNA pellet was washed with 75% (v/v) ethanol, vortexed and then centrifuged at 7,500 x g for 
5 minutes at 4°C. The wash was discarded and the pellet was air dried for 10 minutes. The 
RNA pellet was resuspended in 30 µL diethyl pyrocarbonate (DEPC)-treated water (OmniPur, 
Cat #7732-18-5) and incubated at 55°C for 10 minutes. The RNA yield was quantified using the 
MaestroNano Spectrophotometer. Clean Ultra PureTM DEPC treated water (Invitrogen Life 









Table 2.1: Volumes of reagents required for an RNA extraction from cells  
 
Volumes of reagents required for an RNA extraction from cells in a 6-well plate or T75 
flask. 
Reagent Volume for 6 well Volume for T75 flask 
1X PBS 2 mL 5 mL 
TriZol 400 µL 2.4 mL 
Chloroform 80 µL 480 µL 
Isopropanol 200 µL 1.2 mL 
75% Ethanol 400 µL 2.4 mL 
DEPC-treated H2O 30 µL 50 µL 
 
2.1.2 Reverse transcription 
 
RNA samples underwent reverse transcription to convert RNA into single stranded 
complementary DNA (cDNA), which is required for RT-qPCR (Real Time Quantitative 
Polymerase Chain Reaction) to measure relative gene expression.  
 
To set up the reverse transcription reaction, the reagents listed below were made up to 20 μL 
with DEPC-treated water in 0.2 mL PCR tubes, on ice. A reverse transcription (RT) control (no 
RNA) was prepared by adding DEPC-treated H2O to the VILO-Superscript master mix in 
replacement of the RNA. An RT control was included for each reverse transcription experiment 
to ensure no DNA or RNA contamination. The reagents listed below were mixed and the 20 μL 
samples were briefly microcentrifuged. All samples were transferred to the Kyratec Super 
Cycler to undergo reverse transcription, whereby all samples were held at 25°C for 10 minutes, 
followed by 42°C for 60 minutes and then 85°C for 5 minutes. All cDNA products were stored 
at -20°C.  
 
Reagent Volume/reaction: 
• SuperScript® VILOTM cDNA Synthesis Kit (Invitrogen, Cat 
#11754050) 
 
o 5X VILO reaction mix 4 μL 
o 10X Superscript enzyme mix  2 μL 
• RNA 1 μg 
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2.1.3 RT-qPCR  
 
The master mix was prepared for each primer in 1.7 mL Eppendorf tubes, on ice. The volumes 
listed below for each reagent in the master mix allowed for 4 x 9 µL aliquots and an additional 
20% volume. Each 9 µL aliquot of the master mix was pipetted into a 96-well PCR plate 
(MicroAmp EnduraPlate Optical 96-well Fast Red reaction plate with barcode, Applied 
Biosystems, Cat #4483492) and 1 µL of cDNA was added to each well. For each Taqman gene 
expression primer used (see list below), a no-template-control (NTC) mixture was included to 
ensure there was no DNA contamination throughout the samples. The NTC consists of all 
components described for the sample mix, except the volume of cDNA was replaced with 
DEPC-treated H2O. GAPDH served as the reference gene for each RT-qPCR experiment to 
measure relative expression levels of the gene of interest (see equation on page 48). GAPDH 
is a house keeping gene with stable expression levels, therefore, GAPDH serves as an 
appropriate internal control for RT-qPCR. 
 
A clear adhesive layer was firmly applied to cover the wells to prevent evaporation of the mix 
during the PCR reaction. All air bubbles were removed and the PCR plate was centrifuged for 
10 seconds. The PCR plate was then placed in AB Applied Biosystems StepOne Plus Real-Time 
PCR System. The RT-qPCR run heated the samples to 95°C for 20 seconds and cycled 40 times 
between 95°C for 1 second and 60°C for 20 seconds.  
 
Sample master mix: 
Reagent Volume (4X): 
• Taqman® Fast Advanced Master Mix (Applied Biosystems, Cat 
#4444557) 
25 μL 
• Taqman gene expression assay (20X)  - one of the following primers 2.5 μL  
o ESR1 (ThermoFisher Scientific, Cat #4331182)  
o ESR2 (ThermoFisher Scientific, Cat #4331182) 
o AR (ThermoFisher Scientific, Cat #43311820 
o PR (ThermoFisher Scientific, Cat #4331182) 
o GAPDH (ThermoFisher Scientific, Cat #4331182) 
 
• DEPC-treated H2O  17.5 μL 
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No Template Control (NTC) mix: 
Reagents: Volume (4X): 
• Taqman® Fast Advanced Master Mix (Applied Biosystems, Cat 
#4444557) 
25 μL 
• Taqman gene expression assay (20X)  2.5 μL 
• DEPC-treated H2O 22.5 μL 
 
2.1.3.1 Quantification of relative gene expression 
 
For each RT-qPCR reaction, a cycle threshold (CT) value was obtained, which quantifies the 
number of cycles of RT-qPCR required to amplify the specific DNA segment to a measurable 
threshold. By utilizing the following equation, the CT of one gene can be compared to the CT 
of the reference gene to provide a DCT value. The DCT value provides a normalises the amount 
of RNA used in each RT-qPCR reaction. Relative quantification of a gene was calculated to 
compare the fold-change in expression levels compared to the GAPDH reference gene using 
the following equations. 
 
∆"#$%&'() = 	"#(-).)	/0	1.2)3)$2) −	"#(3)0)3).6)	-).), 89:;<) 
 
The DCT value of one sample can be compared to another DCT value of another sample to 
provide a DDCT value by applying the following equation: 
 
∆∆"# = 	∆"#(2)$2	$%&'()) −	∆"#(6/.23/(	$%&'()) 
 
The DDCT value is used to measure relative expression levels by providing a fold change in 
expression levels of two test samples of interest by applying the following equation: 
 
=/(>	6ℎ%.-) = 	2A∆∆BC  
 
The fold change in gene expression levels describes the relative difference in gene expression 
in the test sample compared with the control sample. For example, when the fold change is 
positive, gene expression is upregulated and when fold change is negative, gene expression is 
downregulated. 
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2.1.4 PCR and agarose gel 
 
PCR of reverse transcription products (single stranded cDNA) or plasmid DNA were analysed 
by gel electrophoresis to determine the presence of specific gene amplification products. PCR 
primers were designed against gene inserts of plasmid DNA to determine if the gene was 
expressed. A NTC (DEPC-treated H2O in replacement of cDNA) was included for each PCR 
experiment to ensure the PCR reagents were not contaminated. The standard PCR run cycle 
is shown at the top of the next page (page 50) in Table 2.2, however, the volumes of reagents, 
the set temperatures and timings of the PCR protocol were optimized for each specific primer 
(primer sequence and annealing temperature/time is detailed in the relevant chapter). The 
Kyratec SuperCYcler PCR machine carried out all PCR reactions. Following PCR, to determine 
if the gene of interest was amplified, the PCR product(s) were visualised by agarose gel 
electrophoresis. 
 
2.1.4.1 General PCR master mix and run settings 
 
PCR master mix: 
Reagent: Volume per reaction: 
• KAPA Hi Fi Hot Start Ready Mix (Kapa Biosystems, Cat 
#KR0370) 
12.5 μL 
• Forward primer  0.75 μL 
• Reverse primer  0.75 μL 
• DEPC-treated H2O  9 μL 
 
cDNA or plasmid DNA (1 μL) was added to the PCR master mix to make the volume up to 25 
μL. In replacement of the DNA volume, DEPC-treated H2O was added to PCR master mix to 
serve as a NTC to control for contamination of reagents.  
 
The PCR protocol follows a standard structure for all PCR experiments performed, however, 
the annealing time and temperature is specific for each primer (noted as x°C and x seconds in 




Table 2.2: Standard PCR run.  
 
Annealing temperature and time are denoted as x as it changes depending on the primer 
sequence. 
Step Temperature Time 
Initial denaturation 95°C 3 minutes 
 35 cycles  
Denaturation 98°C 20 seconds 
Annealing x°C x seconds 
Extension 72°C 60 seconds 
   
Final extension 72°C 5 minutes 
 
2.1.4.2 Agarose gel 
 
PCR products were electrophoresed in a 1.5% (w/v) agarose gel to visualise if the expected 
amplification product size was produced in the PCR reaction. To create an agarose gel, 1X TAE 
buffer was mixed with agarose by carrying out the following procedure: 
 
TAE buffer stock (50X): 
Reagent: For 1 L: 
• Tris base (Bio Froxx, Cat #1125KG001) 242 g 
• Acetate (100% acetic acid)  57.1 mL 
• Ethylenediaminetetraacetic (EDTA) (Calbiochem, Cat 
#16G145210)  
2.92 g (for 0.5 M 
concentration) 
 
Add dH2O to make up to 1 L. For 1X working stock, 20 mL of 50X TAE was diluted in 980 mL of 
deionized water. 
 
1.5% (w/v) agarose gel: 
Reagent: Weight/volume: 
• Agarose low EEO (PanReac AppliChem, Cat #A2114,0500) 1.5 g 
• 1X TAE buffer  100 mL 
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The gel was microwaved to dissolve agarose without boiling. Once cooled to ~60°C, 10 μL of 
SYBR safe DNA stain DNA stain (ThermoFisher, Cat #S33102) was added to the liquid gel and 
then poured into the gel mold with a 10 or 15 lane comb inserted. The gel was left to cool and 
solidify at room temperature for at least 30 minutes. The gel was placed in the tank and filled 
with 1X TAE. The gel was orientated with the lanes at the negative pole to ensure the 
negatively charged DNA moved towards the positive pole. Loading buffer was mixed with the 
PCR samples and the DNA size marker in 0.2 mL Eppendorf tubes using the following protocol:  
 
Gel loading samples: 
PCR samples: Volume per lane: 
• 10X Blue Juice Gel Loading Buffer (Invitrogen, Cat #10816015) 2.5 μL 
• PCR product  22.5 μL 
  
DNA size marker: Volume per lane: 
• Ladder 1kb Plus DNA (Invitrogen, Cat #10787-026) 3.0 μL 
• 10X Blue Juice Gel Loading Buffer 2.0 μL 
• DEPC-treated H2O 15.0 μL 
 
The lanes in the gel were loaded with the ladder or 20-25 μL of PCR product. Electrophoresis 
was carried out at 100 V for 30-45 min. 
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2.2 Protein Applications 
 
2.2.1 Protein extraction 
 
Protein extracts from HeLa cells were used to determine AR expression via Western blot in 
chapter 6.0. 
 




• 50 mM Tris-HCl (pH 7.4)  0.6057 g 
• 150 mM NaCl  0.8766 g 
• 10% sodium dodecyl sulfate (SDS)  1 mL 
• 1% Triton X-100 1 mL 
• 1 mM EDTA 0.0292 g 
• MilliQ water 80 mL 
 
Above components mixed together, pH balanced to 7.4 and made up to 100 mL with HCl. 
Stored at -20°C. 
 
RIPA + inhibitors buffer: 
Reagent: Volume: 
• RIPA buffer 4.25 mL 
• Complete (25X) (EDTA-free, Roche Diagnostics, Cat 
#11873580001) 
200 μL 
• PhosSTOP (10X) (Roche, Cat #04906845001) 500 μL 
• Phenylmethanesulfonyl fluoride solution (PMSF) (100 mM) 





The cell culture media from two T75 flasks of confluent HeLa cells were aspirated followed by 
one wash with 1X PBS. The PBS was removed and the base of the flask was scraped to lift cells. 
The cells were resuspended in RIPA + inhibitors buffer, transferred to a 1.7 mL Eppendorf tube 
and incubated on ice for 30 minutes. The Eppendorf tube was centrifuge at 14,000 x g for 10 
minutes at 4°C. The supernatant was aliquoted into four clean Eppendorf tubes and stored at 
-80°C. 
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1X running buffer: 
Reagent: Volume: 
• 10X MES (1-hydrate for buffer solutions, Cat #A1074,1000)  50 mL 
 
Made up to 500 mL with deionised water. 
 
10X transfer buffer (towbin): 
Reagent: Volume: 
• Tris base (250 mM) (BioFroxx, Cat #1225KG001) 30.3 g 
• Glycine (1.92 mM) (BioFroxx, Cat #1339KG001) 144 g 
 
Made up to 1 L with deionised water. 
 
1X transfer buffer: 
Reagent: Volume: 
• 10X transfer buffer 100 mL 
• Methanol 100 mL 
 
Made up to 1 L with deionised water. 
 
10X TBS (Tris-Buffered Saline): 
Reagent: Volume: 
• Tris base (10 mM)  12.11 g 
• Sodium chloride (100 mM) 58.44 g 
 





• 10X TBS (pH 7.5) 100 mL 
• Tween 20 (Merck, Cat #S6740654403) 500 μL 
 
Made up to 1 L with deionised water. 
 
2.2.2.2 Poly Acrylamide Gel Electrophoresis (PAGE) 
 
Protein samples: 
Reagent: Volume per lane: 
BoltTM LDS sample buffer (4X) (Invitrogen, Cat #B0007) 10 μL 
BoltTM Reducing agent (10X)  (Invitrogen, Cat #B0009) 4 μL 
Protein extract 40 μg 
    
Molecular weight ladder/protein standard: 
Reagent: Volume per lane: 
BoltTM LDS sample buffer (4X) 10 μL 
BoltTM Reducing agent (10X)  4 μL 




The protein samples and the molecular weight ladder were made up to 15 μL with DEPC water. 
Each loading sample was briefly centrifuged and then heated to 100 °C for 10 minutes prior 
to loading the 15 μL sample into the 12-well Bolt 10% Bis-Tris Plus Gel (Invitrogen, Cat 
#NW00105BOX). The gel was inserted into the Life Technologies Mini Gel System and filled 
with 1X running buffer. The lane comb was removed and each well was washed with 1X 
running buffer prior to loading the protein standard and samples into the gel. The PAGE was 
carried out at 150 V for 80 minutes. Following electrophoresis, the gel was transferred onto a 




2.2.2.3 Set-up of the Western transfer 
 
The polyacrylamide gel was washed in 1X transfer buffer at 50 rpm for 15 minutes. The PVDF 
membrane was activated in 100% methanol for 1 minute prior to one 15 minute incubation in 
1X transfer buffer. The fiber pads and filter paper were incubated in 1X transfer buffer for 15 
minutes prior to assembly in the transfer sandwich (Figure 2.1). 
 
Components of the transfer sandwich: 
• Cassette 
• 2x Fiber pads 
• 2x Extra thick Western Blot filter paper (Thermo Scientific, Cat #88615) 
• 1x Immuno-Blot® PVDF Membrane (Bio-Rad, Cat #1620177) 
 
The transfer sandwich was assembled in a cassette and arranged to ensure that the negatively 
charged proteins in the gel would transfer towards the PVDF membrane, which is located 
towards the positive pole of the cassette (red side). Starting with one fiber pad on the black 
side of the cassette, a fiber pad and filter paper were placed below the PAGE gel. A PVDF 
membrane was placed on top of the PAGE gel, followed by a layer of filter paper and a fiber 
pad. All layers were gently rolled over to remove air bubbles and then placed in the BioRad-
Transblot turbo transfer system (Cat #1704155). The transfer system was orientated with the 
red side of the cassette towards the cathode (positive pole) and filled with 1X transfer buffer. 
The transfer was carried out at 100 V (400 mA) for 1 hour and 40 minutes at 4 °C. Once 
transferred, the membrane was incubated in 1X TBS for 5 minutes prior to blocking. 
 
 
Figure 2.1: Configuration of the transfer sandwich. 
 
The transfer sandwich was assembled within a cassette with a red and black side. Within 
the cassette the sandwich was assembled starting at the black pole with the fiber pad, filter 
paper, PAGE gel and PVDF membrane, filter paper and fiber pads. 
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2.2.2.4 Blocking the membrane 
 
Following the Western transfer, the membrane was incubated in 5% skim-milk powder for 1 
hour at 60 rpm to prevent non-specific binding of the antibodies to the membrane. Once the 
membrane was blocked, it was washed with 1X TBS/T across 6 x 5 minute washes to remove 
any residual skim milk solution. 
 
5% Skim-Milk Powder Solution: 
Reagent: Volume: 
• Skim milk powder 5g 
• 1X TBS/T 100 mL 
 
2.2.2.5 Antibody incubations 
 
The membrane was exposed to a solution containing the primary antibody (see Table 2.3 for 
antibodies and concentrations) and incubated overnight at 4 °C on an orbital shaker.  
 
Following overnight primary antibody incubation, the PVDF membrane was subjected to 6 x 5 
minute washes with TBS/T and then incubated in a secondary antibody solution for 2 hours. 
Following secondary antibody incubation, the PVDF membrane was subjected to another 6 x 
5 minute washes with TBS/T. 
 
Table 2.3: Primary and secondary antibodies for Western Blot. 
10 Antibody Concentration 20 Antibody Concentration 
AR  
(mouse monoclonal 
200 µg/mL, Santa 
Cruz Biotechnology, 
Cat #sc-7305) 
1:200 Goat anti-mouse 
HRP 
(2 mg/mL, abcam, 
Cat #6785)  
1:10,000 
GAPDH 




The PVDF membrane was incubated in Super Signal® West Pico Chemiluminescent Substrate 
(ThermoScientific, Cat #334077) for 5 minutes and then probed for secondary antibody using 
Syngene Imager.  
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2.3 Culturing of Yeast-AR Cells 
 




Saccharomyces cerevisiae, YPH500 (MATa, ura3-52, lys2-801, ade2-101, trp1-D63, his3-D200, 
leu2-D1) 
 
Co-transformed with the following plasmids: 
 
• YRpG2 (ARE-lacZ fusion) 
• YEpAR (AR cDNA)  
 




YPD media contains all the essential amino acids necessary for yeast cell growth. The yeast 
extract, peptone (bacterial grade) and nutrient agar were made up to 250 mL with distilled 
water (see the list below for amounts), stirred and autoclaved for sterilisation.  The YPD media 
was stored at 4 °C and melted in the microwave prior to use. 
 
Reagent: Amount: 
• Yeast extract (Cat #Y1625-250G, Sigma Aldrich)  2.5 g 
• Peptone (Cat #104808, MP Biomedicals) 5 g 
• Nutrient agar (Cat #091007617, MP Biomedicals) 1.5% (w/v) 
 
A glucose solution (20 % (w/v)) was prepared for later addition to the YPD media to serve as 
a carbon/energy source for the yeast. The glucose solution was prepared separately from the 
YPD media to avoid denaturing the glucose in the process of autoclaving. The glucose powder 
was dissolved in distilled water then filter sterilised using a 0.2 μm filter syringe (Ahlstrom 
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ReliaPrepTM, Cat #71578103). The glucose solutions were stored in 50 mL falcon tubes at room 
temperature until required. 
 
Double drop out leu-ura media (DOB-leu-ura) 
 
CSM medium lacks two essential components, the leucine (leu) amino acid and the uracil (ura) 
RNA nucleotide. However, the gene encoding one of each are harboured in the AR expression 
and reporter plasmid, respectively. The selective medium ensures that only yeast cells 
expressing both plasmids grow. The DOB medium powder, CSM-leu-ura powder and agar 
were added to 250 mL distilled water (see below for amounts) and then autoclaved prior to 
being poured into agar plates. The agar was omitted when CSM broth was required. CSM 
media was stored at 4 °C. 
 
Reagent: Amount: 
• DOB medium powder (Cat #4025-012, MP Biomedicals)  6.75 g 
• CSM-leu-ura (Cat #4520-212, MP Biomedicals) 0.1675 g 





• Na2HPO4.7H2O (Cat #191441, MP Biomedicals) (60 mM) 16.1 g 
• NaH2PO4.H2O (Cat #191442, MP Biomedicals) (40 mM) 5.5 g 
• KCl (Cat #1049360500, Merck Millipore) (10 mM) 0.75 g 
• MgSO4.7H2O (Cat #0210223001 - 1 lb, MP Biomedicals) (1 mM) 0.246 g 
• b-mercaptoethanol (Cat #444203, Merck Millipore) (50 mM) 2.7 mL 
 




ONPG is the substrate for the b-galactosidase enzyme, which is produced during the bioassay 
procedure when the ARE on the reporter plasmid is activated by AR. Upon cleavage by b-
galactosidase, ONPG is converted to galactose and ortho-nitrophenol, the latter forming a 
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yellow coloured product, which is measured by absorbance at 420 nm. ONPG was dissolved 
in 10 mL of 100 mM phosphate buffer (see list below for amounts). Aliquots stored in -20°C 
freezer and warmed to 30°C prior to use. 
 
Reagent: Amount: 
• 2-Nitrophenyl b-D-galactopyranoside (ONPG) (Cat #N1127-1G, 
Sigma Aldrich) 
4 mg/mL 
• Phosphate buffer:  
o Na2HPO4.7H2O (Cat #191441, MP Biomedicals) (60 mM) 16.1 g/L 




Glycerol stocks of yeast were made by mixing 1 mL of yeast culture (grown in selective DOB 
medium) with 0.5 mL glycerol (80% v/v) in 2 mL Cyro.STM vials (Cat #126280, Greiner Bio-
One) and stored at -80°C. 
 
Reagent: Volume: 
• DOB-leu-ura yeast culture 1 mL 
• Glycerol anhydrous (Cat #56-81-5, AppliChem) 0.5 mL 
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2.3.2 Culturing yeast 
 
YPD agar plate 
 
YPD media melted in the microwave was left to cool prior to the addition of 20% glucose (w/v) 
solution to create a YPD media with 2% glucose (v/v). Next, 25 mL of the 2% glucose 
containing-YPD media was poured into 100 mm agar plates and left to cool and solidify. S. 
cerevisiae-(AR, ARE-lacZ reporter) frozen in glycerol, was streaked onto the YPD agar plate. 
Yeast cells were incubated at 30 °C for 48 – 72 hours until yeast colonies were clearly visible. 
The plates were stored at 4 °C for up to 2 weeks, following IBSC guidelines (ethics number 
201858).  
 
CSM agar plate 
 
The CSM-leu-ura agar media containing agar was melted in the microwave and poured into 
100 mm agar plates and left to solidify at room temperature. Once set, an isolated colony 
from the YPD agar plate was streaked onto the CSM-leu-ura plate and placed in the 30 °C 
incubator for 48 – 72 hours. Once pink yeast colonies were 1-2 mm in diameter, plates were 
stored at 4 °C for up to 2 weeks.  
 
CSM yeast culture 
 
CSM-leu-ura media (non-agar) was pipetted into a conical flask (40 mL) and inoculated with a 
single isolated colony from the CSM-ura-leu agar plate. The culture was incubated at 30 °C on 
an orbital shaker at 300 rpm for 18 – 20 hours.  
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2.3.3 Yeast-AR bioassay 
 
Measuring OD600 of yeast broth 
 
Using a spectrophotometer (Eppendorf Biophotomaker, Global Science), the optical density 
(OD) of the CSM-leu-ura culture was measured at a wavelength of 600 nm (OD600). Fresh CSM-
leu-ura media served as a blank sample (absorbance 0). If required, the culture was diluted 
using the fresh CSM-leu-ura broth to ensure the OD600 measured between 0.6 - 0.7. CuSO4 
was added to the yeast broth 1% (v/v) to activate transcription of AR from the AR expression 
plasmid (YEpAR (AR cDNA)). Yeast broth was aliquoted into the 24-well plate at a volume of 
500 µL per well. The serum treatment protocol for the Yeast-AR bioassay is described in 
Chapter 3, Section 3.2.3. 
 
Treatment of yeast with testosterone 
 
A stock serial dilution series of testosterone (1:3 serial dilution across 3.78 x 10-5 M to 1.9 x 10-
11-M) was added to individual wells of the 24-well plate. Each stock solution of testosterone 
was treated into the yeast culture in duplicate and was diluted 1:100. To achieve a 1:100 
dilution of testosterone, 5 µL of testosterone was added to 500 µL yeast broth. 
 
Isolation of yeast pellet 
 
The following day the assay was performed. The 24-well plates were placed on ice for 20 
minutes to cease the growth of the yeast cells. The OD600 of each well of each 24-well plate 
was measured using the BioTek®, Synergy 2 plate reader to measure the level of yeast growth 
per well. The yeast cultures in each well were resuspended and homogenised by pipetting the 
culture up and down the pipette tip. Next, 400 µL of yeast culture from each well was 
transferred to a corresponding clean Eppendorf tube. Next, all tubes were centrifuged at 
10,000 rpm for 5 minutes to pellet the yeast cells. The supernatant was then removed and 





Lysis of yeast cells and ONPG addition 
 
The yeast pellet was resuspended in 200 μL of Z-buffer, followed by chloroform (15 μL) and 
sodium dodecyl sulphate (SDS) (0.1% w/v, 7.5 μL) to lyse the yeast cells. The Eppendorf tubes 
containing the suspension were vortexed for 10 seconds and incubated at 30 °C, 300 rpm for 
5 minutes. At time 0, 50 μL of ONPG was added to each tube until the yellow colour change 
had stopped developing (approximately 30 minutes). The reaction was stopped by the 
addition of 125 μL of Na2CO3 to each tube and the time recorded. Next, all tubes were vortexed 
for approximately 5 seconds each. The tubes were left to rest on the bench for 5 minutes while 
the chloroform settled to the bottom of the tube. From each tube, triplicate aliquots (100 µL) 
were transferred to separate wells in a 96-well plate. Absorbance at 420 nm was measured 
for each well on a plate reader (BioTek®, Synergy 2) using Gen5 1.11 software. 
 
Measuring OD420  
 
After measuring absorbance at 420 nm, b-galactosidase activity (Miller units) was calculated 
in Microsoft Excel for Mac 2011 (Version 14.6.1) by inserting the following variables into the 
equation below. The OD420 for each well of the 96-well plate, volume in each Eppendorf tube 
(mL), the time it took for the ONPG reaction to occur (~30 minutes) and the average OD600. 
The results of the equation were transferred to GraphPad Prism (Version 8.0) for further 
analysis. 
 







The six replicate values were imported into Prism in side-by-side sub columns. The Miller units 
were transformed into log format (X=log(X)) and then normalised for the maximal value to be 
set at 100% and the minimal value to be set at 0%. The normalised data was fitted to a non-
linear regression sigmoidal curve. The EC50 value for testosterone was derived from the 
sigmoidal dose response curve. A testosterone standard curve was included with every assay 
performed. The average EC50 value and standard error of the mean (SEM) was calculated for 
testosterone.   
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2.4 Cell Culture of HEK293-AR Cells 
 








• Human AR-puromycin expression plasmid (as described in (Akram et al., 2011)) 
• Enhancer/ARE/SEAP construct (Akram et al., 2011) 
 
Phosphate Buffered Solution (PBS) 
 
PBS buffer 10X Dulbecco’s Powder (Cat #A0965, 9010) was made up to 1 L in distilled water 
for a 1X concentration and filtered for sterilisation. PBS was stored at 4°C and warmed to 37°C 
prior to use. 
 
Dulbecco’s Modified Eagle Medium (DMEM) 
 
HEK293-AR cells were cultured in T75 cm2 flasks with DMEM (Gibco Life Technologies, Cat 
#11995-065) containing high glucose (4500 mg/L), L-glutamine (584 mg/L) and sodium 
pyruvate (110 mg/L) for energy supply and phenol red as a pH indicator, supplemented with: 
• Fetal calf serum (FCS) (Hyclone Fetal bovine serum, GeLifeSciences, Cat #SH30406.02)
          10% (v/v) 
• Penicillin/streptomycin (Cat #15140122, Gibco Life Technologies)  5 mL 
• Puromycin dihydrochloride (2.5 mg/mL stock solution, ThermoFisher Scientific, Cat 








HEK293-AR cells were cultured in 96-well plates for the bioassay procedure with DMEM F12 
media (Gibco, Cat #11039-021). DMEM F12 media contains HEPES and no phenol-red, which 
prevents interference with the read out of the assay since phenol can bind and activate AR. 
DMEM F-12 media was supplemented with: 
• Charcoal-stripped FCS        10% (v/v) 
• Penicillin/streptomycin       100 U/mL 
• Puromycin         1.5 μg/mL 
 
FCS-free DMEM F-12 
 
At the time of treating HEK293-AR cells with serum or plasma, the DMEM F-12 (phenol-red 
free) was aspirated from cells and replaced with FCS-Free DMEM F-12 (phenol red free) and 
the test serum/plasma was added secondary (see Table 3.2 treatments). This media was 
supplemented with: 
• Penicillin/streptomycin       100 U/mL 




Testosterone powder (Sigma-Aldrich, Cat #T1500) weighed out to 2.6 mg was reconstituted in 
1 mL of 100% ethanol in a glass vial for a final concentration of 2.6 mg/mL and stored at -20°C. 
 
2.4.2 Charcoal-stripping FCS 
 
To remove endogenous steroids present in FCS, the FCS was treated with activated charcoal 
(Cat #7440-44-00, Sigma Aldrich) prior to addition to the DMEM F12. The procedure involved 
adding 625 mg of charcoal to 250 mL PBS in five aliquots followed by centrifuging at 2000 rpm 
for 20 minutes. The PBS was discarded and the charcoal pellets were resuspended in a total 
of 50 mL FCS between the five aliquots followed by transferring all five aliquots into a single 
50 mL falcon tube. The charcoal-FCS solution was then warmed to 50 °C in a water bath for 30 
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minutes. The serum was then filtered using a 0.2 µm filter syringe to separate the serum from 
the charcoal.  
 
2.4.3 Passaging of HEK293-AR cells 
 
Stock HEK293-AR cells were retrieved from liquid nitrogen storage and thawed in a 37°C water 
bath. Cells were placed in a T75 cm2 flask with DMEM to sustain cell growth. The cells were 
cultured at 37 C, 5% CO2. Cells were passaged at 80-90% confluency.  
 
To begin the passage procedure, the cell culture media was aspirated and cells were washed 
with 5 mL PBS. Cells were trypsinised to lift the cells from the base of the flask using 5 mL 
TrypLETM Express Enzyme (1X), no phenol-red (GibcoTM, Cat #12604021). For optimal trypsin 
activity, the flask was incubated at 37°C for 5 minutes. To inactivate the enzymatic activity of 
the trypsin and prevent degradation of the cells, 5 mL of DMEM was added to the flask. The 
cell suspension was then transferred to a 50 mL Falcon tube and centrifuged at 3000 rpm for 
5 minutes. The supernatant was aspirated, and the cell pellet was resuspended in 5 mL of 
fresh DMEM. The cells were passaged 1:5 by transferring 1 mL of cell suspension into a clean 
T75 cm2 flask with 12 mL fresh DMEM (containing FCS, 10% (v/v)). Cells were incubated at 
37°C, 5% CO2.   
 
2.4.4 Seeding of HEK293-AR cells 
 
HEK293 cells were seeded at the time of passaging into a clear 96-well plate. HEK293-AR cells 
were seeded at a cell concentration of 2.0 x 105 cells/mL in 200 µL phenol-red free DMEM F12 
supplemented with charcoal stripped FCS, penicillin/streptomycin and puromycin. 
 
2.4.5 Quantification of viable cells using Trypan Blue stain 
 
HEK293-AR cells resuspended in the phenol-red free DMEM were counted and assessed for 
cell viability using Trypan Blue stain (Cat #15250-061, Gibco Life Technologies). To determine 
cell viability, 10 μL of Trypan Blue stain was added to 10 μL of suspended cells. The Trypan 
Blue stain indicates non-viable cells, as the stain is permeable to cells with compromised cell 
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membrane integrity. Therefore, blue-coloured cells were excluded from the cell count. Cells 
were counted using a haemocytometer (Nebauer, Cat #HHH1080340), whereby 10 μL of 
Trypan Blue stained cells were pipetted under the glass coverslip on the haemocytometer. 
The haemocytometer displays four 4x4 grids, which allows the number of cells present to be 
counted (see equation below). Cells were seeded at a concentration of 2.0 x 105 cells/mL into 
clear 96-well plate(s) at a volume of 200 μL/well in phenol-red free DMEM and incubated for 







2.4.6 Freezing HEK293-AR cell stocks 
 
Frozen stocks of HEK293-AR cells were prepared by trypsinising and centrifugation, as 
described above. Supernatant was discarded and the cell pellet was resuspended in 5 mL of 
Recovery Cell Culture Freezing Media (Cat #12648-010, Gibco Life Technologies). Next, 1 mL 
aliquots of cell suspension were transferred to 2 mL Cyro.STM vials (Greiner Bio-One, Cat 
#126280) and then placed in a Mr Frosty Freezing Container for transfer to -80°C for 24 hours. 
After a minimum of 24 hours at -80°C, cell vials were then transferred to liquid nitrogen for 
long-term storage.  
 
2.4.7 Bioassay protocol for HEK293-AR bioassay 
 
2.4.7.1 Testosterone dose response curve 
 
Testosterone stock (2.6 mg/ml) was diluted 1:100 for a final concentration of 90 μM 
testosterone and 1% (v/v) ethanol. To achieve a 1:100 dilution, 3 μL of the testosterone stock 
was added to 300 μL media in duplicate wells of the 96-well plate. To achieve a 1:3 dilution 
series of testosterone, 100 μL from the top two wells was carried down to the next two wells 
below and mixed well by pipetting up and down. This was carried out across 12-17 dilutions. 
Cells were incubated at 37 °C, 5% CO2 for 18 hours. 
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2.4.7.2 HEK293-AR SEAP bioassay 
 
After 18-hours treatment, the SEAP assay was performed. The media was not changed prior 
to the assay since the reporter protein, secreted embryonic alkaline phosphatase (SEAP), is 
secreted out of the cell into the media in the presence of an androgenic compound. To 
perform the assay, media (25 μL) was transferred to corresponding wells in an opaque white 
96-well plate. The plate was warmed in a 65°C water bath for 35 minutes to denature 
endogenously SEAP. Then, the plate was cooled to room temperature prior to the addition of 
50 μL of SEAP substrate reagent (Cat #631737, Clontech) to each well to initiate the 
luminescence reaction. The 96-well plate was placed in the 25°C incubator for 30 minutes and 
covered in tin foil due to the light sensitivity of the luminescent reaction. The opaque white 
96-well plate was inserted into the plate reader (Molecular Devices, Spectra Max i3x) and each 
well measured for read for end point luminescence using SoftMax Pro (version 7.0.2) 
software. 
 
2.4.7.3 EC50 of testosterone 
 
The raw luminescence values obtained from the plate reader data were directly transferred 
to GraphPad Prism (Version 8.0). The duplicate values were imported into side-by-side 
columns and the data was transformed, normalised and fitted to a non-linear regression 
sigmoidal curve. The raw luminescence values were transformed into log format (X=Log(X)) 
and then the smallest value in the data set was normalised to 0% and the largest value was 
normalised to 100%. The log-transformed and normalised data was fit to a non-linear 
regression sigmoidal dose response curve. The EC50 value for testosterone was derived from 
the sigmoidal curve generated for each dose response curve. The average EC50 value and SEM 






2.4.7.4 Calculating a ratio of luminescence to maximal testosterone induction for 
serum samples  
 
The raw luminescence values obtained from serum samples were averaged across the 
technical replicates within each experiment. The luminescence values induced by the serum 
and plasma samples were then divided by the luminescence induced by the average of the 
top three points of the testosterone dose response curve for each assay performed by 







The values of the ratio induced by each serum/plasma samples are expressed as a percentage 
of maximal assay activation. See Figure 2.2 (page 70) for a visual representation of the 
calculation. The ratios for each independent experiment were imported into a column table 





Figure 2.2: Visual representation on calculation of serum bioactivity as a ratio to maximal bioassay activation. 
 
All serum and plasma AR- and ER bioactivity is reported as a ratio of maximal assay activation. The maximal level of assay activation is calculated 
from the testosterone or E2 dose response curve. The luminescence from the top three points of the dose response curve is averaged and this 
provides a level of 100% assay activation. To derive a ratio, the luminescence induced by the serum sample is divided by the luminescence induced 
by the maximal luminescence of the dose response curve.  
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2.4.7.5 Statistical analyses of the HEK293-AR bioassay 
 
To determine differences in AR bioactivity between treatments within an experiment, an 
ordinary- or repeated measures one-way ANOVA followed by multiple comparisons post-hoc 
was carried out using GraphPad Prism (version 8.0). A one-way ANOVA was chosen to 
determine statistically significant differences between two variables (i.e. heated serum 
compared with non-heated serum or before chemotherapy compared with after 
chemotherapy). Furthermore, a repeated measures one-way ANOVA was chosen when serum 
or plasma was measured from different time points along a protocol or following an 
intervention. An ordinary one-way ANOVA was chosen when comparing between 
independent variables. The multiple comparisons post-hoc tests were corrected for using a 
Sidaks’ test (strong statistical power). For determining intra-patient changes in serum 
bioactivity where only a single comparison was tested, multiple comparisons were not 
corrected for using (Fishers LSD test). This is because the biological variation from each patient 
is high, whereas, for samples that were derived from the same origin (i.e. same batch of FCS), 
the multiple comparisons were corrected for. When only two conditions were included in the 
experiment (i.e. comparing the treatment time of 24- and 48-hours), a paired- or unpaired t-
test was carried out to determine if there was a statistically significant difference. 
 
2.4.7.6. Serum and plasma samples 
 
Throughout this thesis, both plasma and serum samples were tested in the HEK293-AR 
(Chapters 3.0 and 5.0) and T47D-ER (Chapters 4.0 and 5.0) bioassays. The only component 
that differs between serum and plasma is fibrinogen in plasma (clotting factor). There have 
been no studies that directly compare serum and plasma bioactivity and from experience with 
testing serum and plasma there is no appreciable difference. Equine plasma samples and the 
pre- and post-chemotherapy breast cancer plasma samples were provided to our lab, meaning 
there was no choice between serum and plasma. For the aromatase inhibitor breast cancer 
study (Chapter 5.0), serum was specifically chosen. This is because it became evident that 
there is a matrix interfering effect occurring in the HEK293-AR and T47D-ER bioassays. 
Therefore, it is preferable to have less components in the matrix, hence why serum was 
chosen under this circumstance over plasma.  
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2.5 Cell Culture of T47D-ER Cells 
 




• Estrogen Receptor Luciferase Reporter Ductal Epithelial Breast Carcinoma (T47D) 




ERE-Luciferase (Signosis, Cat #SL-0002) 
 
Phosphate Buffered Solution (PBS) 
 
PBS buffer 10X Dulbecco’s Powder (Cat #A0965, 9010) was made up to 1 L in distilled water 
(1X concentration) and filtered for sterilisation. PBS was stored at 4°C and warmed to 37°C 
prior to use. 
 
Rosewell Park Memorial Institute Medium 1640 (RPMI 1640) 
 
T47D-ER cells were cultured in RPMI 1640 (1X) (Gibco, Cat #11875-093) containing L-
glutamine, phenol red supplemented with: 
• FCS           10% (v/v) 
• Geneticin (G418) (50 mg/mL stock solution, ThermoFisher Scientific, Cat #10131027)






DMEM F-12 media was used to culture T47D-ER cells seeded into a 96-well plate for the ER-
bioassay. DMEM F-12 media contains HEPES and no phenol-red to prevent interference with 
the read out of the assay since phenol can bind and activate ER. DMEM F-12 media was 
supplemented with: 
• Charcoal-stripped FCS       10% (v/v) 
• G418         75 µg/mL 
 
FCS-Free DMEM F-12 
 
At the time of treating T47D-ER cells with serum or plasma, the DMEM F-12 (phenol-red free) 
was removed from cells and replaced with FCS-Free DMEM F-12 (phenol red free) and the test 
serum/plasma was added secondary (see section 1.6.5 for treatments). This media was 




17b-estradiol powder (Calibochem, Cat #3301-1GM) was weighed out to 2.1 mg. The powder 
was reconstituted in 1 mL of 100% ethanol in a glass vial for a final concentration of 2.1 mg/mL 
and stored at -20°C. 
 
2.5.2 Charcoal-stripping FCS 
 
The charcoal stripped FCS used to supplement the DMEM F12 media followed the same 
protocol as section 2.4.2. 
 
2.5.3 Passaging of T47D-ER cells 
 
The passage procedure for T47D-ER cells followed the same protocol as section 2.4.3, except 
cells were passaged at a ratio of 1:2. 
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2.5.4 Freezing T47D-ER cell stocks 
 




2.6 Cell Culture of HeLa cells 
 




Henrietta Lacks (HeLa) cells (human cervical adenocarcinoma, ATCC, Cat #ATCCRMCCL) 
 
Phosphate Buffered Solution (PBS) 
 
PBS buffer 10X Dulbecco’s Powder (Cat #A0965, 9010) was made up to 1 L in distilled water 
(1X concentration) and filtered for sterilisation. PBS was stored at 4°C and warmed to 37°C 
prior to use. 
 
Dulbecco’s Modified Eagle Medium (DMEM) 
 
HeLa cells were cultured in DMEM (Gibco Life Technologies, Cat #11995-065) containing high 
glucose (4500 mg/L), L-glutamine (584 mg/L) and sodium pyruvate (110 mg/L) for energy 
supply and phenol red as a pH indicator, supplemented with 10% (v/v) FCS (Cat #10091155, 
Gibco Life Technologies). 
 
2.6.2 Passaging of HeLa cells 
 
Stock HeLa cells were retrieved from liquid nitrogen storage and thawed in a 37°C water bath. 
The passage procedure for T47D-ER cells followed the same protocol as section 2.4.3 
 
2.6.3 Freezing HeLa cell stocks 
 
The cell freezing procedure for HeLa cells followed the same protocol as section 2.4.6. 
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2.7 Enzyme-linked immunosorbent assays (ELISAs) 
 
2.7.1 Testosterone ELISA kit 
 
The testosterone concentration of serum and plasma samples measured throughout this 
thesis were derived using an ELISA (abcam, Cat #ab108666). Kit instructions were followed 
to measure the testosterone concentration, reported as ng/mL. 
 
2.7.2 17b-Estradiol ELISA kit 
 
The E2 concentration of serum and plasma samples measured throughout this thesis were 
derived using an ELISA (abcam, Cat #ab108667). Kit instructions were followed to measure 




3.0 Towards optimising HEK293-AR 






Cell-based AR-RGBs have been utilised in a range of research applications, including sports 
doping (Houtman et al., 2009), environmental sampling (Luccio-Camelo & Prins, 2011) and 
clinical evaluation of endocrine states or disease (Raivio et al., 2001; Roy et al., 2006). Despite 
their established utility in laboratory-based research, they have not emerged as a routine 
clinical tool. For diagnosing patients with endocrine-related disorders such as hypogonadism 
in males and PCOS in females, it is important to measure the concentration of testosterone in 
blood samples. ELISAs, RIA and GC- and LC/MS are current standard methods for measuring 
absolute testosterone concentrations, the most abundant endogenous androgen. Direct 
immunoassays are used for clinical assessment but they are not very sensitive and lack 
specificity (Stanczyk et al., 2003). GC- and LC/MS are exquisitely sensitive approaches for 
measuring low testosterone concentrations present in children and females (Moal et al., 
2007), however, they are not commonly used since they are expensive and time consuming 
compared with direct immunoassay. Both of these approaches are specific and target only 
testosterone, meaning that other androgenic molecules, either endogenous or exogenous, go 
undetected. Therefore, there may be a place for AR bioassays in routine screening of serum 
and plasma since the net AR bioactivity of serum is unlikely to be solely represented by 
testosterone. AR bioassays could be performed alongside current clinical measures of 
testosterone to help with diagnosis and prognosis of endocrine diseases such as prostate- and 




3.1.1 Mechanism of the HEK293-AR bioassay 
 
Classical AR cell signaling has been exploited in AR-RGBs to provide a measure of AR activation 
by a test sample. Briefly, AR cell signaling is initiated when an androgenic molecule binds to 
an AR located in the cytosol to form a dimeric complex. The dimeric ARs then translocate to 
the nucleus where they operate as transcription factors to initiate gene transcription of 
androgen response genes by binding to promoter regions of the DNA called AREs (for full AR 
cell signalling mechanism refer back to chapter 1.3.3.1).  
 
To generate an AR-RGB, a cell line is transfected with both an AR expression- and reporter 
plasmid with an ARE upstream of a reporter gene. To induce the expression of the reporter 
protein, cells are treated with an androgenic molecule and the recombinant ARs generated 
from the expression plasmid will dimerise and translocate to the nucleus. In the nucleus, ARs 
bind to AREs on the reporter plasmid. Upon binding to the ARE, there is a significant increase 
in reporter gene transcription and subsequent translation into the reporter protein. Levels of 
the reporter protein are measured to determine relative level of AR activation. Luciferase, 
green fluorescent protein (GFP), secreted embryonic alkaline phosphatase (SEAP) and b-
galactosidase are common reporter proteins (Bovee et al., 2007; Akram et al., 2011), with the 
level of luminescence, fluorescence and absorbance measured, respectively. This biological 
approach for testing androgenicity does not require prior knowledge of the molecular 
structure(s) in the test samples allowing androgenic molecules other than testosterone to be 
detected. The main AR bioassay mechanism employed in this study is hosted in HEK293 cells 






Figure 3.1 Mechanism of the HEK293-AR bioassay 
 
(1) The AR is generated by the AR expression plasmid (driven by a strong promoter) to 
induce high AR expression levels in the HEK293 cell. (2) Upon treatment with an androgenic 
molecule, the androgen will enter the cell and bind to an AR. (3) ARs are activated and 
dimerise to form a transcription factor, which (4) binds to the ARE on the reporter plasmid 
(5) to significantly increase gene transcription and translation of the reporter protein, SEAP, 
which is secreted out of the cell into the media. (6) at the time of the bioassay, the SEAP 
substrate is added to a portion of media (which contains the secreted SEAP) (7) to initiate 




3.1.2 Differences between yeast- and mammalian cell-based RGBs 
 
Yeast- and mammalian cell lines have both been utilised as host cell lines for AR-RGBs in 
research settings. However, yeast- and mammalian cells are fundamentally different with 
regards to physiology and structure, which influences their responsiveness when utilised as a 
RGB. Both yeast- and mammalian cells each have their own advantages and disadvantages, 




At present, yeast cell-based RGBs are considered the “gold standard” in both ER- and AR cell 
bioassay measurement (Coldham et al., 1997; Dhooge et al., 2006; Nielen et al., 2006). Yeast 
cells have a thick cell wall, which mammalian cells do not have. The cell wall renders yeast 
cells more resilient in a range of matrices (Graumann et al., 1999; Klis et al., 2002) including 
water sample and environmental extracts (Rehmann et al., 1999; Witters et al., 2001; 
Michelini et al., 2005). Yeast cells do not express endogenous steroid hormone receptors, 
cofactor proteins, steroid hormone metabolising enzymes and endogenous steroid hormone 
receptors. Therefore, the lack interfering factors simplifies the cellular physiology of yeast 
cells, therefore the assay is highly specific to the test substance (Graumann et al., 1999). The 
low metabolic capacity of yeast cells allows for the intrinsic bioactivity of the compound to be 
measured without breakdown or conversion by metabolising enzymes.  
 
Although highly specific, lack of metabolising enzymes in yeast cells also limits the ability of 
the assay to detect pro-androgens. A pro-androgen does not intrinsically possess androgenic 
activity as the parent structure requires metabolism to convert the molecule into an androgen 
(Cooper et al., 2018). The ability to detect pro-androgens can help to predict how the molecule 
may behave in vivo, following first-pass hepatic metabolism. A liver cell line, such as HuH7, 
can be used to directly detect the pro-androgenic potential of a test substance due to the 
expression of steroid hormone metabolising enzymes such as 3a-, 3b-, 17b-HSD and 5a-
reductase (Akram et al., 2011). Although yeast cells cannot directly detect pro-androgens, a 
test substance can be combined with S9 (liver extract) to simulate hepatic metabolism prior 
to treatment upon the yeast cells. Following S9 extraction, the yeast cells can measure the 
bioactivity of the liver extract product and via this protocol, pro-androgens can be detected. 
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Yeast cells have a low cost of handling and maintaining since an aseptic environment is not 
required. Furthermore, glassware can be reused and making media is affordable. In contrast, 
the culturing of mammalian cells is expensive since a specialized tissue culture facility with a 
biological safety cabinet is required. The materials and medias are expensive compared with 




Unlike yeast cells, mammalian cells do express cofactor proteins, steroid hormone receptors 
and steroid hormone metabolising enzymes (Hoogenboom et al., 2001), which can increase 
sensitivity of the assay (Akram et al., 2011) at the potential expense of specificity (Cooper et 
al., 2013). The expression of cofactor proteins, such as MAGE-11 and SRC-1/CBP bind to AF-2 
of AR assist in enhancing and modulating the level of AR transcriptional activity in a ligand-
dependent context (Shang et al., 2000; Shang et al., 2002; Askew et al., 2007). Therefore, the 
expression of cofactor proteins in mammalian cells increases the sensitivity to allow for 
androgenic molecules present at low concentrations to have a greater chance of being 
detected.  
 
GR and PR can cross react with the ARE due to the high level of homology with the DBD of AR 
and the DNA sequences of the response elements (Cato et al., 1987; Gao et al., 2005). 
Therefore, endogenous expression of steroid hormone receptors can overestimate the 
bioactivity of a test sample since other steroid hormone receptors could be activated and 
cross react with the ARE to drive expression of the reporter protein. Therefore, it is important 
to choose a mammalian cell line with low levels of endogenous steroid hormone receptors to 
ensure the readout is specific to AR activation.  
 
Despite the biology of the yeast cell presenting as a good model to measure AR bioactivity, in 
a review by Cooper et al. (2013) it was shown that mammalian cell AR bioassays are more 
sensitive compared with yeast cell-based bioassays, evidenced by a lower EC50 for 
testosterone. Overall, in the design or choice of an AR bioassay, mammalian- and yeast cells 
have different advantages and disadvantages that must be considered. By understanding the 
physiological parameters of the host cell that can interfere with the assay, the interpretation 
of the assay can be better understood. Since the aim of this chapter is to optimise an AR 
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bioassay for clinical evaluation both yeast- and mammalian cell lines were used to determine 
which would be best suited for serum and plasma measurement.  
 
Table 3.1: Comparison of the advantages and disadvantages of the yeast- 
and mammalian cell-based bioassays. 
 Advantages Disadvantages 
Yeast cells 
• Highly specific 
 
• No steroid metabolising 
enzymes 
 
• Only determines 
bioactivity of parent 
structure 
 
• No endogenous steroid 
hormone receptors, highly 
specific, no cross talk 
 
• More resilient to toxic 
substances or different 
matrices due to cell wall 
• Lower sensitivity than 
mammalian cells 
 
• Lower sensitivity 
 
• Do not express cofactor 
proteins 
 
• Cell wall can limit the 
uptake of some 
substances 
 
• More time consuming 





• Increased sensitivity 
compared with yeast cell 
bioassay 
 
• Express cofactor proteins, 
which may improve 
sensitivity 
 
• Can use a liver cell line to 
detect pro-androgens 
 
• Improved ability to take up 
non-steroidal compounds 





• Lower specificity due to 
the cross reactivity that 





• Cannot easily determine 
if bioactivity is parent 
structure or metabolite 




• Expensive to maintain 
relative to yeast cells 
 
• Sensitive to different 
matrices relative to yeast 
 
• Require cell biology 
experienced personnel to 
perform assay 
 84 
3.1.3 Previous applications of AR-RGBs 
 
Environmental sampling is a common application for AR-RGBs (reviewed by (Sonnenschein & 
Soto, 1998; Sultan et al., 2001b; Luccio-Camelo & Prins, 2011)). Steroid extracts from bottled 
water (Wagner et al., 2013) and waste water effluents downstream of a hospital, sewage 
treatment plants and industrial plants (Van Der Linden et al., 2008) have tested positive for 
anti-androgenic and androgenic bioactivity. Furthermore, pure androgenic steroids, phenols, 
plasticisers, such as bisphenol A (BPA), have been shown to possess AR bioactivity (Satoh et 
al., 2001; Krüger et al., 2008). Therefore, due to the endocrine disruptive effects of exogenous 
androgens or anti-androgens, AR-RGBs are utilised for measuring AR bioactivity of a wide 
variety and origins of samples.  
 
Anabolic androgenic steroids are the most commonly abused performance enhancing drug 
due to their ability to increase skeletal muscle hypertrophy (Griggs et al., 1989; Sinha-Hikim 
et al., 2002; Sinha-Hikim et al., 2003), bone mass density (Snyder et al., 1999) and erythrocyte 
cell production (Moriyama & Fisher, 1975; Coviello et al., 2008). As a tactic to bypass screening 
efforts, such as GC/MS, novel androgenic compounds are created. However, a bioassay can 
screen suspect samples to determine if an androgen is present without prior knowledge of 
the structure of the novel androgenic molecule. As a result, AR-RGBs have also been utilised 
in the context of sports doping to identify novel androgenic compounds found in used 
syringes, sports supplements (Death et al., 2004; Akram et al., 2011; Cooper et al., 2018) and 
for screening urine samples (Houtman et al., 2009). 
 
AR-RGBs have also been used to measure serum and plasma AR bioactivity for clinical 
applications. AR bioactivity has been shown to associate well with direct measures of 
testosterone, in both health and disease (Raivio et al., 2001; Roy et al., 2006). Serum AR 
bioactivity has been shown to correlate with phenotype in post-natal (Raivio et al., 2003) and 
pubertal stages in healthy boys and girls (Paris et al., 2002a). AR-RGBs are also effective for 
detecting increased AR bioactivity in PCOS females (Chen et al., 2006a; Roy et al., 2006), 
monitoring the effect of androgen replacement treatment in elderly men (Raivio et al., 2002) 
and determining the effectiveness of anti-androgen treatment in children with congenital 
adrenal hyperplasia (Hero et al., 2005), a condition of hyperandrogenism. The RGB approach 
is currently limited to research but has clinically relevant applications. The main advantage in 
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applying AR-RGBs to environmental sampling, sports doping and clinically-focussed research 
is the identification of androgens in a sample without probing for specific molecular 
structure(s) in the test sample.  
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3.1.4 The controversy surrounding androgens, the androgen receptor 
and breast cancer 
 
In this study, we aimed to redirect the purpose of this assay for clinical assessment by 
measuring the AR bioactivity of breast cancer patient plasma before- and after chemotherapy 
to determine if AR bioactivity has potential to serve as an important clinical measure. The role 
of androgens in the risk and pathogenesis of breast cancer remains controversial. 
Epidemiological studies have shown that high systemic testosterone levels are a risk factor for 
pre- and post-menopausal ER+ breast cancer (Dorgan et al., 1996; Missmer et al., 2004; 
Cummings et al., 2005; Kaaks et al., 2005). However, it has also been shown that this risk 
association between high androgens and breast cancer does not exist (Van Staa & Sprafka, 
2009). As discussed below, it remains unclear and controversial as to whether androgens 
promote or inhibit proliferation of ER+ breast cancer cell lines (for example, MCF-7 and T47D).  
 
Potent androgens such as testosterone and DHT and weaker adrenal androgens such as DHEA 
and androstenedione have been implicated in promoting breast cancer cell proliferation 
through direct interaction with ERa/b (Maggiolini et al., 1999; Miller et al., 2013). The 
aromatisation of testosterone and adrenal androgens into estrogenic metabolites could be 
responsible for activating ERa-mediated cell proliferation (Sonne-Hansen & Lykkesfeldt, 
2005). However, DHT, has been shown to activate ERa and mediate breast cancer cell 
proliferation (Zava & McGuire, 1978; Sonne-Hansen & Lykkesfeldt, 2005). Under estrogen-
deprived conditions, DHT can be converted by 3b-HSD into a weak estrogenic by-product, 
called 5a-androstane-3b,17bdiol (3bAdiol), which can directly activate ERa-mediated gene 
transcription and cell proliferation (Sikora et al., 2009).  
 
Although androgens have been shown to promote ER+ breast cancer cell proliferation, other 
studies have shown that androgens inhibit proliferation of breast cancer cell lines in an AR-
dependent manner and are therefore protective against tumourogenesis (Poulin et al., 1988; 
Szelei et al., 1997; Ando et al., 2002; Ortmann et al., 2002; Macedo et al., 2006). The effect of 
androgens on breast cancer cell proliferation appears to be cell-dependent. DHT was capable 
of inhibiting cell proliferation of T47D cells but stimulated cell proliferation of MCF-7 cells. 
Both of these effects were reversed by hydroxyflutamide, an AR antagonist, suggesting an AR-
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dependent mechanism for the effects of androgens on cell proliferation (Birrell et al., 1995). 
Although it remains unclear whether androgens are protective or adverse for breast cancer, 
research suggests that androgens are capable of interfering with breast cancer cell 
proliferation such that net androgenicity of patient serum may provide insightful information 
for breast cancer patient monitoring. 
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3.1.5 Rationales, aims and hypotheses 
 
Rationale 1: Determining if a yeast- or mammalian cell line is more appropriate for 
serum and plasma AR bioactivity measurement 
 
Serum is the cell free- (erythrocytes and leukocytes), anti-clotting factor-free portion of blood 
and comprises approximately 55% of total blood volume. Electrolytes, antigens, antibodies, 
hormones, lipids, minerals, vitamins, proteins and exogenous substances are carried in serum. 
Plasma contains all these factors and fibrinogen, a protein involved in clotting and delineates 
plasma from serum. Due to the hydrophobic nature of steroid hormones, the majority of 
steroid hormones are buffered in the aqueous phase of serum and plasma through binding to 
serum proteins; albumin and SHBG. Serum and plasma is a complicated matrix for testing due 
to the mixture of all these factors. For AR-RGBs to have clinical relevance, AR bioactivity of 
serum and plasma needs to be measured with high sensitivity and accuracy. Based on the 
fundamental differences in yeast- and mammalian cell physiology, the first part of this chapter 





To compare AR-RGBs hosted in a yeast (S.cerevisiae) and a mammalian cell line (HEK293) for 




Mammalian cells are more sensitive due to cofactor expression but lack specificity due to the 
expression of steroid hormone receptors and metabolising enzymes. Therefore, due to the 
lack of interfering factors, it is expected that the yeast-AR bioassay will be better suited for 
serum measurement.  
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Rationale 2: Screening horse plasma samples for AR bioactivity 
 
Following optimisation of the mammalian AR bioassay for plasma measurement, a large 
number of equine plasma samples (n=99) were provided to the Heather laboratory to assess 
AR bioactivity. This provided an opportunity to test the efficacy of the AR bioassay for equine 
plasma measurement. In the sports doping arena, it has never been investigated as to whether 
high AR bioactivity could serve to highlight suspect plasma samples for further investigation. 
In this study, 99 plasma samples from thoroughbred racehorses on race day were collected 




The initial aim of was to test if AR bioactivity could be measured for all samples. A sub aim was 
to determine if sex differences were measurable between mares and colts and/or a difference 




It is expected that geldings and mares will have low AR bioactivity relative to colts, because 
both groups lack testicular androgen generation. 
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Rationale 3: Breast cancer application of AR bioassay 
 
The AR bioassay was next utilised in a clinical setting to measure the AR bioactivity of breast 
cancer patient plasma (n=9) before- and after chemotherapy. Androgens are reported to both 
positively and negatively affect breast cancer processes; therefore, it may be that monitoring 
AR bioactivity could have clinical meaning. Before such decisions are made, it is first necessary 
to determine if the AR bioassay could detect AR bioactivity in all breast cancer patients. For 
this first study, samples from pre-/peri- and post-menopausal females (aged 43 – 68) were 
tested because there is an expected range of different endogenous circulating sex steroid 
levels. Ultimately, the AR bioassay needs to measure exclusively low levels in post-
menopausal females (Chapter 5.0). However, the first step was to use the assay in this study 





To determine if AR bioactivity of breast cancer patient plasma (9 patients) samples before- 











The general tissue culture protocol and statistical analysis is described in the General Methods 
chapter (Chapter 2.0, Section 2.4) 
 
3.2.1 Treatment protocols for the HEK293-AR Bioassay 
 
Table 3.2 (page 95) provides a summary of the different serum and plasma treatment 
conditions tested on the HEK293-AR bioassay (treatments A-I). A standard testosterone dose-
response curve was carried out for each independent experiment (for a full method see 
Chapter 2.0, Section 2.4.7). The HEK293-AR SEAP bioassay was carried out after 18 hours 
incubation with the test sample(s) as per the instructions in General Methods (Chapter 2.0, 
Section 2.4.7). 
 
3.2.1.1 Testosterone-spiked serum treatment protocol (treatment A and B) 
 
Charcoal-stripped FCS (see protocol in Chapter 2.0, Section 2.4.2, except the final heat 
treatment of the charcoal-serum was carried out at 37°C (not 55°C) for this experiment) spiked 
with testosterone underwent heat treatment to denature serum proteins and increase the 
bioavailable pool of androgens. In duplicate, 9 µL of six concentrations of testosterone (0.5, 
1.5, 4.5, 13 and 45 nM) and 100% ethanol (vehicle control) were spiked into 180 µL of 
charcoal-stripped FCS. Each tube of testosterone-spiked FCS allowed enough volume for 4 
technical replicates of 40 µL per well to be tested with the HEK293-AR cells with an additional 
12.5% for pipetting error. This ensures that the final ethanol concentration is at 1% (v/v) and 
the final serum concentration is 20% (v/v). One duplicate pair for each concentration of 
testosterone-spiked FCS was incubated for 30 minutes at 37°C to allow for the serum proteins 
to bind testosterone, then another 15 minutes to control for the heat-treated sample. The 
other duplicate pair for each testosterone dilution was incubated at 37°C for 15 minutes to 
allow for the serum proteins to bind the steroid, followed by 15 min incubation at 75°C to heat 
denature the serum proteins to increase the bioavailable fraction of testosterone. At the time 
of treating the HEK293-AR cells, the media was replaced with 160 µL of F12 DMEM (no FCS, 
supplemented with puromycin and penicillin/streptomycin) and then 40 µL of heated and 
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non-heated testosterone-spiked FCS was added to the fresh media. Experiments were 
repeated across 8 independent experiments (days). 
 
3.2.1.2 Male- and female serum treatment protocol (treatment C) 
 
Male- (single donor human serum, 50 mL, male aged 23 years, Innovative Research, Lot # 88 
30766C) and female serum (single donor human serum, 50 mL, female aged 25 years, 
Innovative Research, Lot #88 32700A) were tested using the HEK293-AR cells at 5%, 10%, 15% 
and 20% (v/v) final concentration, in quadruplicate. The media was replaced with DMEM F12 
(no FCS, supplemented with puromycin and penicillin/streptomycin) and the serum was 
added to each well containing fresh media. The volume of media was made up to 200 μL to 
cater for the serum concentration required (i.e. for a final concentration of 5% serum, 10 μL 
serum was added to 190 μL media). Experiments were repeated across 5 independent 
experiments (days). 
 
3.2.1.3 Heat treatment of human male and female serum (treatment D) 
 
Due to issues with small volumes of human serum coagulating when heated at 75°C for 15 
minutes, 1 mL of male and female serum was heated to 65°C for 30 minutes. Heated male and 
female serum was tested with the HEK293-AR bioassay in 5%, 10%, 15% and 20% 
concentrations, in quadruplicate. The media was replaced with DMEM 12 (no FCS, 
supplemented with puromycin and penicillin/streptomycin) and the heated serum was then 
added to each well. The volume of media was made up to 200 μL to cater for the serum 
concentration required. HEK293-AR cells were incubated at 37°C, 5% CO2 for 18 hours. 
Experiments were repeated across 5 independent experiments (days). 
 
3.2.1.4 Testosterone-spiked dose response curves of low androgen serum/plasma 
(treatments E, F and G) 
 
Charcoal-stripped FCS, gelding plasma and female serum were spiked with a serial dilution 
series of testosterone. To create a testosterone-spiked serum dilution series for a final 
concentration of 20% (v/v) serum, 11 aliquots of 180 μL of serum/plasma was added to 1.7 
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mL Eppendorf tubes. Next, 9 μL of 1:3 serially diluted testosterone stock solutions (3.7 x 10-7 
M to 6.3 x 10-12 M), were added to each tube of serum. As with treatment A and B, these 
volumes allowed for 4 technical replicates and 12.5% extra for pipetting error. Next, 40 μL of 
serum was added to each well containing 160 μL DMEM F12 (no FCS, supplemented with 
puromycin and penicillin/streptomycin) for a final serum concentration of 20% (v/v). 
 
To create a testosterone-spiked serum dilution series for a final concentration of 10% (v/v) 
serum, 11 aliquots of 90 μL of serum was added to 1.7 mL Eppendorf tubes. Next, 9 μL of 1:3 
serially diluted testosterone stock solutions (3.7 x 10-7 M to 6.3 x 10-12 M), were added to each 
tube of serum. This volume of serum allowed for 4 technical replicates and 12.5% extra for 
pipetting error. Next, 20 μL of serum was added to each well containing 180 μL DMEM F12 
(no FCS, supplemented with puromycin and penicillin/streptomycin). Experiments were 
repeated across 4 independent experiments (days). 
 
3.2.1.5 Thoroughbred racehorse plasma (treatment H) 
 
Gelding (n=66), mare (n=24) and colt (n=9) racehorse plasma samples were obtained on race 
day by Dr Adam Cawley (Australian Racing Forensic Laboratory). The samples were 
subsequently provided to the Heather laboratory for screening AR bioactivity. HEK293-AR cells 
were treated with plasma samples for a final concentration of 15% (v/v). To create a 15% (v/v) 
final concentration, 30 μL plasma was added to 170 μL of DMEM F12 (no FCS, supplemented 
with puromycin and penicillin/streptomycin).  
 
Gelding and mare samples were tested in duplicate across 1-5 independent experiments 
(days) and all colt samples were tested across 3-5 independent experiments (days). 
 
3.2.1.6 Breast cancer patient plasma (treatment I) 
 
Plasma samples from pre-, peri and post-menopausal breast cancer patients (n=9), before- 
and after chemotherapy. The breast cancer patient plasma was received as part of a clinical 
study based in Christchurch called Exploring the Effects of Obesity-Related Inflammation and 
Exercise on Drug Metabolism in Cancer Patients. HEK293-AR cells were treated with patient 
plasma for a final concentration of 15% (v/v). To create a 15% (v/v) final concentration, 30 μL 
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plasma was added to 170 μL of DMEM F12 (no FCS, supplemented with puromycin and 
penicillin/streptomycin). All plasma samples were tested in duplicate across 3 independent 
experiments (days). Experiments were repeated across 3 independent experiments (days). 
 
3.2.2 Statistical analysis 
 
The luminescence values from testosterone-spiked serum/plasma samples (treatment A, B, E-
I) were normalised to ethanol-spiked FCS. All serum and plasma AR bioactivity measures 
(luminescence values) are expressed as a ratio to maximal testosterone. The method of 
analysis is described in General Methods (Chapter 2.0, Section 2.4.7, Figure 2.2). 
 
The protocol to create a testosterone dose response curve and EC50 value is described in 
General Methods (Chapter 2, Section 2.4.7, Figure 2.2). 
 
GraphPad Prism Version 8.0 was used to analyse raw luminescence data and create the 
graphs. To determine differences between heated and non-heated serum, a Students 
unpaired t-test was used and a statistically significant difference is a p value of less than 0.05. 
To determine sex differences between the AR bioactivity of geldings, mare and colt samples, 




Table 3.2: Overview of different serum treatments prior to testing with the HEK293-AR bioassay. 
Treatment Serum Treatment of serum Control Percentage serum (v/v) Number of experiments (days) completed 
A Charcoal-stripped FCS 
Testosterone spiked 
(41.2 nM – 0.51 nM) Ethanol-spiked FCS 20% 8 
B Charcoal-stripped FCS 
Testosterone spiked 
(41.2 nM – 0.51 nM) 
+ 75°C for 15 minutes 
Ethanol-spiked FCS 20% 8 
C Male/Female No treatment --- 5%, 10%, 15% and 20% 5 
D Male/Female 65°C for 30 minutes --- 5%, 10%, 15% and 20% 5 
E Female Testosterone spiked (3.7 x 10-7 M to 6.3 x 10-12 M) Ethanol-spiked FCS 10% and 20% 4 
F Gelding Testosterone spiked (3.7 x 10-7 M to 6.3 x 10-12 M) Ethanol-spiked FCS 10% and 20% 4 
G FCS Testosterone spiked (3.7 x 10-7 M to 6.3 x 10-12 M) Ethanol-spiked FCS 10% and 20% 4 
H Thoroughbred racehorse plasma No treatment --- 15% 1-5 
I Breast cancer patient plasma No treatment --- 15% 3 
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3.2.3 Serum treatment protocols for the yeast-AR bioassay 
 
3.2.3.1 Testosterone-spiked serum treatment protocol (treatment G) 
 
The testosterone-spiked FCS experiment was carried out in the yeast-AR bioassay to 
determine if testosterone suspended in serum could be detected in the yeast-AR 
bioassay. A testosterone standard curve was carried out alongside each experiment and 
the protocol can be found in General Methods (Chapter 2.0, Section 2.3.3) 
 
Testosterone was spiked into 200 µL charcoal-stripped FCS by adding 12 µL of 
testosterone (suspended in 100% (v/v) ethanol) across four concentrations (0.5, 1.5, 
4.5, 13 and 45 nM) and 100% (v/v) ethanol alone (vehicle control). Each tube of 
testosterone-spiked FCS allowed enough volume for 2 technical replicates of 106 µL per 
well to be tested with the yeast-AR cells. Testosterone- and ethanol-spiked FCS was 
incubated for 30 minutes at 37°C to allow for the serum proteins to bind the steroid. 
Table 3.2 provides a summary of this serum treatment carried out on the yeast-AR 
bioassay in this chapter. 
 
In a 24-well plate, 500 µL of CSM yeast broth was added to each well. To create a 20% 
(v/v) FCS and 1% (v/v) ethanol concentration in the yeast broth, 106 µL of each 
testosterone-spiked FCS and ethanol-spiked aliquot was added to each well, in 
duplicate. Plates were then placed in the orbital shaker incubator (300 rpm, 30°C) for 
18 – 20 hours. Experiments were repeated across 4-6 independent experiments (days). 
 
3.2.3.2 Statistical analysis 
 
The Miller units from testosterone-spiked serum samples (treatment G) were 
normalised to ethanol-spiked FCS. All serum AR bioactivity measures (Miller units) are 
expressed as a ratio to maximal testosterone. The method of analysis is described in 
General Methods (Chapter 2.0, Section 2.4.7, Figure 2.2). 
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On Excel (Version 16.34), raw absorbance values (OD420) were converted to Miller units 
(refer to Chapter 2.0, Section 2.3.3 for equation). Miller unit values were imported into 
GraphPad Prism (Version 8.0) to create the graph. The statistical tests used to 
determine significant changes between tested parameters are detailed throughout the 






3.3.1 EC50 of testosterone in the HEK293-AR and yeast-AR bioassay 
 
The HEK293-AR (mammalian) and yeast-AR (S.cerevisiae) RGBs were utilised to measure the 
AR bioactivity of testosterone. A representative dose-response curve and corresponding EC50 
value show that the HEK293-AR and yeast-AR bioassays are both responsive to testosterone 
(Figure 3.2A and B). The average EC50 ± SEM for testosterone in the HEK293-AR and yeast-AR 
bioassays measured 2.7 ± 0.8 nM and 3.5 ± 0.2 nM, respectively (Table 3.3). When applying a 
steroid in the form of testosterone, the HEK293-AR and yeast-AR bioassays are of similar 
sensitivity (Students unpaired t-test, p>0.05).  
 
Table 3.3: The mean EC50 ± SEM (nM) of testosterone in the yeast- and 
HEK293-AR cell bioassays.  
 
The number of independent experiments carried out in the HEK293-AR and yeast-AR 
bioassays is shown below.  
 




Yeast -AR 3.5 0.2 10 





Figure 3.2: Representative dose-response curves for testosterone in 
HEK293-AR and yeast-AR bioassays. 
 
A. Testosterone in the yeast-AR and B. HEK293-AR bioassays. The highest and lowest Miller- 
and luciferase units were normalised to 100% and 0%, respectively. The red dashed line 
shows the log concentration of testosterone (molar - M) (x-axis) required to activate 50% 
(EC50) of the b-galactosidase enzyme (Miller units) in the yeast-AR bioassay (A) and 
luciferase enzyme (relative light units - RLU) in the HEK293-AR bioassay (B) (y-axis). The 
above dose response curves for the yeast-AR and HEK293-AR bioassays are representative 
of 10 and 37 independent experiments, respectively. 










































3.3.2 The HEK293-AR bioassay is more appropriate for serum 
measurement 
 
Testosterone-spiked charcoal-stripped FCS was used to assess the ability of both the HEK293-
AR and yeast-AR bioassays to measure testosterone in serum (treatment A in Table 3.2). 
Testosterone-spiked FCS at physiological (41 - 13 nM) and sub-physiological levels (1.5 - 4.5 
nM) were detected in the HEK293-AR bioassay (Figure 3.3A). Whereas only the highest 
concentration testosterone (41 nM) was reliably detected in the yeast-AR bioassay (Figure 
3.3B). The AR bioactivity of testosterone-spiked charcoal-stripped FCS was below 
quantification for all concentrations up to and including 13 nM since the SEM error bars 
crossed the x-axis. The HEK293-AR bioassay displayed lower variability (SEM) compared with 
the yeast-AR bioassay. However, the yeast-AR and HEK293-AR bioassays assays showed a 
serum matrix effect as 41 nM of testosterone-spiked FCS produced an average of 18% and 
26% of maximal AR bioactivity, respectively (Figure 3.3A and B, page 102). However, 41 nM of 
testosterone in the standard curve is capable of inducing maximal AR bioactivity. Overall, the 
results of this section are not in agreement with the hypothesis since the HEK293-AR bioassay 
is far more superior yeast-AR bioassay for measuring AR bioactivity of serum. Due to this 
finding, the HEK293-AR bioassay was chosen to move forward with for future experiments. 
 
Serum is a complex matrix of proteins, electrolytes, antigens and metabolic waste products. 
All of these components have the potential to interfere with the AR bioassay. To determine if 
steroid binding proteins in the serum were responsible for the observed serum interference 
effect in the HEK293-AR bioassay, testosterone-spiked charcoal-stripped FCS was heated to 
denature the steroid binding proteins and thus increase the bioavailable pool of androgens 
(treatment B, Table 3.2). Heated testosterone-spiked charcoal-stripped FCS increased AR 
bioactivity significantly relative to non-heated testosterone-spiked charcoal-stripped FCS for 
all concentrations of spiked testosterone (repeated measures one-way ANOVA followed by 
multiple comparisons tests between non-heated and heated serums for each concentration 
of spiked testosterone. The multiple comparions were corrected for using the Sidaks’ test) 
(Figure 3.3C, page 102). While the HEK293-AR bioassay could detect the increase in 
bioavailable androgens as evidenced by the increase in AR bioactivity, heat-treatment did not 
solve the serum matrix effect because 41 nM of heated testosterone-spiked charcoal-stripped 
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FCS induced an average of only 35% of the maximal readout. This shows that serum matrix 
interferes with maximal readout capability. 
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Figure 3.3: AR bioactivity of testosterone-spiked FCS in the HEK293-AR and 
yeast-AR bioassays. 
 
A. AR bioactivity (mean ± SEM) of testosterone-spiked FCS (0.5 - 41 nM) in the HEK293-AR 
bioassay (n=8), B. AR bioactivity of testosterone-spiked FCS (0.5 – 41 nM) in the yeast-AR 
bioassay (n=4-6) and C. the effect of heat treatment on testosterone-spiked FCS on AR 
bioactivity in the HEK293-AR bioassay (n=8). Charcoal-stripped FCS was spiked with 
testosterone across 5 concentrations (0.5 – 41 nM) and incubated at 37°C to allow 
testosterone to bind the serum steroid binding proteins (A and B). Testosterone-spiked FCS 
was then heated to 75°C (grey bars) to denature serum steroid binding proteins and release 
testosterone. Serum AR bioactivity is reported as a ratio of luminescence to maximal 
testosterone (T) (refer to Chapter 2.0, Section 2.4.7, Figure 2.2 for analysis). (*p<0.0332, 
**p<0.0021, repeated measures one-way ANOVA followed by multiple comparisons tests). 
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3.3.3 HEK293-AR bioassay measures sex differences of human serum 
 
Given that the HEK293-AR bioassay could measure testosterone in serum and importantly, 
small changes in androgen bioavailability, the next question was whether the HEK293-AR 
bioassay could detect sex differences in AR bioactivity between male- and female derived 
serum (treatment C, Table 3.2). Figure 3.4A and B shows an expected difference in the AR 
bioactivity between male- and female derived serum (non-heated). Male serum induced ~100-
fold higher AR bioactivity compared with female serum in the HEK293-AR bioassay (non-
heated serum across 5-20% serum (v/v) concentrations in Figure 3.4A and B). The higher AR 
bioactivity of male serum was in keeping with the higher testosterone concentration 
measured by ELISA, 1.86 ng/L in male versus 0.38 ng/L in female serum (Table 3.4).  
 
Moreover, there was a significant increase in AR bioactivity for heat-treated male- and female 
derived serum (treatment D, Table 3.2). This was consistent across all volumes of serum added 
to the culture media (*p<0.033, **p<0.002, ***p<0.0002, repeated measures one-way 
ANOVA followed by a multiple comparisons test between non-heated and heated serums for 
each concentration of serum. A Sidaks’ multiple comparisons test was carried out to correct 
for multiple comparisons). AR bioactivity increased up to 2.3-fold and 8.5-fold following 
heating of male and female serum, respectively. The higher fold-change for female serum may 
reflect the expected higher SHBG levels in female serum (Lecomte et al., 1998; Kalme et al., 
1999). Therefore, the HEK293-AR bioassay is clearly able to measure testosterone in a serum 
matrix, sex and bioavailability differences of FCS, human male and female serum. 
 
Table 3.4: Concentration of testosterone in male- and female derived 
serum measured by ELISA.  
 




Human Male 1.86 6.45 




Figure 3.4: AR bioactivity of male- and female derived serum measured by 
the HEK293-AR bioassay. 
 
AR bioactivity (mean ± SEM) of human male (blue bars) and female (red bars) serum. 
HEK293-AR cells were treated with male- and female derived serum across 5-20% (v/v) final 
concentration. Both male- and female derived serum was heated to 65°C for 30 minutes to 
denature serum steroid binding proteins and thus increase the bioavailable portion of 
androgens. HEK293-AR cells were treated with heated male- and female derived serum 
(hashed bars) across 5-20% (v/v) (hashed bars). AR bioactivity is reported as a ratio of 
luminescence to maximal T (refer to Chapter 2.0, Section 2.4.7, Figure 2.2 for analysis). 
Across all 4 concentrations of male- and female derived serum, heated serum significantly 
increased in AR bioactivity relative to non-heated serum (*p<0.033, **p<0.002, 
***p<0.0002, repeated measures one-way ANOVA followed by a multiple comparisons test 
between non-heated and heated serum for each serum concentration. The dashed line in 











































3.3.4 Serum and plasma is interfering with AR bioactivity  
 
The previous experiment identified a serum matrix effect that suppressed maximal activity. 
To better understand the matrix interference that leads to suppression of maximal AR 
bioactivity, a dose-response curve was generated for testosterone, or testosterone-spiked 
into serum and plasma of known low androgen levels (for example; gelding plasma, FCS or 
human female serum) (treatment E-G, Table 3.2 in the methods section of this chapter). From 
the dose-response curves, EC50 and maximal AR bioactivity (luminescence) values were 
derived for serum and plasma treated at 10% and 20% (v/v) final concentrations (Figure 3.5). 
The data shows that maximal AR bioactivity was suppressed by all plasma- and serum 
exposures. However, as expected, 20% (v/v) serum/plasma suppressed maximal AR bioactivity 
to a greater extent than 10% (v/v) serum/plasma and this was statistically significant (ordinary 
one-way ANOVA, followed by a multiple comparisons test between the 10% and 20% 
concentration of each serum and plasma sample). For gelding plasma and FCS, although 
maximal AR bioactivity is reduced, the sensitivity (EC50) of the assay remained unchanged 
compared with the control testosterone dose response curve. The mean EC50 for FCS and 
gelding plasma ranged between 1.0 x 10-9 M to 1.7 x 10-9- M (1.0 nM to 1.7 nM). In contrast, 
the mean EC50 for testosterone measured in the presence 20% (v/v) human female serum was 
significantly higher EC50 measuring 6.9 x 10-9 M (6.9 nM), respectively (****p<0.001, ordinary 
one-way ANOVA, followed by a comparison to the control testosterone dose response curve 
testosterone). However, the testosterone dose response curve in 10% (v/v) female serum 
remained unchanged from the control testosterone dose response curve. This observation is 
most likely due to higher concentration SHBG protein in female serum (Dunn et al., 1981) that 




Figure 3.5: Maximal induction of testosterone-spiked serum and 
plasma measured by the HEK293-AR bioassay 
 
A. Mean ± SEM of the maximal induction of the testosterone dose-response curves for 
testosterone spiked FCS, equine gelding plasma and human female plasma at 10% (red 
bars) and 20% (blue bars) (v/v) final concentration. There is significant reduction in AR 
bioactivity between 10% and 20% (v/v) FCS, gelding plasma and female serum 
(*p<0.033, **p<0.002, ***p<0.0002, ordinary one-way ANOVA). AR bioactivity is 
reported as a ratio of luminescence to maximal T (refer to Chapter 2.0, Section 2.4.7, 
Figure 2.2 for analysis) (n=3-5). B. Average ± SEM EC50 of testosterone spiked-FCS, -
equine gelding plasma and -human female plasma at 10% and 20% (v/v) final 
concentration (molar concentration of testosterone). There was a significant increase 
in EC50 for testosterone-spiked female serum at 10% and 20% (v/v) final 















































3.3.5 Screening equine plasma using the HEK293-AR bioassay  
 
Plasma samples derived from thoroughbred racehorses (n=99) were screened in the HEK293-
AR bioassay to determine if AR bioactivity was measurable (treatment H, Table 3.2 in the 
methods section of this chapter). All horse plasma samples induced a measurable level of AR 
bioactivity, measuring between 1% and 13% of maximal AR bioactivity (Figure 3.6). Once it 
was determined that the HEK293-AR bioassay was capable of measuring AR bioactivity of all 
plasma samples, the data was analysed to determine if there was a sex difference (geldings 
versus colts and mares versus colts), or a difference between colts and geldings. There was no 
significant difference between gelding, mare and colt plasma AR bioactivity (p>0.05, ordinary 
one-way ANOVA). The inability to discern a difference in AR bioactivity between groups is 
likely due to the low number of colt plasma samples supplied and the large spread of data 
within each group.  
 
This data shows mean AR bioactivity and a high level of variability (SEM) amongst geldings, 
mares and colts. The mean AR bioactivity for gelding, mares and colt horses measured 4.1%, 
4.1% and 4.7%, respectively. The SEM provides a measure of variability within each group, 
which enable outlier samples to be identified (i.e. those that exceed the SEM). The measure 
of variability is most reliable from the gelding plasma samples since the number of samples 
(n=66) is reasonable and may better reflect the population average. The SEM for gelding 
horses measured 0.3% and 5 outliers were identified (ROUT method to identify outliers in 
GraphPad Prism shown in green box in Figure 3.6). The mares have a slightly higher value SEM, 
likely due to the lower number of samples (n=24) measuring 0.5%. Within the mare group, 
there were 2 outliers were identified (ROUT method to identify outliers in GraphPad Prism 
shown in green box in Figure 3.6). The colt plasma samples had the highest SEM, measuring 
1%. However, high SEM is likely due to the low number of samples (n=9) and no outliers were 
derived from this small data set. 
 
As some gelding and mare samples showed high AR bioactivity, these samples were next 
tested for testosterone concentration by ELISA. All colt plasma samples were expected to 
contain measurable levels of testosterone, however, the preliminary screen showed low AR 
bioactivity (relative to gelding and mare averages). Due to this observation, all colt samples 
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were tested for absolute testosterone concentration by ELISA (all samples tested by ELISA are 
shown as red dots, Figure 3.6).  
 
Interestingly, only 3 colt samples contained measurable levels of testosterone by ELISA, 
measuring 1.37 ng/mL, 0.29 ng/mL and 0.67 ng/mL (labelled on graph and shown as yellow 
dots with red border in Figure 3.6). The gelding and mare samples that had high AR bioactivity 
had no detectable levels of testosterone by ELISA.  
 
There was little association between testosterone concentration and AR bioactivity. Of the 
colt samples that had a measurable level of testosterone, the two highest AR bioactivity 
samples had different testosterone concentrations (0.67 ng/mL and 1.37 ng/mL). The third 
colt sample with detectable testosterone (0.29 ng/mL), had the lowest level of testosterone 
and the lowest AR bioactivity. The AR bioactivity of this sample lies at about the middle of all 
horse samples tested, yet no other colt samples had a detectable level of testosterone.  
 
Overall, the HEK293-AR bioassay was able to measure AR bioactivity of horse plasma samples 
that were below the limit of quantification by immunoassay. However, sex differences are 
unable to be determined from this data due to the low number of mare and colt samples. This 
data demonstrates that the HEK293-AR bioassay was able to provide information on AR 
bioactivity levels and outliers of gelding racehorse plasma samples, which could be relevant 





Figure 3.6: AR bioactivity of race equine plasma samples screened in the 
HEK293-AR bioassay. 
 
The mean ± SEM AR bioactivity of equine gelding (n=66), mare (n=24) and colt (n=9) plasma 
samples. HEK293-AR cells were treated with plasma samples at a 15% (v/v) concentration 
to assess for AR bioactivity. All dots represent the AR bioactivity measured for each horse 
plasma sample and is reported as a ratio of luminescence to maximal T (refer to Chapter 
2.0, Section 2.4.7, Figure 2.2 for analysis) (y-axis). The samples in the green box show those 
samples that are outliers within each group (ROUT method for identifying outliers in Prism 
8). The red dots highlight those samples tested for testosterone in the ELISA but yielded no 
detectable level of testosterone. The samples that had a measurable level are shown as 
yellow dots with a red border. The testosterone concentration derived from the ELISA is 
pointing towards the corresponding sample. There was no difference in AR bioactivity 
between geldings, mares and colts (p>0.05, ordinary one-way ANOVA). Each plasma sample 
was screened across 1-5 independent experiments (days).  
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3.3.6 Screening plasma samples from breast cancer patients using 
the HEK293-AR bioassay 
 
To determine if the HEK293-AR bioassay could be used to monitor human clinical samples, 
plasma samples from 9 breast cancer patients were screened (treatment I, Table 3.2 in the 
methods section of this chapter). AR bioactivity was measured before-, and after, the onset 
of (neo-) adjuvant chemotherapy (Figure 3.7). The HEK293-AR bioassay could measure AR 
bioactivity of all patient samples. The AR bioactivity measured for all patient samples was low, 
measuring between 0.045% and 4.5% of maximal induction by testosterone, which is in 
keeping with female patients having naturally low androgen levels. Patients 4 and 5 increased 
in AR bioactivity after chemotherapy (*p<0.033, repeated measures one-way ANOVA, 
followed by a multiple comparisons test between the before- and after chemotherapy sample 
for each patent. Using a Fisher LSD test, no correction for multiple comparisons was carried 
out). Whether such changes are clinically important cannot be determined from this study 
due to the low number in the sample. Furthermore, as for the equine samples, ELISA could 
measure testosterone in only 3 of 18 samples tested; patient 2 (after chemotherapy), patient 
3 (before chemotherapy) and patient 9 (before chemotherapy) (Table 3.5). The testosterone 
ELISA results contrast with the HEK293-AR bioassay that measured AR bioactivity in all 
samples and could detect changes before-, and after-, (neo-) adjuvant chemotherapy. These 
results show that the HEK293-AR bioassay is able to detect the presence of androgens in 
samples where testosterone is too low to be detected by standard ELISA. Such data suggests 
that HEK293-AR bioassay may be able to provide clinically relevant information.  
 
Table 3.5: Concentration of testosterone measured in breast cancer 
plasma samples measured by ELISA.  
 




2 (after) 0.007 0.024 
3 (before) 0.019 0.066 




Figure 3.7: AR bioactivity of breast 
cancer patient plasma samples 
before-, and after-, (neo-) adjuvant 
chemotherapy measured in the 
HEK293-AR bioassay. 
 
Mean ± SEM AR bioactivity of 9 breast 
cancer patient plasma samples. HEK293-
AR cells were treated with patient plasma 
at a 15% (v/v) final concentration to assess 
for AR bioactivity. AR bioactivity is 
reported as a mean ± SEM ratio of 
luminescence to maximal T (refer to 
Chapter 2.0, Section 2.4.7, Figure 2.2 for 
analysis) (y-axis). The grey bars represent 
the AR bioactivity before chemotherapy 
and the white bars show the level of AR 
bioactivity after chemotherapy where no 
change was detected. The red hashed bars 
show the plasma samples that significantly 
increased in AR bioactivity following 
chemotherapy (*p<0.033, repeated 
measures one-way ANOVA followed by 
multiple comparisons test between the 
before- and after chemotherapy sample 
for each patient). Each plasma sample was 





Overview of main findings 
 
A major finding of this study shows that the mammalian HEK293-AR bioassay outperformed 
the current standard yeast-AR bioassay for measurement of serum AR bioactivity. Throughout 
these experiments, it became apparent that the serum matrix was interfering with the 
maximal read-out of the assay. Despite the interference, the assay could still reliably measure 
serum and plasma AR bioactivity. The HEK293-AR bioassay screened 99 plasma samples from 
thoroughbred racehorses and all plasma samples were measurable. Furthermore, high-level 
outlier samples could be identified within gelding and mare populations. These outliers could 
potentially be red-flags for future investigation. To redirect the purpose of the assay towards 
a clinical focus, breast cancer patient plasma all had measurable AR bioactivity and some intra-
patient changes were also detected. Interestingly, for both racehorse and breast cancer 
patient plasma there was a disconnect between testosterone concentration and AR 
bioactivity. This finding could be of significance to anti-doping agencies or clinicians due to the 
possibility of either (1) raised AR bioactivity owing to doping with an androgen or (2) net 
plasma AR bioactivity being attributable to an androgen other than testosterone, which could 
be of biological importance. 
 
The comparison between yeast- and mammalian cells for measuring serum AR 
bioactivity 
 
The first step in this study was to determine if yeast or mammalian cells are more sensitive 
for measurement of serum AR bioactivity. This study demonstrated that the mammalian 
HEK293-AR bioassay outperformed the gold standard yeast-AR bioassay (Coldham et al., 1997; 
Dhooge et al., 2006; Nielen et al., 2006) for measuring AR bioactivity of testosterone spiked 
into serum. By directly comparing the yeast-AR and HEK293-AR systems, this study was able 
to show that the HEK293-AR bioassay outperformed the yeast-AR bioassay. AR bioactivity was 
measurable from sub- through to supra-physiological (0.5 – 41 nM) concentrations of 
testosterone spiked into serum in the HEK293-AR bioassay, whereas, only 41 nM testosterone 
(high physiological) was reliably detected in the yeast AR bioassay (Figure 3.3A and B). These 
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results demonstrate that the HEK293-AR bioassay is a more reliable measure of serum AR 
bioactivity.  
 
Yeast-AR bioassays have been commonly utilised in research settings to identify novel 
steroidal AR agonists solubilised in a simple solvent such as ethanol or dimethyl sulfoxide 
(DMSO) (Bovee et al., 2007; Bovee et al., 2010). Furthermore, clinically focused studies have 
utilised yeast-based bioassays to measure serum ERa (Klein et al., 1995) and AR bioactivity, 
however, no clinically relevant findings have been discovered (Fourkala et al., 2011). Whereas, 
other clinical studies utilising yeast cells as a host to measure ERa bioactivity have shown that 
ERa bioactivity demonstrates low-, but increased, risk towards breast cancer (Widschwendter 
et al., 2009) and disorders of sexual development (Sultan et al., 2001a). Due to the clear 
disparity in performance between the yeast and mammalian cells, which was uncovered in 
this chapter, it is likely that correlations between bioactivity and disease could be more readily 
derived if a mammalian cell was utilised instead. Since yeast cells are not a sensitive measure 
for detecting androgens in a serum matrix, it may help to explain why AR bioassays are yet to 
emerge as a clinically relevant tool.  
 
The poor sensitivity of the yeast-AR bioassay towards serum measurement could be due to a 
form of serum interference. However, the serum interference is unlikely to be arising due to 
interference at the level of the reporter enzyme (b-galactosidase) and substrate (ONPG) 
reaction since the supernatant on the yeast cells is removed during the bioassay procedure. 
Additionally, it does not appear that the yeast cells are hindered in their uptake of steroidal 
molecules relative to the HEK293 cell line since the dose-response curves to pure testosterone 
produced similar EC50 values. These results were discordant with a study that showed that a 
yeast cell line outperformed a mammalian cell line (MCF-7) for the detection of estrogenic 
agonists in an ERa-RGBs (Coldham et al., 1997). However, in contrast, yeast-AR bioassays have 
been shown to be less sensitive (higher EC50) than mammalian cells (Akram et al., 2011). 
Theoretically, yeast cells should be ideal for bioassay measurement due to the lack of steroid 
hormone metabolising enzymes and steroid hormone receptors, which render the cells highly 
specific to the test substance tested.  
 
A possible explanation for the improved sensitivity of the HEK293-AR cells is the endogenous 
expression of steroid hormone metabolising enzymes, which renders the cells more sensitive 
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to the test substance, testosterone. Since HEK293 cells express 5a-reductase (Akram et al., 
2011), it is possible that testosterone was converted into DHT in HEK293 cells, which is a 
potent androgen, and is in part contributing to a higher level of AR bioactivity. However, 
HEK293 cells also express the P450-aromatase enzyme (Akram et al., 2011), which would 
lower the AR bioactivity since the product of testosterone aromatisation is the formation of 
E2. Therefore, the presence of metabolising enzymes does not fully explain why the HEK293-
AR bioassay could measure sub-physiological concentrations of testosterone, unlike the yeast 
cells. The expression of cofactor proteins in the HEK293-AR cells could render the cells more 
sensitive to testosterone by assisting the transcriptional activity of AR when bound to 
testosterone. Therefore, the presence of cofactors may enhance reporter gene expression 
under low androgen concentrations. Cofactor proteins of AR support the folding of the AR 
protein to allow the interaction between the N- and C-termini, which is necessary for AR 
transcriptional activity (Ikonen et al., 1997; He et al., 2000; He et al., 2002a; He et al., 2002b) 
 
The mechanism underpinning the suppressed AR bioactivity of serum in the yeast-AR bioassay 
is undetermined. However, for the purposes of this study, the HEK293-AR bioassay was shown 
to serve as a good model to move forward with applying AR bioassays in a clinical context by 
measuring serum and plasma. The HEK293-AR bioassay was utilised as a model to determine 
if the assay to could measure (1) androgen bioavailability and (2) sex differences, which are 
two important intrinsic parameters of serum relevant to AR bioactivity measurement. 
 
HEK293-AR bioassay can measure bioavailability changes of testosterone-spiked 
serum 
 
The HEK293-AR bioassay was a sensitive tool used to detect differences in testosterone 
bioavailability since heated testosterone-spiked serum induced higher AR bioactivity than 
non-heated testosterone-spiked serum (Figure 3.3C). Serum was heated to 75°C to denature 
the serum proteins and release any bound testosterone, thereby, increasing the bioavailable 
pool of testosterone. For 0.5 and 1.5 nM spiked-testosterone, the AR bioactivity increased ~2-
3-fold upon heating. However, as the concentration of spiked-testosterone increased, the 
change in AR bioactivity upon heating decreased (~1.5-fold increase). This observation is likely 
due to over saturation of the steroid binding proteins in the FCS. A possible reason for this 
observation could be due to the lower capacity of FCS to binding steroids relative to human 
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serum. Compared with human serum, bovine serum has been shown to have 10% lower 
concentration of SHBG, which means the binding capacity of testosterone in bovine serum is 
reduced (Sedelaar & Isaacs, 2009). Thus, it is plausible that FCS also has a lower concentration 
of SHBG than human serum and approaches saturation at physiological concentrations (4.5 
nM). This finding was depicted by smaller changes in AR bioactivity upon heating for higher 
concentrations of spiked testosterone compared with lower testosterone concentrations. 
Importantly, this experiment was able to demonstrate that the HEK293-AR bioassay was 
capable of measuring small but meaningful changes in serum AR bioactivity. 
 
HEK293-AR bioassay can measure sex- and bioavailability changes in human serum 
containing endogenous androgens 
 
The HEK293-AR bioassay was also capable of measuring sex- and bioavailability differences in 
human serum, which contains endogenously synthesized androgens. Firstly, male serum 
induced a higher level of AR bioactivity than female serum and secondly, both serums 
increased in AR bioactivity upon heating. Both of these results were expected since it is well 
established that male serum contains a higher content of androgens compared with female 
serum and heat-induced denaturation of serum proteins would increase the bioavailable pool 
of androgenic hormones.  
 
In this study, the HEK293-AR bioassay could reliably measure a difference in AR bioactivity 
between male- and female derived serum across 5-10% (v/v) serum concentration (Figure 
3.4). This was an important test to ensure the assay could measure expected sex differences 
since the future application is to use the assay to measure intra-patient changes in AR 
bioactivity. Therefore, if the assay is unable to detect a sex difference, then it would be 
unlikely that intra-patient changes could also be detected. The concentration of testosterone 
in the male and female serum measured 1.86 and 0.34 ng/mL in the testosterone ELISA, 
respectively. The concentration of testosterone in the male serum is low, especially 
considering the age of the male is 23-years old. The concentration range of testosterone for a 
healthy eugonadal 23-year old male is approximately 600 ng/dL, which equates to 6 ng/mL 
(Bhasin et al., 2001). Therefore, the concentration of testosterone in the male serum used in 
this study is ~4-fold lower than expected. Either, the ELISA is not a sensitive measure for 
accurate detection of the full level of testosterone in the serum or the male could be 
hypogonadal. A testosterone concentration of 3 ng/mL contributes to the diagnosis of 
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hypogonadism (Carnegie, 2004). The HEK293-AR bioassay performed reliably since the female 
serum, which had a low concentration of testosterone measuring 0.34 ng/mL, was also clearly 
detected despite expected low levels of endogenous androgens. The low concentration of 
testosterone in the male and female serum could be explained by the potential lack of 
sensitivity of the ELISA towards specifically testosterone. An alternative and more sensitive 
approach for measuring testosterone would be the use of a GC/MS since cross reactivity is 
reduced and sensitivity is improved. However, immunoassay is the main clinical technique 
used to measure testosterone, therefore, unlike the clinical standard, the HEK293-AR bioassay 
could reliably measure the AR bioactivity and a more appreciable sex difference between the 
serum samples.  
 
Heated male- and female serum increased AR bioactivity relative to non-heated serum (Figure 
3.4). Upon heating serum, the steroid-binding proteins, SHBG and albumin are denatured, and 
endogenous androgens are readily available to the cell. Since the free testosterone in serum 
is ~1-2%, it would be expected that upon heating the serum, the AR bioactivity would increase 
~50-fold. However, the serum AR bioactivity increased ~2-fold and up to 8-fold for male and 
female serum, respectively. There are two possible explanations for this observation, either 
the heating protocol did not denature all steroid binding proteins or a larger portion of 
androgens in the non-heated serum are able to activate the assay (larger bioavailable pool). 
The kinetic properties between testosterone and steroid binding proteins could be influencing 
the AR bioactivity measurement. Testosterone binds to SHBG and albumin with different 
affinities and capacities. SHBG binds ~45% of total testosterone and albumin binds ~50% of 
total testosterone (Dunn et al., 1981). Furthermore, SHBG binds testosterone with a higher 
affinity than albumin (Sedelaar & Isaacs, 2009). As a result, albumin-bound testosterone is 
considered to be part of the bioavailable pool of testosterone (Manni et al., 1985; Vermeulen 
et al., 1999). Therefore, in this experiment, the non-heated serum could be capable of 
measuring the free and albumin-bound portions of testosterone within the serum. Therefore, 
the increase in AR bioactivity of ~40-50% upon heating could be due to the release of the 
SHBG-bound testosterone. The larger fold change in AR bioactivity between heated- and non-
heated female serum is explained in greater detail in the next section but this likely owes to 
the expected higher SHBG concentration (Lecomte et al., 1998). Overall, this set of 
experiments shows that the AR bioassay could be measuring the albumin-bound portion of 
androgenic molecules in serum. 
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Serum interference in the HEK293-AR bioassay 
 
Throughout this study, serum interference with the bioassay was a common issue and is of 
important consideration for serum measurement. The first sign of serum interference arose 
in the testosterone-spiking experiments (Figure 3.3). In a standard testosterone dose 
response curve, 41 nM of testosterone was capable of inducing 100% activation of the assay. 
However, when 41 nM testosterone was spiked into FCS this activated the assay to less than 
40% of maximal assay activation. Therefore, a component of the serum is buffering the 
bioavailable concentration of testosterone in the serum, which is not allowing all androgenic 
steroids to enter the cell and interact with ARs. 
 
The serum interference effect was further investigated in the experiment where a dose 
response of testosterone was spiked into low endogenous androgen plasma and serums 
(Figure 3.5). The low androgen serums utilised were FCS, human female serum and equine 
gelding plasma. Both 10% and 20% (v/v) serum spiked with a dose response of testosterone 
lowered the maximal activity of the assay (level of induction). Relative to the control dose 
response curve, the maximal induction of the 10% (v/v) testosterone-spiked serum/plasma 
dose response curve was lowered and this was further suppressed by 20% (v/v) testosterone-
spiked serum/plasma dose response curve. Therefore, this shows that serum is interfering 
with the AR bioassay by reducing the maximal activity of the assay. 
 
The maximal induction of the assay with the 10% (v/v) testosterone-spiked serum dose 
response was reduced ~20% when compared to the maximal read-out induced by the 
standard testosterone dose response curve (Figure 3.5A). However, the treatment protocol 
for the standard (control) testosterone dose response curve involves treating the cell culture 
media is directly treated with a dilution series of testosterone. The cell culture media already 
contains 10% (v/v) charcoal-stripped FCS. However, prior to addition into the cell culture 
media, the charcoal-stripped serum is heated to 50°C during the charcoal stripping process 
(Chapter 2.0, Section 2.4.2 for charcoal-stripping method). Whereas, the charcoal-stripped 
FCS used in the testosterone-spiking experiments was incubated at 37°C instead of 50°C to 
preserve protein structure. Preserving protein structure was an important step for the 
purpose of determining if serum proteins are interfering with the maximal read-out of the 
assay. As shown in this study (Figure 3.3), incubating testosterone in FCS that contains more 
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intact and functional protein, suppresses the inducibility of the AR bioassay. Therefore, the 
serum proteins are likely a point of interference for the HEK293-AR bioassay. 
 
There was an increase in EC50 for testosterone-spiked female serum at 20% (v/v) but no 
change in EC50 for testosterone-spiked female serum treated at 10% (v/v), gelding plasma 
(10% and 20% (v/v)) or FCS (10% and 20% (v/v)) (Figure 3.5B). This increase in EC50 could be 
indicative of a high concentration of SHBG in the 20% (v/v) female serum. Relative to age-
matched males, females generally have higher concentrations of SHBG (Lecomte et al., 1998), 
which could owe to E2-induced liver production of SHBG (Kalme et al., 1999). Since female 
serum has a higher concentration of E2 compared with male serum, this in part explains the 
observed sex difference.  
 
Although SHBG concentration was not measured in this study, the potential higher level of 
SHBG in females means that a higher concentration of testosterone needed to be spiked into 
the serum to overcome the enhanced steroid buffering properties. Therefore, a higher 
concentration of testosterone is required to activate AR to 50% compared with a serum with 
lower SHBG. Overall, a higher concentration of SHBG in female serum would help to explain 
why the EC50 of testosterone-spiked female serum, especially at the higher serum 
concentration of 20% (v/v), was higher than the other testosterone-spiked serums and 
plasma.  
 
An alternative mechanism of serum interference could be occurring during the SEAP bioassay. 
The cell culture media is heated to 65°C, which denatures all proteins in the media (including 
serum proteins). The culture media is then treated with the SEAP substrate to induce a 
luminescence reaction. However, the coagulated protein aggregates could be physically 
interfering with the reaction between SEAP and its substrate. Therefore, the potential amount 
of luminescence that can be induced may be suppressed.  
 
AR bioactivity of equine plasma 
 
To determine the screening potential of the HEK293-AR bioassay, equine gelding, mare and 
colt plasma samples were tested. Firstly, all horse plasma samples were detected by the AR 
bioassay. However, the most important finding of this experiment showed that the HEK293-
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AR bioassay serves as a useful screening tool for the purposes of identifying outlier samples 
that lie above the expected mean of each group. Since there were 66 gelding samples supplied 
to our lab, it was possible to show that the mean AR bioactivity of the group measured ~4% 
of maximal AR bioassay activation with a SEM of ~0.3%. The inter-horse variability in AR 
bioactivity was very small, which allowed for the identification of samples that were greater 
than the SEM. These outlier samples can be “red flagged” for follow up investigation since it 
is possible that horses with an above average AR bioactivity could have been doped with an 
androgenic agent.  
 
There were no significant differences in AR bioactivity between geldings, mares and colts. 
However, it is to be expected that there would be no difference between geldings and mares, 
but it was expected that colts would have a higher level of AR bioactivity than both geldings 
and mares. Mares are female and geldings are castrated males, therefore both have low 
endogenous androgens due to the lack of testicular testosterone supply. However, since colts 
are intact, they have a supply of testicular testosterone and should therefore have higher net 
androgenicity than mares and geldings. If a larger number of colt samples were available for 
testing, this would allow for a more accurate depiction of the average androgenicity of the 
population, which may reveal a sex difference relative to geldings and mares.  
 
In the gelding and mare populations, some high and low (lying above or below SEM error bars) 
AR bioactivity plasma samples were tested for testosterone in an ELISA and all contained an 
undetectable level of testosterone. All of the colt samples (n=9) were tested by ELISA for 
testosterone and 3 out of 9 samples had a detectable level of testosterone measuring 
between 0.29 – 1.37 ng/mL. A study has shown that the testosterone concentration for 
geldings and colts is typically <0.1 ng/mL and 2.0 ng/mL, respectively (Inoue et al., 1993). The 
concentration of testosterone in most horse samples tested may be below the limit of 
quantification of the immunoassay (0.1 ng/mL). 
 
The colt samples with detectable testosterone had an AR bioactivity measurement less than 
the AR bioactivity of some of the outlier samples in the gelding and mare populations, which 
also did not contain a detectable concentration of testosterone. This raises an interesting 
finding, that despite undetectable levels of testosterone in most samples, there was a 
moderate or high level of induced AR bioactivity across geldings, mares and colts. The 
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disconnect between AR bioactivity and testosterone concentration also supports the idea that 
an androgen other than testosterone could be responsible for the high AR bioactivity of some 
outlier samples in the gelding and mare populations. Overall, the HEK293-AR bioassay 
provides more information than testosterone ELISA alone in an equine population. The AR 
bioassay measurement can be used to identify outlier samples, which could be suspect for the 
presence of an androgenic agent.  
 
AR bioactivity of breast cancer patient plasma 
 
To provide a clinical focus to this study, human breast cancer patient plasma samples were 
tested in the AR bioassay. In this study, it was shown that all breast cancer patient samples 
were measurable in the HEK293-AR bioassay. All samples produced low (less than 0.4% of 
maximal assay induction), yet detectable levels of AR bioactivity. Patient plasma was received 
across two time points, before- and after (neo-) adjuvant chemotherapy, which was important 
for the purpose of determining if temporal, intra-patient changes could be detected by the AR 
bioassay. Indeed, for 2 out of 9 patients, temporal changes were observed. The low number 
(n=9) and the wide age range (43-68 years) of the patients in this study means that no 
conclusions can be drawn from this population in terms of the association between breast 
cancer, chemotherapy and AR bioactivity. However, the AR bioassay proved successful for 
measuring the AR bioactivity of a small clinical population since all plasma samples provided 
a reliable readout. 
 
AR bioactivity was measurable across all patients despite only 3 out of 18 samples containing 
a detectable level of testosterone. Since plasma samples were provided from two different 
time points (before- and after chemotherapy) from each patient, temporal, intra-patient 
changes could be monitored. For patients 4 and 5 there was a significant increase in AR 
bioactivity after-chemotherapy. Whereas, all other patients did not change in AR bioactivity. 
Despite an observed increase in AR bioactivity for patients 4 and 5, there was no detectable 
level of testosterone before- or after-chemotherapy for patients 4 and 5. Despite no detection 
of testosterone, the post-chemotherapy sample for patient 4 had the highest level of AR 
bioactivity across the cohort.  
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Interestingly, the testosterone concentration for patient 2 goes from below detection to a low 
testosterone concentration. However, if the bioactivity results are taken into account, the net 
bioactivation of AR remains the same. On the contrary, for patient 3, there was a decline in 
testosterone concentration after chemotherapy accompanied by no net change in AR 
bioactivity. For patients 2, 3, 4 and 5 the results of the testosterone ELISA and the AR bioassays 
are discordant. Such findings in future larger cohorts could provide an important clinical proxy. 
These changes in testosterone concentration coupled with a maintained level of AR bioactivity 
could be a mechanism of compensation between androgenic molecules. This concept is 
further supported in patient 4 where the concentration of testosterone was below the level 
of quantification for both samples (before- and after chemotherapy), yet, the level of AR 
bioactivity increased following chemotherapy. It could be postulated that adrenal androgens 
could be responsible for the increase in AR bioactivity following chemotherapy. Adrenal 
androgens include DHEA and androstenedione and would go undetected by the testosterone 
ELISA. No clinical significance of the increase in AR bioactivity for patient 4 and 5 despite 
undetectable levels of testosterone can be inferred from this study alone, however, 
observations of this sort should be investigated further in larger cohorts. 
 
If a larger population of patients were recruited in this study, outlier samples could be 
detected in a similar manner to the thoroughbred gelding and mare racehorse populations. 
There could be clinically relevant information to be obtained from high AR bioactivity (above 
population average), changes in AR bioactivity over time or the disconnect between 
testosterone concentration and AR bioactivity. Since the role of androgens and AR activity in 
breast cancer is largely still undetermined, the use of an AR bioassay could help to unpack the 




This study demonstrated that the mammalian cell line (HEK293-AR) outperformed the current 
standard cell line (yeast-AR), for measuring serum AR bioactivity. There is clearly a serum 
matrix effect that needs to be overcome to improve assay performance and interpretation of 
results. Thoroughbred racehorse plasma samples were all measurable in the HEK293-AR 
bioassay. From this population data, outlier samples could be identified that could be suspect 
for doping with an androgen. This study provides a platform to further investigate the 
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relationship between AR bioactivity and breast cancer since all patient samples were 
measurable. Like with the equine plasma, there was a disconnect in results between AR 
bioactivity and testosterone concentration. This information requires future investigation to 
determine if AR bioactivity is able to identify horses that have been doped with an androgen 
or breast cancer patients that are at higher risk of future relapse.  
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4.0 Optimisation of the T47D-ER 





The T47D-ER bioassay reports on the level of combined ERa and ERb activation by a test 
substance since both ER isoforms are endogenously expressed in this cell line. The 
optimisation steps of the T47D-ER bioassay taken in this chapter for best interpretation of 
serum and plasma measurement is crucial to help determine if ERa and ERb-RGBs have the 
potential to provide clinically relevant information. This chapter utilises plasma from breast 
cancer patients to determine if the optimised T47D-ER bioassay is capable of providing more 
information than E2 ELISA alone. 
 
4.1.1 Why is it important to measure estrogen levels clinically? 
 
The ability to measure E2 levels with high sensitivity and accuracy in a clinical population is 
important for women with PCOS, patients with disorders of sexual development, ovarian 
cancer, breast cancer, menopause and fertility disorders (infertility). Physiological E2 
concentrations can vary between <3 pM and 73 nM, therefore, a standardised measure is 
difficult to accurately encompass the entire physiological range (Stanczyk & Clarke, 2014). 
Currently, E2 immunoassays are routine methods employed, however, the sensitivity of 
current methods is under scrutiny since at low end levels of E2, there is high variability and 
the results tend to overestimate the concentration of E2 due to cross reactivity with 
conjugated metabolites and precursor molecules of E2 (Stanczyk et al., 2010; Stanczyk & 
Clarke, 2014). Since it is understood that immunoassay and RIA are not very reliable for 
measuring low E2, it is recommended that GC- or LC/MS is used instead. GC-or LC/MS are 
quantitative analytical chemistry techniques that are exquisitely sensitive for detecting 
specific chemical structures in a sample, such as E2. However, GC- and LC/MS are not 
commonplace clinical techniques due to their laborious, expensive and low throughput 
nature. Therefore, to accompany current clinical E2 measurement techniques such as 
immunoassay, ER-RGBs could serve as a useful tool. ER-RGBs measure the physiologically-
important, bioavailable pool of total estrogens in the serum that converge on activating ERa/b 
cell signalling. ER-RGBs are a functional approach to estrogen measurement whereby the level 
of ERa and/or -b activation by a test sample is a proxy for the level of net estrogenicity of a 
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sample. Furthermore, it provides an understanding of how ERa and/or -b mediate gene 
transcription respond to all the components of serum rather than just E2.  
 
4.1.2 The value of measuring ER bioactivity 
 
Although E2 is the most potent endogenous estrogen, it is not the only molecule capable of 
activating ERa and/or -b. In fact, it is well established that estrogen mimicking molecules of 
synthetic (xenoestrogens) (Bonefeld-Jørgensen et al., 2001; Matthews et al., 2001; Meerts et 
al., 2001; Plíšková et al., 2005; Pinto & Reali, 2009; Wagner & Oehlmann, 2009; Zhang et al., 
2014) and plant origin (phytoestrogens) (Zava et al., 1998; Sotoca et al., 2010) are capable of 
activating ERa and/or -b, thereby mimicking the action of endogenous estrogens. Due to the 
persistent nature of some active estrogenic molecules in the environment, such as plastic 
monomers, they have also been detected in human serum, milk (Noren & Meironyte, 2000; 
Solomon & Weiss, 2002), adipose tissue and placenta (Lopez-Espinosa et al., 2007). Therefore, 
exposure to these molecules have the potential to disrupt the endocrinology of an organism 
and their offspring, which poses serious health and survival risks. The presence of these 
endocrinologically-relevant compounds would be missed by current measures that specifically 
target measurement of E2. 
 
4.1.3 Previous applications of ER-RGBs 
 
Since estrogen mimicking molecules can persist in human tissues, they have the potential to 
interact with intracellular ERa and/or -b and either activate or inhibit ERa and/or -b cell 
signalling pathways. Downstream implications of long term exposure to xenoestrogens can 
increase the risk of infertility, disorders of sexual development (Paris et al., 2006; Gaspari et 
al., 2011; Paris et al., 2013) and cancer of the breast, prostate, testicles and thyroid (Fernandez 
& Russo, 2010; Soto & Sonnenschein, 2010). GC/MS cannot effectively screen for novel 
estrogenic contaminants if they are not structurally characterised. However, ER-RGBs can 
characterise the estrogenicity of a sample without prior knowledge of the molecular 
structure(s) within the sample. This means ER-RGBs can help to classify the biological 
relevance of being exposed to such samples. BPA (Matthews et al., 2001), polyethylene 
terephthalate (PETs) (Wagner et al., 2013), polychlorinated biphenyls (PCBs) (Plíšková et al., 
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2005) and polybrominated diphenyl ethers (PBDEs) (Meerts et al., 2001) are plastic monomers 
that have been detected in water samples and have demonstrated weak but measurable ERa 
and/or -b bioactivity (Pinto & Reali, 2009) in ER-RGBs.  
 
In fact, common place food items such as cows milk, cheese, fish, tofu, chocolate, bread and 
infant formula have all demonstrated ER activity in ER-RGBs (Zava et al., 1998; Behr et al., 
2011; Stypuła-Trębas et al., 2015). The exposure to synthetic and naturally occurring 
estrogenic molecules can summate in the plasma and potentially interfere with ERa and/or -
b cell signalling and disrupt the homeostasis of an organism. This provides impetus to account 
for all estrogenic molecules in the serum, and not just measure E2 alone.  
 
ER-RGBs have also been used to measure biological matrices including serum (Lim et al., 
2014a), urine extracts and (Kinjo et al., 2004) saliva ER bioactivity (Zava et al., 1998). Saliva ER 
bioactivity was shown to sharply increase 1-2 hours post-soy milk consumption and then 
return to baseline levels after 5 hours, showing that temporal changes over time could be 
detected using an ER-RGB (Zava et al., 1998). Whereas consumption of non-phytoestrogen 
containing foods did not change ER bioactivity of saliva (Zava et al., 1998). Furthermore, an 
MCF-7 (ER+ breast cancer cell line) ER-RGB was validated as a tool to detect a sharp increase 
in serum ER bioactivity of serum from male participants following ingestion of E2 valerate (Li 
et al., 2009b). 
 
ER-RGBs have previously been employed as a technique in a research clinical context. Serum 
and plasma ERa bioactivity has been shown to be elevated in the context of pubertal 
development in girls and boys (Paris et al., 2002b), menopause (Wang et al., 2005), disorders 
of sexual development (Paris et al., 2006; Gaspari et al., 2011; Paris et al., 2013), hip fractures 
(Lim et al., 2012) breast- (Widschwendter et al., 2009; Fourkala et al., 2011; Lim et al., 2014a) 
and lung cancer (Lim et al., 2014b) (more detail in Chapter 5.0, Section 5.1.2) in patients versus 
controls. Most interestingly, a link between exposure to estrogenic contaminants and 
disorders of sexual development has been established through the use of ER-RGBs (Paris et 
al., 2006; Paris et al., 2013). Neonates and young children born with ambiguous genitalia or 
other disorders of sexual development, such as premature thelarche may have been exposed 
to endocrine disrupting chemicals (EDCs) from fertilisers in utero from their mothers living in 
agriculture settings (Paris et al., 2006). The reported ERa bioactivity was higher in exposed 
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cases relative to cases whose mothers had not been exposed to EDCs (Paris et al., 2006; Paris 
et al., 2013). Despite elevated ERa bioactivity in cases that had been exposed, there was no 
difference in E2 concentration relative to non-exposed patients (Paris et al., 2006; Paris et al., 
2013). This then raises the question if exposure to EDCs can also increase the risk for other 
endocrine disorders, such as breast cancer. Measuring E2 levels alone would overlook this 
very important component of estrognenicity, which is physiologically relevant. Therefore, 
these studies provide a solid platform for investigating whether ER bioassays can provide 
clinicians additional information about patients serum profiles alongside immunoassay or RIA 
data.  
 
4.1.4 The mechanism of the T47D-ER bioassay 
 
ER-RGBs have been engineered to mimic classical ERa/b signalling for the purpose of 
providing a measure of the functionality of a test sample towards ERa/b (Balaguer et al., 1999; 
Legler et al., 1999; Matthews et al., 2001; Bovee et al., 2004; Wilson et al., 2004; Wang et al., 
2014b).The level of ERa/b activation induced by a test sample provides a measure of the net 
estrogenicity of a sample. The main approaches used to create an ER-RGB  are,: (1) 
transfection of a reporter gene plasmid into a mammalian cell line that endogenously 
expresses high levels of ERa and/or -b; (2) co-transfection of an ERa or -b expression plasmid 
and a reporter plasmid into a cell with no-, or low level, endogenous ERa or -b expression 
(refer back to Chapter 1, Section 1.7, Figure 1.8). Upon treatment with an estrogenic test 
sample, the estrogenic molecules will enter the cell and bind and activate endogenous-, or 
recombinant, ERa or -b. The activated receptors form a dimeric complex that functions as a 
transcription factor that binds to an ERE upstream of a reporter gene on the reporter plasmid 
to induce expression of a reporter protein. GFP as a reporter protein can be directly measured 
for fluorescence or, if an enzyme, such as luciferase is generated, the plate can be read for 
luminescence following addition of a substrate, such as luciferin.  
 
In this study, T47D cells, which endogenously express both ERa/b were utilised (Figure 4.1). 
Under this mechanism, when treated with an estrogenic molecule, the endogenous ERa/bs 
are activated and function to transcribe the luciferase reporter gene by binding to ERE on the 
reporter plasmid. At the time of the measuring reporter gene activation, the luciferase 
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enzyme reacts with the luciferin substrate that is added to the T47D cell lysate. Luciferin 
interacts with the luciferase enzyme and together with adenosine triphosphate (ATP) and O2, 
luminescence is generated. This bioassay approach allows for light to be emitted in response 
to endogenous ERa/bactivation by a test sample and the level of luminescence is proportional 
to the level of ERa/b activation. 
 
 
Figure 4.1: Mechanism of T47D-ER bioassay. 
 
(1) Estrogenic molecules diffuse into the cell and binds to endogenous ERa/b (located in the 
nucleus), (2) the activated ERa/bs dimerise, (3) the dimeric ERa/bs translocate to the ERE 
on the reporter plasmid upstream of the reporter gene, (4) this promotes the expression of 
the luciferase reporter protein. (5) At the time of the bioassay, the cells are lysed and 
exposed to the luciferin substrate, which interacts with luciferase and together with O2 and 
ATP, is converted into oxyluciferin, CO2 and adenosine monophosphate (AMP) by-products 








Since molecules other than E2 can be detected with ER-RGBs and exposure to such molecules 
has been shown to translate into clinical pathophysiology (Paris et al., 2006; Gaspari et al., 
2011; Paris et al., 2013), there is impetus to develop and optimise an ER bioassay for 
meaningful clinical interpretation and to determine if there is value in using an ER bioassay to 
companion current E2 measures.  
 
Following the previous chapter, where a mammalian cell line was best suited for measuring 
serum AR bioactivity, a human breast cancer cell line, T47D, was used for this study to 
determine if an ER bioassay has potential clinical value by assessing ER bioactivity of plasma 




• To optimise the T47D-ER bioassay for the most effective assay performance for serum 
and plasma measurement of estrogen activity. 
 
• To determine if the T47D-ER bioassay provides additional information to current 




The T47D-ER bioassay will measure ER bioactivity of breast cancer patient plasma and provide 





This chapter has a focus on optimizing the cell culture conditions for inducing the best activity 
of the T47D-ER cells. The cell culture protocol used in this study for T47D-ER cells are described 
in general methods (Chapter 2.0, Section 2.5). The statistics for this chapter are described in 
sections 4.2.1.5 and 4.2.1.6 
 
4.2.1 Optimisation of bioassay protocol for T47D-ER cells  
 
In this chapter, steps were taken to optimise the T47D-ER bioassay. An overview of the 
bioassay procedure and the changed variables are shown below (Figure 4.2, page 131). In 
optimisation of the T47D-ER bioassay, the final ethanol concentration that (step 1 on Figure 
4.2) T47D-ER cells were exposed to, the treatment time (step 2 , Figure 4.2), the cell seeding 
density (step 3, Figure 4.2) and serum concentration in the cell culture media and test samples 
(step 4, Figure 4.2) were all tested for their effect on assay performance.  
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Figure 4.2: Overview of optimisation steps of the T47D-ER bioassay. 
 
The yellow box highlights the general steps of the T47D-ER bioassay. On day 1, the cells are seeded into 96-well plates, on day 2 the cells are treated 
with E2 or the test sample (serum/plasma) and on day 3 or 4 the assay is performed. On the day of the assay, Bright Glo reagent is added to the cells 
and the plates are read using a plate reader for luminescence. (1) The first optimisation step involved lowering the ethanol concentration (used to 
dissolve E2) that the cells are exposed to from 1% (v/v) to 0.01% (v/v). (2) The second optimisation step involved changing the time of treatment 
from 24- to 48 hours. (3) The third optimisation step compared two different cell seeding concentrations. (4) The serum concentration in the cell 
culture media and test serum/plasma samples was the final step in assay optimisation. 
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4.2.1.1 Seeding of T47D-ER cells 
 
T47D-ER cells were seeded at the time of passaging into clear 96-well plate(s) in DMEM F-12 
media, supplemented with: 
• Charcoal-stripped FCS         10% or 2% (v/v) (step 4 in Figure 4.2) 
• G418          75 µg/mL 
 
T47D-ER cells were seeded at two different cell concentrations (2.5 x 105 cells/mL and 5.0 x 
105 cells/mL) in 100 µL to determine the optimal cell seeding concentration (step 3 on figure 
4.2). Cells were counted using the trypan blue staining method (Chapter 2, Section 2.4.4.1). 
 
4.2.1.2 E2 dose response curves 
 
E2 dose response curves were used as the standard for ensuring the assay was operational 
and consistent between assays (EC50 in pM range). The first step in optimising assay 
performance was to alter the final ethanol concentration that cells were exposed to. The final 
ethanol concentrations tested in this experiment were 1% (v/v), 0.1% (v/v) and 0.01% (v/v) 
(step 1 on Figure 4.2). 
 
E2 was dissolved in ethanol and the final ethanol concentration was diluted to 1% (v/v), 0.1% 
(v/v) and 0.01% (v/v) in DMEM F12 cell culture media supplemented with: 
• Charcoal-stripped FCS               10%, 2% or 0% (v/v) 
• G418          75 µg/mL 
 
For a final concentration of 1% (v/v) ethanol, 1 µL of the ethanol-dissolved E2 stock solutions 
that had been serially diluted 1:3 (7.5 x 10-8 M to 4.7 x 10-14 M) and stored in glass vials were 
added directly to each well into 100 µL media (1:100 dilution) across 14 dilutions.  
 
For a final starting concentration of 0.1% (v/v) of ethanol, the ethanol-dissolved E2 stock (1.4 
µM) was diluted across two dilution steps. E2 was first diluted 1:100 by adding 10 µL to 990 
µL DMEM F12 media (supplemented with 10% (v/v) charcoal-stripped FCS and G418). The E2-
spiked media was mixed well and 15 µL was transferred to 135 µL media on top of cells, in 
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duplicate, to further dilute the ethanol/E2 concentration 10-fold for a final dilution of 1:1000 
(step 1 and 3 in Figure 4.3). The final starting concentration of ethanol was 0.1% (v/v) and the 
starting concentration E2 was 1.4 nM (Figure 4.3). 
 
 
Figure 4.3: Protocol for creating an E2 dose response curve. 
 
Ethanol was diluted to a final concentration of 0.1% (v/v) and 0.01% (v/v) by diluting the E2 
stock 1:1000 and 1:10,000, respectively. (1) For a final concentration of 0.1% (v/v) of 
ethanol, 1.4 µM of E2 was added to 990 µL of DMEM F12 media (1:100 dilution) in a 1.7 mL 
Eppendorf tube. (2) Similarly, for a final concentration of 0.01% (v/v) of ethanol, 37 µM of 
E2 was added to 1 mL of DMEM F12 media (1:1000 dilution) in a 1.7 mL Eppendorf tube. (3) 
From the Eppendorf tube, 15 µL was transferred into two wells (duplicate) of a 96-well plate 
that contained 135 µL of DMEM F12 media (1:10 dilution). This created a 1:1000 and 
1:10,000 dilution of ethanol/E2. The final starting concentration of ethanol was 0.1% (v/v) 
and 0.01% (v/v), respectively. (4) To create a serial dilution, 50 µL from the top two wells 
was pipetted down to the wells below, mixed well and repeated down the plate from A1 
and 2 down to H1 and 2 and up and across to A3 and 4 and down to H3 and 4. 
 
The same procedure was carried out to lower the E2-dissolved ethanol concentration to 0.01% 
(v/v), except, 1 µL of E2 (37 µM) was added to 1 mL DMEM F12 media (supplemented with 
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10% (v/v) charcoal-stripped FCS and G418). From there, the E2-spiked media was mixed well 
and 15 µL was transferred to 135 µL media (on top of cells), in duplicate, which further diluted 
the ethanol/E2 concentration 10-fold for a final dilution of 1:10,000 (step 2 and 3 in Figure 
4.3). The final concentration of ethanol was 0.01% (v/v) and the starting E2 concentration was 
37 nM (Figure 4.3).  
 
For both 0.1% (v/v) and 0.01% (v/v) starting ethanol concentrations, the E2-treated wells were 
mixed well. Next, 50 µL of media was transferred to the wells below containing 100 µL media 
(1:3 dilution). This serial dilution procedure was repeated over approximately 16 steps (step 
4 in Figure 4.3).  
 
As a vehicle control, 10 µL or 1 µL of 100% ethanol was spiked into 1 mL DMEM F12 
(supplemented with charcoal-stripped FCS (10%) and G418 (75 ug/mL)) to dilute the ethanol 
1:100 and 1:1000, respectively. The ethanol-spiked media was diluted 1:10 by adding 10 µL to 
90 µL media on cells, in duplicate, for a final ethanol concentration of 0.1% (v/v) and 0.01% 
(v/v), respectively. Cells were incubated at 37°C, 5% CO2 for 24 or 48 hours (step 2 on Figure 
4.2). The luminescence induced by the E2 dose response curve was normalised to the 
luminescence produced by the ethanol vehicle control. 
 
4.2.1.3 Plasma and serum samples 
 
To determine the optimal concentration of serum to treat T47D-ER cells, cells were treated 
with a dilution series of human pre-menopausal female serum (single donor human serum, 50 
mL, female aged 25 years, Innovative Research, Lot #88 32700A). The 20% (v/v) serum was 
diluted 1:3, across 8 steps, in duplicate. To achieve a 20% (v/v) concentration of serum, 
duplicate wells with 120 µL DMEM F12 (supplemented with G418 and no FCS) were treated 
with 30 µL of serum. For a 1:3 serial dilution series, 50 µL from the starting wells was carried 
down to the wells below containing 100 µL media and mixed by pipetting up and down. 
 
Once the optimal final concentration of serum was determined to be 2% (v/v), cells were 
treated with 2 µL of breast cancer patient plasma (added to 98 µL DMEM F12 (supplemented 
G418, no FCS)). The breast cancer patient plasma was received as part of a clinical study based 
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in Christchurch called Exploring the Effects of Obesity-Related Inflammation and Exercise on 
Drug Metabolism in Cancer Patients. This is the same plasma as used in Chapter 3. 
 
4.2.1.4 Bright Glo assay 
 
T47D-ER cells express the luciferase enzyme in response to activation of endogenous ERa and 
-b. Therefore, to measure the net ER activation level in response to a test substance, cells 
were treated with Bright-GloTM Luciferase Assay System (Promega, Cat #E2610), which 
contains a cell lysis buffer and luciferin substrate. Luciferin is converted into light in the 
presence of luciferase, O2 and ATP (Figure 4.1), therefore the light emission is proportional to 
the level of ER-induced gene transcription occurring in the cells.  
 
The 96-well plate containing the T47D-ER cells were removed from the 37°C incubator. The 
media on the cells was aspirated and 100 µL of Bright Glo reagent (Promega, Cat #E2610) was 
added to each well to lyse the cells and introduce luciferin to initiate light emission in the 
presence of luciferase. Following a 2 minute incubation at room temperature, 100 µL of cell 
lysate was transferred to a 96-well white opaque plate. The white opaque 96-well plate was 
inserted into the plate reader (Molecular Devices, Spectra Max i3x) and each well measured 
for end-point luminescence using SoftMax Pro (version 7.0.2) software. 
 
4.2.1.5 EC50 of E2 
The luminescence values obtained from the plate reader data were directly transferred to 
GraphPad Prism Version 8.0. The duplicate values were imported into side-by-side columns 
and the data was transformed, normalised and fitted to a non-linear regression sigmoidal 
curve. The raw data (luminescence values) were converted into log format (X=log(X)). The 
maximal log data was normalised to 100% and the minimal log data is normalised to 0%. The 
logged, normalised data was fitted to a non-linear regression sigmoidal dose response curve, 
to derive an EC50 value. The EC50 is the concentration of E2 (molar) that induces 50% of the 
normalised luminescence. The EC50 value for E2 was derived from the sigmoidal curve 
generated for each dose response curve. The average EC50 value and SEM was calculated for 
E2. An E2 standard curve was included in every assay performed.  
 
 136 
In this chapter, the E2 dose response curves created for optimising treatment time, cell 
seeding density and serum concentration are shown where the luminescence from each 
concentration of E2 along the dose response has been averaged across all individual 
experiments (Figures 4.3C, 4.4C and 4.5C). This provides an average curve, with an EC50 value 
shown alongside the curve. However, when reporting the mean EC50 ± SEM, the mean and 
SEM is derived from the EC50 values across each individual dose response curve for the 
respective set of experiments. For this reason, the EC50 displayed for the average dose 
response curve graph differs slightly to the reported mean EC50 ± SEM generated from all 
curves. Note that, EC50’s calculated from either approach are within the SEM range. 
 
4.2.1.6 Calculating a ratio of luminescence to maximal E2 induction for serum 
samples  
 
The raw luminescence values obtained from serum and plasma samples were averaged across 
the duplicates. For serum and plasma measurements, all luminescence values were reported 
as a ratio to maximal luminescence induced by the E2 dose response curve, which is a measure 
of maximal assay performance (refer to Chapter 2.0, Figure 2.2). The luminescence values 
from the serum/plasma were then divided by the luminescence induced by the top three 
points of the E2 dose response curve for each assay performed by following the following 
equation:  
 
!"#$%	#%	'"($'")	*2 = -.'$/0120/20	%3	104.'/6)"1'"-.'$/0120/20	%3	'"($'")	*2  
 
The ratios for each independent experiment were imported into a column graph in GraphPad 
Prism (Version 8.0) and the experiment was repeated a minimum of three times. Outliers were 
removed by the ROUT method (GraphPad Prism (Version 8.0)). The statistical tests used to 
determine significant changes between tested parameters are detailed throughout the results 
section. The same rationale and choice of statistical tests is the same as the HEK293-AR cells 




4.3.1 Optimisation of the ethanol concentration that T47D-ER cells 
were exposed to during assay incubation time  
 
The first step required to optimise the T47D-ER bioassay was to establish if the bioassay could 
detect E2, since E2 is the most potent endogenous ligand of ERa/b. To determine if E2 was 
able to activate the assay, cells were exposed to a serial dilution of E2 (7.5 x 10-8 M to 4.7 x 10-
14 M) to create a dose response curve and to derive an EC50 value. However, the standard 
treatment protocol for testosterone and the HEK293-AR bioassay did not translate into an 
effective treatment protocol for E2 and the T47D-ER bioassay. In the HEK293-AR bioassay, 
testosterone dissolved in 100% ethanol and diluted to 1% (v/v) final concentration of ethanol 
in the cell culture media is effective for generating a testosterone dose response curve 
(Chapter 3.0, Section 3.3.1, Figure 3.2). However, the same approach for E2 in the T47D- ER 
bioassay was ineffective for creating an E2 dose response curve (Figure 4.3A). The final ethanol 
concentration was subsequently lowered to 0.1% and 0.01% (v/v) in cell culture media to 
determine if lower ethanol concentrations would enable generation of an E2 dose response 
curve (Figure 4.3B and C). Final ethanol concentrations of 0.1% and 0.01% (v/v) did generate 
a dose response curve (Figure 4.3B and C), with EC50 measuring 6.7 pM and 5.6 pM, 
respectively. Therefore, it appears that high percentage ethanol (1% (v/v)) is interfering with 






Representative E2 dose 
response curves for 
optimisation of the 
final starting ethanol 
concentration in the 
T47D-ER bioassay. 
 
A. E2 (1.5 mg/mL) dissolved 
in 100% ethanol was diluted 
1:100 to a final 
concentration of 6.1 x 10-6 – 
4.7 x 10-14 M (log) 
corresponding to a final 
ethanol concentration that 
cells were exposed to of 1% 
(v/v). B. E2 (2.5 mg/mL) 
dissolved in 100% ethanol 
was diluted 1:1000 (0.1% 
(v/v)) to a final starting 
concentration of 1.4 nM E2 
and serially diluted 1:3. This 
produced a dose response 
curve with a corresponding 
EC50 value of 6.7 nM. C. E2 
(2.5 mg/mL) dissolved in 
100% ethanol was diluted 
1:10,000 (0.01% (v/v)) to a 
final starting concentration 
of 37 nM E2 and serially 
diluted 1:3. This produced a 
dose response curve with a 
corresponding EC50 value of 
5.6 pM. The concentration 




4.3.2 Optimisation of treatment time for T47D-ER cells that led to 
improved assay performance  
 
The next step was to determine if time of treatment for the assay could be improved. With 
the overarching aim of this assay being to test serum or plasma samples, it is imperative that 
the dynamic range of the assay be as large as possible. The dynamic range is the difference 
between the minimal and maximal luminescence values induced by high and low 
concentrations of E2, respectively. Since serum and plasma samples will be tested at a single 
percentage of total volume on the cells, it is important that relative changes in luminescence 
can be detected on an inter- and intra-patient basis rather than an all or nothing response. 
The standard treatment time for the T47D-ER bioassay is 24 hours (Signosis, Cat #SL-0002) 
(Legler et al., 1999). Both 24- and 48 hour treatment incubation periods were tested to see if 
48 hours could improve the dynamic range of the T47D-ER bioassay. T47D-ER cells were 
treated with a dilution series of E2 (3.8 x 10-9 M to 7.1 x 10-15 M) and incubated for 24- and 48 
hours to compare differences in the E2 dose response curves. The E2 dose response curve 
generated from 48 hour data induced a higher level of luminescence (level of induction) from 
baseline relative to the 24 hour dose response curve (Figure 4.4A, page 140). After 
quantification of the level of induction for 24- and 48 hours incubation, it is reported that on 
average the values are 10,224 ± 4255 RLU and 35,183 ± 2673 RLU, respectively (n=4 for 24 
hours, n=12 for 48 hours). The induction of luminescence (D luminescence) was significantly 
higher for 48 hours incubation (**p<0.01, Students unpaired t-test) compared with 24 hours 
incubation (Figure 4.4B). Importantly, the longer 48 hour treatment time did not correspond 
with a change in EC50 of E2 (p>0.05, Students unpaired t-test) (Figure 4.4C). The EC50 of E2 at 
24- and 48 hours measured on average 6.9 x 10-12 M (6.9 pM) ± 2.3 x 10-12 M (2.3 pM) (n=12) 
and 7.8 x 10-12 M (7.8 pM) ± 1.5 x 10-12 M (1.5 pM) (n=4). This was expected as sensitivity of 
the assay should not change with time.  
 
Once it was determined that 48 hours treatment time was superior to 24 hours, the 48 hour 
treatment time was incorporated into the standard treatment protocol for the next series of 
experiments. Once all the experiments were carried out, an average ± SEM for each point of 
the dose response curve was obtained across all optimisation experiments (n=12) and used as 
the reference curve in the analysis and graphs of all three experiments (the reference curve is 
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shown as the blue line with squares for the dose response curves and blue bars in the bar 
graphs in Figures 4.4-4.6). 
 
Figure 4.4: 
Optimisation of the 
treatment time of 
T47D-ER cells with E2. 
 
A. Each point of the E2 dose 
response curves are 
expressed is mean 
luminescence – SEM for 24 
hour treatment (red) (n=4) 
and mean luminescence + 
SEM for 48 hour (shown as 
hr) treatment (blue), n=12. 
The mean minimum 
(dashed line) and maximum 
luminescence (full line) for 
24- and 48 hours treatment 
is shown to illustrate the 
induction of luminescence. 
B. The mean induction 
levels of luminescence 
between the 24 hour and 48 
hour treatment of the E2 
dose response curves (A) is 
expressed as mean + SEM, 
n=4. The difference in 
luminescence between 
minimum and maximum 
luminescence was 
significantly greater at 48 
hours compared with 24 
hours treatment time with 
E2 (**p<0.01, Student 
unpaired t-test). C. The 
luminescence values (same 
curves as A) were 
normalised to measure the 
EC50 of E2. There was no 
significant difference in the 
EC50 of E2 between 24- and 
48 hour treatment time 
periods (*p>0.05, Students 
unpaired t-test). The 
concentration of E2 is 
expressed in log format 
(molar concentration). 
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4.3.3 Optimisation of the cell seeding density of T47D-ER cells for 
improved assay performance 
 
Given the treatment time was increased to 48 hours to enhance the dynamic range, the cell 
seeding concentration was reconsidered since cells were 100% confluent at the time of 
starting the bioassay (day 4 of the T47D-ER bioassay). Therefore, the cell seeding density was 
reduced by 50% to 2.5 x 105 cells/mL to determine if the assay performance could be improved 
to allow for cell division to occur during the 48 hour treatment period. The lower cell seeding 
density (2.5 x 105 cells/mL) was compared to the high cell seeding density (5.0 x 105 cells/mL) 
by treating cells for 48 hours with a dilution series of E2 (3.8 x 10-9 M to 7.1 x 10-15 M) (Figure 
4.5).  
 
The E2 dose response curves produced show that there was a greater induction of 
luminescence for the higher cell seeding density measuring 35,183 ± 2673 RLU (n=12) (same 
curve as in section 4.3.2), relative to the lower cell seeding density measuring 21,622 ± 2698 
RLU (n=3) (Figure 4.5A). The induction of luminescence (D luminescence) was significantly 
higher for the high cell seeding density (**p<0.01, Students unpaired t-test) compared with 
the low cell seeding density (Figure 4.5B). The higher cell seeding density was not dampening 
the sensitivity of the assay compared with the lower cell seeding density because there was 
no change (p>0.05, Students unpaired t-test) in EC50 of E2 (Figure 4.5C). When quantified, the 
EC50 of E2 at the lower cell seeding density measured on average ± SEM 6.6 x 10-12 M (6.6 pM) 
± 1.4 x 10-12 M (1.4 pM).  
 
Overall, T47D-ER cells seeded at the higher cell seeding concentration of 5.0 x 105 cells/mL 
followed by treatment for 48 hours was deemed most optimal for generating the largest 




Figure 4.5: Optimisation of the seeding density of T47D-ER cells. 
 
A.  E2 dose response curves for higher and lower seeding densities of T47D-ER cells is 
shown. For each concentration of E2, the mean luminescence + SEM is shown for the higher 
cell seeding density (blue) and mean luminescence - SEM for lower cell seeding density 
(orange) is shown. The average minimum (dashed line) and maximum (full line) 
luminescence for higher and lower seeding densities is depicted to show the change in 
luminescence. B. The difference between maximal and minimal luminescence of the E2 
dose response curves seeded at higher and lower density are expressed as mean + SEM, 
n=3. The difference in luminescence was significantly greater for the higher seeding density 
compared with the lower seeding density (**p<0.01, Student unpaired t-test). C. The 
luminescence values (same curves as A) were normalised to measure the EC50 of E2. There 
was no significant difference in the EC50 of E2 when treated upon both higher and lower 
cell seeding densities (p>0.05), Students unpaired t-test). The concentration of E2 is 
expressed in log format (molar concentration). 
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4.3.4 Determining the baseline of the T47D-ER ER bioassay 
 
The baseline of the T47D-ER ER bioassay when treated for 48 hours at a cell seeding density 
of 5.0 x 105 cells/mL corresponded to a minimum luminescence readout of ~20,000 RLU 
(Figure 4.4A and 4.5A). Since the aim of this study was to optimise the assay for serum and 
plasma measurement, an appropriate control and baseline of the assay needed to be 
established to separate the test samples capable of activating ERa/b from those that are not. 
Since the baseline of the assay is ~20,000 RLU under standard treatment, it was next 
investigated whether the FCS in the media was responsible for this high baseline. The minimal 
promoter of the luciferase reporter plasmid in the T47D-ER cell line will drive a small amount 
of luciferase expression independent of ERa/b activation. Therefore, it is desirable that the 
baseline of the assay is as close to the minimal promoter activity as possible. Therefore, the 
charcoal-stripped FCS concentration in the media was lowered to 2% (v/v) (magenta) and 0 % 
(v/v) (green) and compared to the standard treatment condition, which contains 10% (v/v) 
charcoal-stripped FCS (blue) (Figure 4.6). 
 
The average E2 dose response curves obtained show that 0% (v/v) and 2% (v/v) FCS produced 
the same baseline level, which is lower than the 10% (v/v) FCS (Figure 4.6A). The baseline for 
2% (v/v) FCS and serum-free E2 dose response is approximately 10,000 RLU. Therefore, the 
lower serum percentages were capable of lowering the baseline of the assay.  
 
The level of induction (D luminescence) between all FCS concentrations remained the same 
(p>0.01234, ordinary one-way ANOVA, multiple comparisons corrected for using Sidaks’ test) 
(Figure 4.6A and B). It is important that the inducibility of the assay is not compromised due 
to lower FCS in the media, as this would suggest the cells are not thriving under these 
conditions. Furthermore, the EC50 of E2 remained unchanged between all concentrations of 
FCS (p>0.1234, ordinary one-way ANOVA, multiple comparisons corrected for using Sidaks’ 
test)  (Figure 4.6C). Showing that the sensitivity of the assay was not altered. The low serum 
media was successful at lowering the baseline of the assay without interfering with the 
dynamic range and sensitivity of the assay towards E2. Due to this finding, the next experiment 
sought to discover if serum or ethanol was responsible for the heightened ER bioactivity in the 
E2 dose response curve containing 10% (v/v) FCS.  
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Figure 4.6: Determining assay induction and sensitivity changes based on 
the concentration of FCS. 
 
A. E2 dose response curves with 10%-, 2%- and 0% charcoal-stripped FCS. For each 
concentration of E2, the mean ± SEM of luminescence is shown. The average minimum 
(dashed line) and maximum (full line) luminescence for each 10%-, 2%- and 0% charcoal-
stripped FCS show the induction of luminescence for each percentage of FCS. B. The 
difference between maximal and minimal luminescence of the E2 dose response curves 
with 10%-, 2%- and 0% charcoal-stripped FCS are expressed as mean + SEM, n=3. The 
difference in luminescence was not significantly different between 10%-, 2%- and 0% 
charcoal-stripped FCS (p>0.1234, ordinary one-way ANOVA). C. The luminescence values 
(same curves as A) were normalised to measure the EC50 of E2. There was no significant 
difference in the EC50 of E2 when treated in media containing 10%-, 2% or 0% charcoal-
stripped FCS (p>0.1234, ordinary one-way ANOVA). The concentration of E2 is expressed in 
log format (molar concentration).  
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4.3.5 FCS causing interference of the T47D-ER bioassay 
 
In the previous experiment, it was observed that 0% (v/v) and 2% (v/v) FCS lowered the 
baseline of the assay compared with 10% (v/v) FCS without interfering with important assay 
parameters (dynamic range and EC50). Therefore, it appears that both ethanol (Figure 4.3) and 
serum (Figure 4.6) are capable of interfering with assay performance. To determine if serum 
or ethanol is responsible, T47D-ER cells were treated with 10% (v/v) of charcoal-stripped FCS 
alone (blue bar) and with 1% (v/v), 0.1% (v/v) and 0.01% (v/v) ethanol (E2-deprived conditions) 
to determine if the serum or ethanol was responsible for interference with the assay (Figure 
4.7). There was no significant difference between serum only (10% (v/v) conditions and when 
co-treated with ethanol at a final concentration of 1% (v/v), 0.1% (v/v) and 0.01% (v/v) 
(ordinary one-way ANOVA, p>0.1234, multiple comparisons corrected for by the Sidaks’ test). 
Therefore, under E2-deprived conditions, ethanol is not interfering with the assay and serum 
is primarily responsible for the heightened baseline of the assay.  
 
 
Figure 4.7: Determining the interference of the T47D-ER bioassay 
 
T47D-ER cells were treated with DMEM F12 media containing 10% (v/v) charcoal-stripped 
FCS alone and with 1%, 0.1% and 0.01% (v/v) ethanol to determine if serum or ethanol is 
the source of assay interference. All concentrations of ethanol co-treated with serum did 
not significantly change ER bioactivity relative to serum alone (p>0.1234, ordinary one-way 
ANOVA). Therefore, serum is the source of interference under E2-deprived conditions. 
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4.3.6 Optimisation of the final serum concentration for the 
treatment of T47D-ER cells 
 
Since 2% (v/v) charcoal-stripped FCS induced low ER bioactivity measuring less than 20% of 
maximal assay activation, pre-menopausal female serum was tested at 2% (v/v). Results show 
that 2% (v/v) pre-menopausal female serum induced ~90% of maximal assay activation (Figure 
4.8). This shows that the estrogenic molecules in the pre-menopausal female serum are 
detected by the T47D-ER bioassay. Increasing and decreasing volumes of pre-menopausal 
female serum were tested (up to 20% (v/v) and down to 0.009% (v/v)) to determine the 
optimal concentration of serum for measuring ER bioactivity. A dose response effect was 
observed and 2% (v/v) saturated the bioassay. Therefore, 2% (v/v) of test serum and plasma 
was chosen to move forward with since it provided good inducibility of the assay and is a 
volume (2 µL serum/98 µL media) that can be pipetted accurately. 
 
 
Figure 4.8: Testing pre-menopausal female serum in the T47D-ER bioassay. 
 
A starting concentration of 20% (v/v) was diluted 1:3 across 8 steps in DMEM F12 media 
(no FCS). ER bioactivity starts at a maximal level of ~90% for 20-2.2% (v/v) serum 
concentration and steadily drops to ~40% of assay threshold at 0.009%. ER bioactivity 















































4.3.7 Screening breast cancer patient plasma samples using T47D-ER 
bioassay 
 
The next step was to determine if plasma samples could be measured using the T47D-ER 
bioassay. Clinical samples are often in plasma form, therefore it is important to showcase the 
versatility of the assay. Breast cancer patient plasma was received from 9 breast cancer 
patients before (grey bars) and after (white bars) (neo-) adjuvant chemotherapy to test the 
level of ER bioactivity (Figure 4.9, page 149). The menopausal status of each patient was not 
provided as information to our lab, however, the age range of 43 – 68 years of age is indicative 
of pre-/peri-/post-menopausal females. Due to the low number of patient plasma acquired in 
this study, the aim was to determine if ER bioactivity was measurable in this small cohort of 
patients and whether there were differences in the outcome of the T47D-ER bioassay 
compared with the E2 ELISA. There was a significant decrease after chemotherapy for 2 out 
of 9 patients. Patient 2 and 5 experienced a decrease in ER bioactivity (repeated measures 
one-way ANOVA followed by multiple comparisons test between the before- and after 
chemotherapy sample for each patient).  
 
Intra-patient variability was considerably high. For example, plasma from patient 8 before 
chemotherapy did not induce ER bioactivity above baseline on 2 occasions, whereas other 
experiments induced up to ~80% of maximal activation. Overall, breast cancer patient plasma 
was measurable in the T47D-ER bioassay and changes in ER bioactivity were observed for 2 
out of 9 of the patients (Figure 4.9, page 149).  
 
The E2 concentration from each sample was measured using an E2 ELISA and the results 
amoung each patient were variable, ranging from undetectable (patient 6, 7, 8 and 9 after 
chemotherapy) up to 47 ng/mL. For every patient, except for patient 4, there was a decrease 
in E2 levels after the onset of chemotherapy. The drop in E2 concentration for only patients 2 
and 5 was represented in the T47D-ER bioassay. Overall, the results of the T47D-ER bioassay 
coupled with the E2 ELISA show that generally the ER bioactivity remained steady despite a 
decrease in E2 for most patients.  
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Table 4.1: E2 concentration measured in plasma samples by ELISA.  
 
Breast cancer patient plasma samples before- and after (neo-) adjuvant chemotherapy 
were tested for E2 by ELISA. Units expressed in both pg/mL and pM (rounded to 2 decimal 
places). 
Patient samples E2 concentration pg/mL pM 
1 before 10.88 39.94 
1 after 5.88 21.58 
   
2 before 29.70 109.03 
2 after 10.12 37.15 
   
3 before 8.94 31.82 
3 after 1.25 4.59 
   
4 before 3.94 14.46 
4 after 3.34 12.26 
   
5 before 6.95 25.51 
5 after 0.50 1.84 
   
6 before 28.64 105.14 
6 after Undetected --- 
   
7 before 0.16 0.59 
7 after Undetected --- 
   
8 before 47.09 172.88 
8 after Undetected --- 
   
9 before 6.50 23.86 





Figure 4.9: ER bioactivity of breast cancer patient plasma samples before-, and after-, (neo-) adjuvant chemotherapy 
measured in the T47D-ER bioassay 
 
Mean ± SEM ER bioactivity of 9 breast cancer patient plasma samples. T47D-ER cells were treated with the plasma samples at a 2% (v/v) concentration 
to assess for ER bioactivity. ER bioactivity is reported as a mean ± SEM ratio to the maximal induction of the assay induced by E2 (y-axis). The grey 
bars represent the ER bioactivity before chemotherapy and the white bars show the level of AR bioactivity after chemotherapy where no change 
was detected. The green hashed bars show the plasma samples that significantly decreased in ER bioactivity following chemotherapy (*p<0.033, 
***p<0.0002, Repeated measures one-way ANOVA followed by multiple comparisons test between the before- and after chemotherapy sample for 
each patient). The red dashed line shows the average luminescence induced by the serum free blank across all experiments to highlight where the 
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Following stringent optimisation of the T47D-ER bioassay for plasma measurement, the most 
important finding of this study shows that the T47D-ER bioassay could measure ER bioactivity 
of plasma samples from breast cancer patients. The results of the ER bioassay were discordant 
with the results of the E2 ELISA. The E2 ELISA measured a decrease in E2 for 8 out of 9 patients, 
however, ER bioactivity levels only decreased for 2 out of 9 patients. This finding could indicate 
that the estrogenicity of the serum remains elevated despite the clinically measured variable, 
E2, showing a decrease. 
 
Ethanol and E2 cross talk 
 
Ethanol is solvent, which dissolves the E2 powder used to treat the T47D-ER bioassay. It was 
apparent in this study that a 1% (v/v) concentration of ethanol on the cells was interfering 
with ER bioactivity since an E2 dose response curve could not be created. Therefore, the first 
step in optimising the T47D-ER bioassay was to lower the ethanol concentration to prevent 
assay interference. Interestingly, according to the literature, there appears to be a functional 
relationship or crosstalk between ethanol and ER cell signalling. Ethanol consumption has 
been shown to increase E2 concentration in post-menopausal females who are prescribed 
estrogen replacement therapy (Ginsburg et al., 1995). Furthermore, the observations in a 
human clinical study have shown a positive synergistic relationship between E2-hormone 
replacement therapy and ethanol consumption and the risk of ER+ breast cancer (Gapstur et 
al., 1995). In vivo studies have also demonstrated a relationship between ethanol-treated 
mice and an increased rate of loss of bone mineral density, which was protected by E2 
treatment (Chen et al., 2006b). 
 
In this study, it was demonstrated that ethanol was interfering with assay performance since 
a dose response curve could not be generated from cells treated with E2 diluted in ethanol at 
a final 1% (v/v) concentration. Therefore, it could be speculated that ethanol may be acting as 
a ligand for ERa and/or -b and oversaturating ERs and their transcriptional response. 
However, T47D-ER cells treated with ethanol at 1%, 0.1% and 0.01% (v/v) concentration under 
E2-depreived conditions did not induce ER bioactivity (Figure 4.7). The results of this study are 
in agreement with a previous study by Fan et al. (2000), where it was shown that ethanol 
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alone was not acting as an agonist to ER in the T47D-ER and MCF7-ER bioassays. However, co-
treatment of E2 and ethanol have been shown to operate synergistically to activate ER-
mediated gene transcription in vitro (Fan et al., 2000). Although, we did not investigate the 
effect of ethanol on cellular proliferation, previous studies have shown that ethanol 
upregulates cellular proliferation of ER+ breast cancer cell lines, but not ER- breast cancer cell 
lines (Singletary et al., 2001). Taken together, it is likely that ethanol is interfering with ER cell 
signalling.  
 
Due to the rapid decline of estrogens at the onset of menopause, women are at higher risk of 
osteoporosis and high consumption of alcohol can accelerate this (Sampson, 2002). Bone 
formation is an ERa-mediated process (Nakamura et al., 2007) and a study showed that 
ethanol was capable of suppressing ER-mediated gene expression in bone cells (Chen et al., 
2009). Therefore, this observation could help explain the link between alcohol consumption 
and low E2 during menopause in the development of osteoporosis, since ERa mediated gene 
transcription is suppressed. Such studies demonstrate that there is a functional relationship 
between E2, ethanol and ERs. 
 
In the context of breast cancer, ethanol appears to augment ER-mediated cell signalling when 
liganded with E2. However, on the contrary, ethanol suppresses ERa in the context of 
osteoporosis (Chen et al., 2009). In both cases, ethanol is exacerbating disease progression in 
an ERa-dependent manner. Overall, this could suggest that ethanol is functioning in a 
cofactor-like, cell-dependent manner rather than as a ligand capable of activating ER signalling 
independently. Based on the inability to create an E2 dose response curve at a final 1% ethanol 
(v/v) concentration, the ethanol concentration was lowered to 0.1% and 0.01% (v/v), which 
allowed E2 dose response curves to be generated. Since E2 suspended in 0.01% (v/v) ethanol 
could reliably produce a dose response curve with an average EC50 of 5.6 pM, this was used as 
the standard treatment for the E2 standard curve. 
 
Time of treatment 
 
The next step of the study was to determine if the standard 24 hour incubation period was 
most optimal for T47D-ER bioassay performance (protocol provided with cells purchased from 
Signosis, Cat #SL-0002)(Legler et al., 1999). Screening serum and plasma samples involves 
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treating with a single volume of serum and plasma rather than a serial dilution. Therefore, it 
is imperative to create a large dynamic range of the assay to ensure that serum and plasma 
samples can induce ER bioactivity across a wide range of luminescence values. A large dynamic 
range of the assay improves the chances of more accurate detection of intra- and inter-patient 
differences. To determine the dynamic range of the assay, the difference in luminescence 
between the minimum and maximum luminescence of the E2 dose response curve was 
calculated (D luminescence).  
 
The standard time for treatment of ER-bioassays is 24 hours (Jausons-Loffreda et al., 1994; 
Legler et al., 1999; Matthews et al., 2001; Sonneveld et al., 2004; Wilson et al., 2004; Wang et 
al., 2014a), however, one study treated for 16 hours (Balaguer et al., 1999) and another 
treated for 48 hours (Bonefeld-Jørgensen et al., 2001). In this study, it was clearly 
demonstrated that 48 hours was the optimal time to induce maximal ER activation.  
 
The longer time frame for treating T47D-ER cells could allow for enhanced transcriptional 
activity of ERs to occur. T47D-ER cells endogenously express ERa and -b and their expression 
levels could be altered by their level of activation. The following studies have investigated the 
effect of E2 on ERa mRNA, protein expression and transcriptional activity. In MCF-7 cells, E2 
treatment suppressed ERa mRNA expression and protein levels for up to 48 hours. Whereas, 
ER-mediated gene transcription initially decreased for one hour post-treatment but steadily 
increased 3-24 hours post-treatment. However, the transcriptional activity of ERs was not 
measured beyond 24 hours (Saceda et al., 1988). In vivo experiments have shown that ERa 
mRNA and protein expression in both adult and immature rats followed a biphasic response 
to E2 treatment over 72 hours. Whereby, ERa expression decreased up to 6 hours post-
treatment, then increased to exceed baseline levels after 24 hours and then returned to 
baseline levels by 72-hours (Nephew et al., 2000). Another study demonstrated there was a 
long-term effect of E2 treatment on ERa expression in hepatic cells of Xenopus laevis. It was 
shown that a single dose of E2 was capable of increasing ERa mRNA 18-fold for 125 days but 
the transcriptional activity of the receptors peaked at 14 days post treatment (Barton & 
Shapiro, 1988). Overall the results of these studies show that ERa expression is influenced by 
E2 treatment, but transcriptional activity of the receptors is most optimal up to 48 hours post-
treatment and less optimal within the first 0-6 hours post-treatment. Furthermore, ERa 
expression levels may not be a reliable proxy for the net transcriptional activity of the 
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receptors. Therefore, based on receptor expression and activity levels, 48 hours treatment for 




The time course of treatment and cell seeding density can influence the metabolic status of 
the cells, which is a crucial aspect of cell culture to consider. After determining that 48 hours 
treatment was more optimal than the standard 24 hours, it was next shown that a cell seeding 
density of 5.0 x 105 cell/mL was more optimal than 2.5 x 105 cells/mL. Since cells were 100% 
confluent at the time of the assay when seeded at the recommended 5.0 x 105 cells/mL, it was 
hypothesised that a lower cell seeding density may allow for a higher assay read out. This is 
because cells can undergo cell division at a higher rate and therefore, be more 
transcriptionally active. However, a higher cell seeding density coupled with a longer 
treatment time of 48 hours limits space and nutrient availability, which serves as a limitation 
to this method. This also raises an important question as to whether the cellular environment 
can interfere with ER cell signalling. Confluent cells are more prone to utilising the available 
glucose and leading to the accumulation of cytotoxic substances such as lactate and ammonia, 
both of which can substantially increase the pH of the media. Furthermore, ammonia has been 
shown to reduce the activity of antioxidant enzymes and increase superoxide formation in rat 
brains (Kosenko et al., 1999). This can activate apoptosis cell signalling pathways or induce a 
stressed state due to the accumulation of reactive oxygen species (reviewed by (Lennon et al., 
1991; Buttke & Sandstrom, 1994)). E2 has been shown to be protective against oxidative stress 
in neurons and in cardiovascular disease by upregulating antioxidant enzymes and decreasing 
the production of free radicals (Strehlow et al., 2003; Florian et al., 2004). However, in the 
context of breast cancer, E2 has been implicated in inducing unbalanced redox state (Sipe Jr 
et al., 1994; Mobley & Brueggemeier, 2004) leading to DNA damage and further tumour 
growth in an ER dependent process (Sastre-Serra et al., 2010). However, the expression of 
GPR94 is a proposed mechanism in place to allow cells to survive high levels of oxidative stress 
(Dejeans et al., 2012). Therefore, despite the potential for metabolic disturbances to the cells, 
breast cancer cells are equipped to survive highly oxidative environments. This is supported 
by the results of this study that showed the higher cell seeding density did not affect the 
transcriptional activity of the cells since the dynamic range of the assay was increased and the 




It was observed in the transformed E2 dose response curves that the luminescence (standard 
dose response curve shown in blue) baseline of the assay was high (~20,000 RLU). Therefore, 
it was investigated as to whether components of the media were responsible for this 
observation. This was an important step in optimising the assay for meaningful interpretation 
of results when testing patient plasma to ensure that positive samples do not appear below 
the limit of detection. Therefore, ensuring the result of a sample is not discounted as a false 
negative result when in fact the baseline of the assay could be overestimated. To optimise the 
baseline of the assay, the concentration of charcoal-stripped FCS in the media was lowered to 
2% (v/v) and 0% (v/v) to determine if this would lower the baseline level of luminescence. 
Both low FCS concentrations lowered the baseline level of luminescence in the assay. This 
finding clearly demonstrated the cause of the high background was the charcoal-stripped FCS 
in the media.  
 
A possible theory underlying the interference arising from FCS is that FCS is activating cell 
signalling pathways that lead to E2-independent activation of ERa. It has been shown that 
SHBG can bind GPRs and increase cytosolic cAMP (Rosner et al., 1992; Fissore et al., 1994), 
which activates downstream kinases such as PKA. PKA can activate ERa in a ligand-
independent manner and lead to transactivation of ERa. The presence of SHBG in charcoal-
stripped FCS could explain the observed high baseline with 10% (v/v) FCS in the media. 
Another possible reason for the observed high baseline is the interference arising from growth 
factors in the serum. Growth factors (i.e. IGF-1 and EGF) activate transmembrane growth 
factors receptors (i.e. IGF-1-R and ERGF-R), of which lead to downstream intracellular 
signalling and activation of MAPKs. MAPKs are capable of phosphorylating ER at Ser-118, - 94, 
-106, -124, which can initiate ligand independent activation of ER (Ignar-Trowbridge et al., 
1993; Kato et al., 1995b; Tremblay et al., 1997; Tremblay et al., 1999; Chen et al., 2002).  
 
ER bioactivity of breast cancer patient plasma samples 
 
To test the efficacy of the T47D-ER bioassay towards measuring clinical samples, our lab 
received plasma samples from 9 breast cancer patients at two time points. The first sample 
was taken before chemotherapy and the second was taken after the onset of chemotherapy. 
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The two time points allowed for calculating intra-patient changes. Patients 1, 3, 4, 6, 7, 8 and 
9 did not show a significant change in ER-mediated bioactivity between the two time points 
of blood collection. However, patients 2 and 5 experienced a significant decrease in ER 
bioactivity. Since high E2 and ERa bioactivity (Lim et al., 2012) are risk factors for breast 
cancer, the decrease in ER bioactivity could potentially serve as prognostic surrogate marker 
to show these patients are at a low risk of relapse. However, due to the limitation of sample 
size, no comment or conclusion can be inferred from this data set. 
 
Interestingly, the E2 levels decreased for all patients, except patient 4, but ER bioactivity only 
decreased for patient 2 and 5. The disconnect in results obtained from the ELISA and ER 
bioactivity shows that the bioassay is able to provide more information. For example, patient 
8 had the highest level of E2 (47 pg/mL) before chemotherapy and then the second time point 
showed no detectable level of E2. However, the ER bioactivity remains measurable without a 
change between time points. This trend was also observed for patients 1, 3, 6, 7 and 9. This 
could be because other estrogenic molecules to E2 are driving ER bioactivity. The ER 
bioactivity could represent the summation of endogenous estrogens (i.e. 3b-adiol, E1) or 
exogenous estrogens (i.e. phytoestrogens or xenoestrogens from the environment). This 
concept will be explored further in discussion of the next chapter (Chapter 5.1, Section 5.4). 
 
This study alone cannot make any conclusions about a relationship between ER bioactivity and 
breast cancer. The purpose of this study was to test the ability of the T47D-ER bioassay to 
measure plasma samples to validate its use in a clinical setting. To associate patients with risk 
of relapse (disease-free survival or survival odds), a larger cohort of patients would need to 
be recruited (>100 patients) and 5- and 10-year follow up studies are also required. 
Furthermore, a larger recruitment of patients would enable the effect of chemotherapy on ER 




In this chapter, an optimised protocol for the T47D-ER bioassay has been established (see 
Appendix 9.1 for a full optimised protocol for the T47D-ER bioassay). It has been shown that 
treating cells for 48 hours is able to increase the dynamic range to a greater extent than 24 
hours. Furthermore, despite 100% confluency of the cells at the time of the assay following 
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48 hours treatment, the cell seeding concentration of 5.0 x 105 cells/mL was more optimal 
than 2.5 x 105 cells/mL. Under both circumstances, the longer treatment time coupled with 
the higher cell seeding density improved the dynamic range of the assay without altering the 
EC50.  
 
Once the general assay protocol was established, it was shown that FCS, which is a necessary 
component of cell culture media, was inducing ER-mediated bioactivity despite having 
undergone charcoal-stripping treatment to remove endogenous steroids. This information is 
important for understanding the baseline of the assay for improved interpretation of the 
results of patient plasma ER bioactivity. By knowing the baseline of the assay, the chances of 
detecting false-negative samples is greatly reduced. A lower baseline of the assay could be 
achieved when cells were treated with media containing 2% or 0% (v/v) charcoal-stripped FCS.  
 
The takeaway from this study shows that the T47D-ER bioassay is capable of measuring ER 
bioactivity of breast cancer patient plasma. From this small study of 9 patients, ER bioactivity 
was detected in some samples with undetectable levels of E2. Most importantly, despite a 
decrease in E2 levels observed for the majority of patients, ER bioactivity remained elevated 
for 6 out of 9 patients and this finding could be of clinical importance.  
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 5.0 Monitoring of serum from ER+ 
breast cancer patients for ER- and AR 







Breast cancer is the most common cancer and the second most common cause of cancer-
related death in females aged 40 - 45 (Miki et al., 2007; Ferlay et al., 2010). Breast cancer is 
diagnosed at alarmingly high rates, representing one in ten cancers diagnosed each year 
world-wide. In 2012, there were 1.67 million new diagnoses (Ferlay et al., 2015) and 
incidences of the disease only continues to increase for all ages.  The global health burden of 
breast cancer impacts men and women in both developed and developing countries, with 
developing countries experiences slightly higher rates of incidence (Ferlay et al., 2015). New 
Zealand has one of the highest breast cancer incident rates in the world, along with Europe, 
North America and Australia. In 2002, Australia and New Zealand experienced an incidence of 
84.6 new breast cancer cases out of 100,000 people (Ferlay et al., 2010). In New Zealand there 
are 3300 new cases in 2014 as reported by the New Zealand Breast Cancer Foundation.  
 
5.1.1 Estrogen receptor positive breast cancer 
 
Breast cancer can be generally classified into 5 main subtypes based on hormone receptor 
expression (luminal A, luminal B or basal-like) and localisation within the breast (ductal or 
luminal). Basal-like tumours are the most aggressive form and do not express steroid hormone 
receptors. Basal-like tumours are more prevalently diagnosed in younger, pre-menopausal 
females aged approximately 52 years (Anderson et al., 2006). Whereas, the expression of 
steroid hormone receptors in Luminal A and B tumours render these tumour subtypes 
towards a more favourable prognosis compared with basal-like tumours. This is because 
steroid hormone receptors are targeted in therapy to subside cellular proliferation. The 
average age of diagnosis with Luminal A/B cancer is the age of 74 years, which represents the 
postmenopausal population (Anderson et al., 2006). 
 
This study focuses on post-menopausal females with ER+ breast cancer, therefore luminal A/B 
classification. The general risk factors associated with ER+ positive breast cancer include those 
that are modifiable such as BMI > 30 kg/m2 (Cummings et al., 2005; Li et al., 2009a) smoking, 
drinking more than 7 alcoholic beverages per week and taking hormone replacement therapy 
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(Hwang et al., 2005). ER+ breast cancer is also associated with non-modifiable risk factors such 
as age, genetic predisposition (mutation of BRAC1 gene) (Tung et al., 2010), early age of 
mernache (Cancer, 2012) and late onset menopause (Cancer, 2012). Additionally, 
endocrinological markers have been shown to be associated with ER+ breast cancer risk. In a 
study conducted by (Key et al., 2002), total E2, free E2, non-steroid hormone binding globulin-
bound E2 (free and albumin bound E2), estrone and estrone sulfate were measured and 
shown to positively correlate with the risk of breast cancer. In another study, higher quartile 
levels of E2 and estrone were associated with increased odds ratio of breast cancer when 
adjusted for BMI in post-menopausal women (Cauley et al., 1999). E2-induced cellular 
proliferation is the main mechanism underlying the pathogenesis of ER+ breast cancer growth. 
Therefore, by lowering circulating estrogens, the tumour can regress. Based on the 
established risk associated with high levels of estrogens, E2 levels are monitored in the clinic 
to determine the efficacy of breast cancer treatments, such as aromatase inhibitor therapy 
(AIT) designed to significantly reduce estrogens from circulation (Lipton et al., 1995).  
 
There is less understanding of the association between androgens and the risk of ER+ breast 
cancer. However, it has been demonstrated that high levels of androstenedione, 
dehydroepiandrosterone, dehydroepiandrosterone sulfate and testosterone increase risk for 
ER+ breast cancer (Key et al., 2002). Furthermore, in a study of 7,676 females, high 
testosterone levels were shown to be a predictor of 5-year risk of ER+ breast cancer 
(Cummings et al., 2005). Refer back to chapter 3.0, section 3.14 for the controversy 
surrounding androgens and breast cancer. 
 
It has been established through the use of cell-based ER bioassays that exogenous estrogen-
mimicking molecules (such as synthetic xenoestrogens and phytoestrogens) can activate ERs 
(Petit et al., 1997; Snyder et al., 2001; Schreurs et al., 2004). Therefore, the consumption of 
such compounds through exposure in drinking water, food or environmental contamination 
could lead to the presence of such compounds within plasma, thereby driving increased ER 
bioactivity (Zava et al., 1998; Matthews et al., 2001; Behr et al., 2011; Wozniak et al., 2014). 
For ER+ breast cancer patients, whose therapy is aimed at lowering circulating estrogens by 
administration of an aromatase inhibitor, the presence of exogenous xenoestrogens have the 
ability to render current therapies less effective. Steroid hormone receptor bioassays provide 
a summated measure of the ability of all factors, both stimulatory and inhibitory within a 
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substance (i.e. serum or plasma) to activate a certain receptor. Therefore, via measurement 
of gene activation, the activity of a specific receptor can be measured in response to any 
substance capable of activating ERa/b. ERs can be activated by compounds other than classical 
endogenous estrogens, therefore, exposure to estrogen mimicking molecules can contribute 
to breast cancer tumor growth. Interestingly, in a study by Lim et al. (2014a), it has been 
reported that there is a stronger association between the risk of ER+ breast cancer and serum 
ERa bioactivity than E2 levels and this could be because all estrogenic molecules are 
represented in the bioassay-based measurement compared with direct E2 measurement. 
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5.1.2 Can ER- and AR bioactivity provide clinically important 
information? 
 
ERb bioactivity and lung cancer 
 
Clinical studies have used ER-RGBs to show that estrogenicity levels do not correlate well with 
E2 levels in women with a high risk of lung cancer (Lim et al., 2014b). Through the use of HeLa-
ERa and -ERb cell lines, serum was tested from 222 post-menopausal, Chinese lung cancer 
patients and it was shown that high ERb-mediated bioactivity was associated with lower 
survival rates. For every serum sample, E2 and E1 levels were measured by LC/MS and SHBG 
levels measured by chemiluminescent immunoassay (the SHBG concentration allows the free 
E2 level to be determined) but there was no risk associated with E1 or E2 concentrations or 
SHBG levels. The highest tertile of ERb bioactivity was associated with poorer prognosis in lung 
cancer patients and this association remained regardless of histology or stage of disease. 
These findings suggest that non-endogenous and not yet identified estrogenic molecules 
present in serum are signaling specifically via ERa and exacerbating the disease state (Lim et 
al., 2014b). The ability of the ER-RGB to detect a level of estrogenicity of serum above that of 
the equivalent bioactivity induced by the measured endogenous E2 level strongly supports 
the value of ER-RGBs as a clinical tool. 
 
ERa bioactivity and incidence of hip fractures  
 
The risk of hip fractures greatly increases with low E2 levels, especially upon the onset of 
menopause in females (Lim et al., 2012). This risk is also evident from the level of serum ERa 
bioactivity, whereby hip fracture risk was reduced in the highest quintiles of free E2 and ERa-
mediated bioactivity (Lim et al., 2012). Serum from post-menopausal women (140 case- and 
278 age-matched controls) from the Singapore Chinese Health Study were used in the study 
and analysed for ERa bioactivity using HeLa-ERa cell RGB. Through the use of this ER-RGB, it 
could be determined, that not only higher levels of E2 are protective against hip fractures, but 
ERa-mediated bioactivity was also protective in post-menopausal women. Once again 




ERa and ERb bioactivity and breast cancer risk 
 
Three landmark studies, based in Europe and Singapore, have been used to assess serum ER-
bioactivity of patients with breast cancer using ERa and -b-RGBs (Widschwendter et al., 2009; 
Fourkala et al., 2011; Lim et al., 2014a). In the first study, post-menopausal breast cancer 
patients demonstrated an independent association between serum ERa- and ERb bioactivity 
and breast cancer risk (Widschwendter et al., 2009). Serum collected from 380 post-
menopausal women following breast cancer diagnosis showed that ERa and ERb bioactivity 
(measured in yeast-ERa and -ERb-RGBs) in the highest quintile had a respective 7.57- and 
10.14-fold increase in risk for ER+ breast cancer compared to age-matched controls.  
 
A second study by Fourkala et al. (2011) tested retrospective serum samples from post-
menopausal women who developed breast cancer 0.5 – 5 years after blood sample collection. 
These serum samples were applied to yeast-ERa and -ERb-RGBs and ERa bioactivity was 
increased more than two years prior to diagnosis compared with age-matched controls, that 
did not develop breast cancer (Fourkala et al., 2011). This finding suggests that increased ERa 
bioactivity is a risk factor that precedes breast cancer development and diagnosis. The result 
remained after adjustment for serum E2, free E2, E1, androstenedione, testosterone, free 
testosterone, DHEAS and SHBG levels. ERb and AR bioactivity were also measured but no 
correlation with breast cancer risk was shown. 
 
In support of these findings, a third study conducted by Lim et al. (2014a) showed the highest 
quintile of ERa bioactivity strongly and independently correlated with breast cancer risk. ERa 
bioactivity was measured in serum from 169 post-menopausal breast cancer patients and 426 
controls using HeLa-ERa and -ERb-RGBs. The 5th quintile levels of E1 associated with breast 
cancer risk, but the risk was eliminated after adjustment for ERa bioactivity, suggesting that 
E1-mediated activation of ERa could be underlying breast cancer risk. 
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In this study, post-menopausal females with ER+ breast cancer were recruited to measure 
serum ER- and AR bioactivity following the onset of letrozole therapy (Aromatase inhibitor 
study). Post-menopausal females have low E2 and E1 levels due to ovarian shut down (~3 
pg/mL). Low levels of E2 and E1 are generated in the post-menopausal female from conversion 
of testosterone and androstenedione, respectively, by the enzyme P450-aromatase (Figure 
5.1). Patients are prescribed aromatase inhibitor therapy for 5-years following surgery to 
significantly reduce estrogens in the circulation (see visual rationale in Figure 5.2, page 168). 
By reducing the concentration of estrogens in the circulation, the risk of ER+ breast cancer cell 
proliferation can be greatly reduced. 
 
 
Figure 5.1: Action of the aromatase enzyme 
 
Aromatase converts androstenedione and testosterone into estrone and estradiol, 
respectively. The reaction that occurs involves three steps; the first two occur around the 
methyl group off C10 (C19), which is later cleaved from the steroid. The final and third 




Figure 5.2: Visual rationale and hypothesis. 
 
Post-menopausal females with ER+ breast cancer were recruited to this study (1). With 
menopause, endogenously synthesized androgens and estrogens naturally decline (2a and 
2b). Post-menopausal females generate low levels of estrogens (E2 and E1) from the 
conversion of androgen precursors (testosterone and androstenedione) through the action 
of the aromatase enzyme (3). Estrogens are known risk factor for ER+ breast cancer and 
because of this (4), neo-/adjuvant therapies (such as aromatase inhibitors) are prescribed 
to patients to decrease circulating estrogens (5). The association between androgens and 
breast cancer risk is controversial (6). It is predicted that aromatase inhibitor therapy (7), 
will reduce estrogens markedly (8) and ER bioactivity will be low. The pool of precursors, 
androgens may increase, thereby increasing AR bioactivity (9). 
 
Despite lowering circulating E1 or E2 by ~90% (Geisler et al., 2008) the risk of relapse within 
5-years of letrozole treatment is ~20% (Group, 2005; Regan et al., 2011). Whilst on aromatase 
inhibitor therapy, the concentration of E2 is generally below the limit of detection of clinically 
used immunoassays (Stanczyk et al., 2003). 
 
Immunoassays specifically measure E2 and therefore, other endogenous and exogenous 
estrogenic molecules present in plasma, go undetected. There is risk of exposure to estrogen-
mimicking molecules present in the environment, drinking water and food (Zava et al., 1998; 
Matthews et al., 2001; Furuichi et al., 2004; Leusch et al., 2010; Chou et al., 2014; Wozniak et 
al., 2014; Stypuła-Trębas et al., 2015). The presence of estrogenic contaminants in plasma and 
serum (Noren & Meironyte, 2000; Solomon & Weiss, 2002) could hinder the efficacy of 
aromatase inhibitor therapy since non-classical, exogenous estrogens could be responsible for 
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ER-driven cellular proliferation and tumour progression. RGBs provide an alternative approach 
to measure the net activation ERa/b, which allows all estrogenic molecules to be captured. 
Via this approach, the biological effect of the serum can be determined and compared with 
E2 concentrations. 
 
Since controversy surrounds androgens and the risk of breast cancer, there is still no therapy 
that targets androgens. Furthermore, it is expected that the inhibition of aromatase will 
increase the pool of androgens since less is being converted into estrogens (Van Londen et al., 
2011). Through the use of an AR-RGB, the effect of aromatase inhibitor therapy on AR 
bioactivity can be determined. Follow up studies can use this data to help determine if there 
is an association between AR bioactivity and risk of breast cancer. 
 
During the time frame of this PhD, 4 out of targeted aim of 30 patients were recruited onto 
the aromatase inhibitor study to see how letrozole treatment would affect ER- and AR- 
bioactivity. All patients were post-menopausal females and provided blood samples at 2 or 3 
defined time points. The first sample was taken before the initiation of letrozole treatment 
and the second and third samples were taken 4- and 12-weeks after starting letrozole 
treatment (Figure 5.3). Within the PhD time frame, some patients did not provide their 12-
week blood sample. 
 
 
Figure 5.3: Aromatase inhibitor study design 
 
Following surgery to remove the breast tumour and chemo- and/or radiotherapy, 
postmenopausal females with ER+ breast cancer were recruited to the study by Oncologists, 
Dr Lousie Bremer and Dr Blair McLaren. Patients provided a blood sample before starting 





Overall, this study aims to address if changes in ER- and AR bioactivity before-, and after, 
aromatase inhibitor therapy can be measured. Importantly, this is the start of a larger study 
where in future all three time points from at least 30 patients will be measured. Although ER-
RGBs have been used in a clinical research context previously (Widschwendter et al., 2009; 
Fourkala et al., 2011; Lim et al., 2012; Lim et al., 2014a; Lim et al., 2014b), the novelty of this 
study is to track ER bioactivity over 3 time points using a RGB that is capable of reporting on 




• To measure ER bioactivity in the T47D-ER bioassay before-, and 4-weeks after starting 
aromatase inhibitor therapy with letrozole. 
 
• To measure AR bioactivity in the HEK293-AR bioassay before-, and 4-weeks, after 
starting aromatase inhibitor therapy with letrozole. 
 
• To compare intra-patient and inter-patient bioactivity levels to absolute E2 and 




• ER bioactivity will decrease after the onset of letrozole treatment. Furthermore, E2 will 
go undetected by immunoassay following the onset of letrozole treatment.  
 
• Following the onset of letrozole treatment, AR bioactivity may rise because androgens 
are not being converted to estrogens, therefore the pool of androgens may increase. 
Furthermore, testosterone will go undetected by immunoassay due to the expected 





5.2.1 Aromatase inhibitor clinical study 
 
The steps taken before the first patient was recruited onto the study took at least 29 months 
and involved five major key steps; 1.) clinician engagement, 2.) study design, 3.) human ethics, 
4.) assigning research nurses and 5.) meeting with the personnel from Southern Community 
Laboratory (SCL). The steps involved in developing this clinical study are shown and explained 
in greater detail in Figure 5.4. The patient information sheets and consent form can be found 
in Appendix 9.2. The Ethics Committee reference number is H17/110. 
 
Since this study is still currently underway with a target of 30 patients to recruit, Table 5.1 
shows the current status with the number of patients and samples received. This table details 
the dates of when patient samples arrived to our laboratory. Patients 1-4 were included in this 
study since 2 or more blood samples/time points were provided in time. The inclusion and 
exclusion criteria given to the oncologists for the recruitment of patients is listed in Table 5.2. 
 
Patients 5-8 have not been included in this PhD since they have only provided one 0-week 
sample. For some patients, their 0-week sample was provided more than 4-weeks prior to 
their second sample (patient 1 and 5). Their 0-week sample is still prior to the onset of 
letrozole, but due to other treatments (such as radiotherapy) the onset of letrozole treatment 
was delayed. However, their 4-week sample was always provided 4-weeks after the onset of 
letrozole.  
 
Each patient number was provided by the research nurse and the structure follows BER-X-AB. 
Where, BER is the name of the clinical study, which stands for Breast Estrogen Receptor. X is 
the number of the patient recruited onto the study and AB is the initials of the patient. Sample 
number 1, 2 and 3 associates with 0-, 4- and 12-weeks, respectively. 
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Table 5.1: Current status of patients recruited onto the study. 









BER-3-ET 1 03.09.19 2 08.10.19 
BER-4-DE 1 06.11.19 2 04.12.19 
BER-5-WM 1 21.11.19 
BER-6-CA 1 08.01.20 
BER-7-BS 1 08.01.20 
BER-8-MC 1 22.01.20 
 
Table 5.2: Inclusion and exclusion criteria for the aromatase inhibitor study 
Inclusion Exclusion 
• Post-menopausal females • Pre-menopausal females 
• ER positive tumour  
• Planned aromatase inhibitor 
therapy. Including patients that had 
prior chemotherapy, ER blocker 
treatment (i.e. Tamoxifen) and/or 
radiotherapy 
 
• Willing to provide 3 blood samples  




5.2.2 Blood handling 
 
Two 6 mL red-top blood tubes (BD Vacutainer, Cat #367837) of blood were taken from each 
patient that had been recruited to the study before, 4-weeks and 12-weeks after the onset of 
aromatase inhibitor therapy with letrozole. Blood samples were collected by personnel at 
Southern Community Laboratories (SCL) in Dunedin Hospital. Blood samples were kept at 4°C 
at SCL and our laboratory was notified to collect the sample(s) as soon as possible. The blood 
samples were transferred on cool packs at 4°C to the laboratory. Once in the laboratory, the 
blood samples were centrifuged at 4°C for 15 minutes at 225 rpm. The serum was carefully 
removed and 100 µL aliquots were snap frozen in liquid nitrogen and stored at -80°C. 
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5.2.3 T47D-ER bioassay 
 
The serum samples were tested in the T47D-ER bioassay to determine the ER bioactivity of 
each patient, before and 4-weeks (and 12-weeks for 2 patients) after starting letrozole 
treatment. T47D-ER cells were seeded in clear 96-well plates following the protocol in 
Appendix 9.1. The following day after cell seeding, the media on top of the cells was aspirated 
and replaced with 98 μL DMEM F12 (supplemented with 75 μg/mL G418 (FCS free)). Each 
serum sample was tested in duplicate at a final concentration of 2% (v/v) by adding by 2 μL of 
serum for a final volume of 100 μL. Cells were incubated at 37 °C, 5% CO2 for 48 hours. 
Duplicate wells with 100 μL DMEM F12 supplemented with 75 μg/mL G418 (FCS free) served 
as the blank. The Bright Glo bioassay was carried out following the 48 hour incubation period.  
Each serum sample was tested in the T47D-ER bioassay across six independent experiments. 
An E2 standard dose response curve was carried out with each experiment and the analysis of 
the serum samples can be found in Appendix 9.1. 
 
5.2.4 HEK293-AR bioassay 
 
The serum samples were tested in the HEK293-AR bioassay to determine the AR bioactivity, 
before and 4-weeks after starting letrozole treatment. HEK293-AR cells were seeded in clear 
96-well plates following the protocol in the General Methods (Chapter 2.0, Section 2.4.4 and 
2.4.5). The following day after cell seeding, the media on top of the cells was aspirated and 
replaced with 170 μL DMEM F12 media (supplemented with penicillin/streptomycin and 1.5 
μg/mL puromycin (FCS free)). Each sample was tested in duplicate at a final concentration of 
15% serum (v/v) by adding 30 μL serum to 170 μL (supplemented with penicillin/streptomycin 
and 1.5 μg/mL puromycin (FCS free)) for a final volume of 200 μL. Cells were incubated at 37 
°C, 5% CO2 for 18 hours. Serum samples were not normalised to a blank well since the 
background of the assay is very low (<100 RLU). The HEK293-AR bioassay was carried out 
following the 18 hour incubation period as per the same protocol in General Methods 
(Chapter 2.0, Section 2.4.7). Serum was tested in the HEK293-AR bioassay across five 
independent experiments. A testosterone dose response curve was carried out with each 
experiment and the analysis of the serum samples can be found in General Methods (Chapter 
2.0, Section 2.4.7). 
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The HEK293-AR bioassays were carried out before the T47D-ER bioassays and during the 
T47D-ER bioassays, patient 1 provided their 12-week blood sample. This meant that the 12-
week sample is only shown in the T47D-ER bioassay and not the HEK293-AR bioassay. 
Furthermore, this sample was tested on three independent experiments. 
 
The statistical tests used to determine significant changes between tested parameters are 
detailed throughout the results section. The rationale and choice of statistical tests is the same 




Figure 5.4: Development of clinical study 
 
The development of this clinical study started in March 2017. The first step involved engaging the oncologist specialists; Dr Louise Bremer and Dr 
Blair McLaren, through educating about the proposed study. Following clinical support to move forward, the study design was refined and the human 
ethics and study protocols, patient consent forms and information sheets were created. This material was sent to the University of Otago, Ngaī Tahu 
consultation committee and the Southern District Health Board to approve human ethics. The Dunedin School of Medicine approved the study once 
the ethics was approved. Following ethics approval, the clinical operational aspect was organised by assigning research nurses to coordinate patients 
providing blood samples at the correct time points. Before the first patient could be recruited to the study, we had to meet with SCL to organize 
ordering red-top blood tubes, coordinating receiving blood samples from patients and organizing collection by Heather lab. By August 2019, the first 




The T47D-ER and HEK293-AR bioassays were utilised in this study to measure the net 
estrogenic and androgenic bioactivity of post-menopausal females with ER+ breast cancer 
before-, and after, starting letrozole treatment. Testosterone and E2 concentration of each 
serum sample was determined using an ELISA for the purposes of comparing the outcome of 
the bioassays to a quantitative measurement.  
 
5.3.1 Serum ERa/b bioactivity of breast cancer patients before- and 
after letrozole treatment 
 
The serum from 4 ER+ post-menopausal breast cancer patients was measured in the T47D-ER 
bioassay across 6 independent experiments (days) to determine serum ER bioactivity (Figure 
5.5). The ER bioactivity of each serum sample before letrozole treatment (baseline sample at 
0-weeks) induced the highest ER bioactivity for all time points for all 4 patients. The mean ± 
SEM (n=6) ER bioactivity for patient 1, 2, 3 and 4 measured 22.4% ± 3.0%, 19.2% ± 2.9%, 41.3% 
± 5.5% and 25.3 % ± 4.4%, respectively. 
 
Following aromatase inhibitor therapy, the ER bioactivity of all 4-week serum samples 
significantly reduced relative to their own baseline (**p<0.002, ***p<0.0002, mixed effects 
analysis (Geisser-Greenhouse correction), followed by multiple comparisons between 
baseline and 4-weeks (for patients 1-4) and 4-weeks and 12-weeks (for patients 1 and 2),  the 
multiple comparisons were corrected using a Sidaks’ test), measuring (mean ± SEM, n=6) 8.4% 
± 1.7%, 8.8% ± 2.2%, 11.2% ± 2.8% and 11.7% ± 2.4%., for patients 1, 2, 3 and 4 respectively. 
Patient 1 and 2 provided blood samples following 12-weeks of letrozole treatment and results 
showed that serum ER bioactivity remained suppressed relative to their 4-week sample. 
Patient 1 did not show a statistically significant change from the 4-week ER bioactivity reading, 
indicating that ER bioactivity continued low at 12-weeks (ns = p>0.1234, mixed effects one-
way ANOVA, corrected for multiple comparisons with Sidaks’ test, n=3-6). Whereas, patient 2 
experienced a further small, yet significant decline of 0.01 ER bioactivity at 12-weeks of 
letrozole treatment relative to their 4-week sample (*p<0.033, mixed effects one-way ANOVA, 
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corrected for multiple comparisons with Sidaks’ test, n=6). The SEM for each patient (inter-
assay variability) remained low for all patients measuring on average 30%.  
 
An attempt at quantifying the absolute E2 concentration for each serum sample was made by 
ELISA. E2 was only detected in the baseline (0-weeks) serum sample for patient 1, 3 and 4. 
Patient 1 (0-weeks) had the highest E2 concentration, measuring 6.1 pg/mL, followed by 
patient 4 (0-weeks) measuring 3.7 pg/mL and patient 3 (0-weeks) had the lowest E2 
concentration of 0.6 pg/mL (Table 5.3).  
 
Table 5.3: E2 concentration of breast cancer patient serum samples 
measured by ELISA.  
 
Units expressed in both pg/mL and pmol/L. All values rounded to the nearest 1 decimal 
place. 
Serum sample E2 concentration pg/mL pmol/L 
Patient 1 (0-weeks) 6.1 22.3 
Patient 3 (0-weeks) 0.6 2.3 




Figure 5.5: Serum ER bioactivity of 4 post-menopausal women with ER+ breast cancer before-, 4- and 12-weeks after 
letrozole treatment. 
 
The ER bioactivity of each serum sample is expressed as a ratio of maximal induction of the T47D-ER bioassay by E2 (mean ± SEM) (see Chapter 
2.0, Figure 2.2 and Appendix 9.1 for analysis). For each patient, the blue bars represent the ER bioactivity of the baseline (0-week) serum 
sample, the grey bars depict the 4-week serum sample and the white bars for patient 1 and 2 are shown by the white bars. There was a 
signification reduction in ER bioactivity for all patients between baseline- and 4-weeks after starting letrozole. ER bioactivity remained 
suppressed relative to baseline at 12-weeks for both patients 1 and 2 (ns = p>0.1234, *p<0.033, **p<0.002, ***p<0.0002, mixed effects 
analysis followed by multiple comparisons corrected with a Sidak’s test). 
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5.3.2 Serum AR bioactivity of breast cancer patients before- and after 
letrozole treatment 
 
The AR bioactivity of 4 patients was measured using the HEK293-AR bioassay across 5 
independent bioassays (Figure 5.6). Overall, the AR bioactivity was low for all patients, 
measuring on average 0.20% of maximal AR bioactivity. Only patient 1 experienced a change 
in AR bioactivity after starting letrozole, with a significant decrease in AR bioactivity at the 4-
week time point relative to baseline (*p<0.033, repeated measures one-way ANOVA, followed 
up by multiple comparisons between corrected for multiple comparisons with Sidaks’ test). 
For patient 1, the mean ± SEM of maximal AR bioactivity declined from 0.20% ± 0.02% to 0.15% 
± 0.01% (Figure 5.6). Only Patient 2 provided a 12-week serum sample within the timeframe 
of the PhD. AR bioactivity for patient 2 remained consistently low with an average AR 
bioactivity of 0.1% of maximal testosterone AR bioactivity (Figure 5.6). Patient 3 induced the 
highest level of AR bioactivity, measuring 0.45% and 0.39% of maximal AR bioactivity before-
, and after, the onset of letrozole treatment, respectively (Figure 5.6).  
 
Patient 3 was the only patient to have a detectable level of testosterone as measured by ELISA. 
The second serum sample, at 4-weeks post-letrozole treatment, measured 0.008 ng/mL (Table 
5.4). Despite no difference in AR bioactivity between the two time points for patient 3, there 
was no detectable level of testosterone in their baseline serum sample (before letrozole 
treatment). 
 
Table 5.4: Testosterone concentration of breast cancer patient serum 
samples measured by ELISA.  
 
Units expressed in both ng/mL and nmol/L. 
Serum sample Testosterone concentration ng/mL nmol/L 




Figure 5.6: Serum AR bioactivity of 4 post-menopausal women with ER+ breast cancer before-, 4- and 12-weeks after 
letrozole treatment. 
 
The AR bioactivity of each serum sample is expressed as a ratio of maximal induction of the HEK293-AR bioassay by testosterone (mean ± SEM) (refer 
to Chapter 2.0, Section 2.4.7, Figure 2.2 for analysis). For each patient, the AR bioactivity of the baseline (0-week) serum sample is shown by the 
green bars, AR bioactivity 4-weeks after starting letrozole is shown by the grey bars and the AR bioactivity of the 12-week serum sample for patient 
2 only is shown by the white bar. For patients 2, 3 and 4, there were no significant intra-patient changes between baseline- and 4-weeks treatment 
with letrozole, however, there was a significant reduction in AR bioactivity for patient one following the onset of treatment with letrozole (ns = 
p>0.1234, *p<0.033, repeated measures one-way ANOVA (Geisser-Greenhouse correction), multiple comparisons between the serum sample before 
































1 2 3 4
Before letrozole
4-weeks after starting letrozole




Overview of findings 
 
The high risk of breast cancer relapse in the years after taking aromatase inhibitors such as 
anastrozole or letrozole is considerably high, measuring on average 20% (Group, 2005; Regan 
et al., 2011). Therefore, this study was established to determine if ER- and/or AR bioactivity 
can provide information that immunoassay alone cannot. This information may highlight 
some anomalies that could be important for the prognosis of a patient. 
 
The most important finding of this study was demonstrating that ER bioactivity is significantly 
reduced upon letrozole treatment and that despite dropping to low levels, there is still a 
detectable level of ER bioactivity. Having only tested 4 patients, this trend was very consistent 
across all participants. When compared to the current clinical measure, immunoassay, the E2 
levels of each sample did not associate well with the ER bioactivity measurement since E2 was 
only detected in the 0-week samples for patients 1, 3 and 4. Therefore, there could be more 
information to be gained from the ER bioassay that the current clinical measurement 
(immunoassay) of E2 can provide. AR bioactivity of patient serum was low, yet measurable 
across all patients, with an unexpected significant reduction in bioactivity for patient 1. Only 
patient 3 at 4-weeks had a measurable level of testosterone. Once again, the bioassay 
measurement provided different information compared with the immunoassay result for 
testosterone. Overall, this study provides good grounds for further investigation into the 
changes in ER and AR bioactivity following aromatase inhibitor therapy across the full 30 
patients for the purpose of determining if RGBs have the potential for future clinical 
application. 
 
ER bioactivity  
 
Upon blockade of the aromatase enzyme, the production of E2 and E1 from testosterone and 
androstenedione, respectively, is halted. Therefore, as expected, ER bioactivity for all 4 
patients decreased following the administration of letrozole. All ER bioactivity measured was 
very low and it is likely that ER bioactivity for letrozole-treated samples represents minimal 
promotor activity of the reporter plasmid (baseline of assay) with very little ER activation. 
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Since the bioactivity of pre-treated serum samples (~20%) was higher than post-treatment 
(~10%), yet still below the previously optimized baseline as determined previously in T47D 
chapter 4 (serum free baseline shown in Chapter 4.0, Figure 4.6A), it shows that the baseline 
of the assay still requires further optimisation. Future assays could use a standard serum 
sample obtained from post-menopausal females treated with letrozole as a means of 
determining the baseline of the assay, which would be in context of the samples being treated. 
Based on these 4 patients, it is likely that the baseline and minimal promotor activity of the 
reporter plasmid is ~10% of T47D-ER bioassay activation. These results are exciting as with 
this bioassay we can provide to the clinician an absolute zero for ER bioactivity for post-treated 
samples. Any rise from this baseline (~10% for minimal induction) is meaningful and therefore 
we can see that a small change that exceeds 10% of maximal assay induction provides a 
positive read-out. 
 
Comparing this to E2 levels, as measured by ELISA, we note that not every patient could record 
a value prior to letrozole treatment. This is in keeping with the limit of detection for such 
quantitative measurements and further highlights how difficult it is to get meaningful data 
from this population of post-menopausal females where endogenous E2 (and testosterone) 
are notoriously low (Stanczyk et al., 2010). By striking comparison, bioassay measurements 
(including a true measurable baseline) were detected for all patient samples.  
 
Importantly, since all ER bioactivity measurements drop after the onset of letrozole treatment 
to the same level (~10%), it is unlikely that a xenoestrogen is present in an appreciable 
concentration to alter ER activation in these patients. If a xenoestrogen was capable of driving 
ER mediated gene transcription, following letrozole, the ER bioactivity would not decrease as 
low as 10% of assay activation. To assess this in future experiments, 4-weeks post-letrozole 
serum could be spiked with a dose of xenoestrogen (i.e. BPA) to ensure the assay is capable 
of measuring other estrogenic molecules in serum.  
 
AR bioactivity  
 
The AR bioactivity of all 4 patients was extremely low (0.1-0.5% of maximal assay activation 
by testosterone) yet still measurable by the HEK293-AR bioassay. There was an unexpected 
reduction in AR bioactivity for patient 1. However, no change was observed for the other 3 
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patients, which would suggest the net androgenicity of serum is unaffected by letrozole 
treatment. Serum AR bioactivity was expected to increase since it has been shown that upon 
letrozole treatment in both young and elderly males (T’Sjoen et al., 2005) and post-
menopausal females (Van Londen et al., 2011), aromatase inhibition increases testosterone 
levels. In males, net testosterone increases due to increased gonadotropin release, thereby 
stimulating increased testicular-testosterone production (T’Sjoen et al., 2005). However, in 
post-menopausal females, the free fraction of testosterone increased due to letrozole 
reducing SHBG concentrations (Van Londen et al., 2011). However, the total testosterone level 
did not change upon treatment with an aromatase inhibitor (Van Londen et al., 2011). The 
lower SHBG concentration is likely due to the reduction in E2-driven SHBG synthesis (Kalme et 
al., 1999). Overall, the increased bioavailable portion of testosterone and other androgens in 
the serum due to lower SHBG was expected to be reflected in the outcome of the AR bioassay. 
 
The testosterone concentration (~0.6 nM) in post-menopausal females is approximately 10 - 
20 times higher than E2 (~0.04 nM) (Vermeulen & Verdonck, 1978; Simpson, 2002). 
Furthermore, only 0.15% of testosterone is converted into E2 through aromatisation in 
females (Longcope et al., 1969), which supports the concept that small changes have a lower 
chance of detection in the HEK293-AR bioassay. Therefore, the results would present as no 
change in AR bioactivity, as seen with patients 2-4. Interestingly, patient 3 had the highest AR 
and ER bioactivity levels at 0-weeks, which nicely illustrates how a proportionally larger pool 
of estrogens are synthesized from a larger pool of androgens.  
 
The only serum sample with a detectable level of testosterone was the 4-week sample from 
patient 3. Therefore, it could be interpreted the testosterone concentration increases from 
below the level of detection, up to 0.008 ng/mL, despite no change in AR bioactivity. However, 
the concentration of testosterone in patient 3 at 4-weeks was on the cusp of the limit of 
detection of testosterone in the ELISA (0.10 ng/mL) and may not reflect a true change or 
decrease in testosterone for this patient. Therefore, the testosterone ELISA utilised in this 
study may have sensitivity limitations and low concentrations of testosterone in the sample 
may be more accurately detected by GC- or LC/MS (Moal et al., 2007). 
 
With a larger number of patients, which will be investigated in future, it would be interesting 
to observe if changes in AR bioactivity tend to decrease (as observed for patient 1) or not 
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change (as observed for patients 2, 3 and 4). AR bioactivity changes or the stability of AR 
bioactivity could have prognostic value especially when paired with the results of a 
quantitative measurement of testosterone. However, due to the low number of patients 
recruited onto this study, it is impossible to make inferences about the population  based on 
this study.  
 
Limitations and future directions 
 
Steroid hormone metabolism of HEK293-AR and T47D-ER cells 
 
Steroid hormone metabolising enzyme expression in HEK293-AR and T47D-ER cells can alter 
the specificity of the assay, which is a key limitation to this study. HEK293-AR cells express 
P450-aromatase (Akram et al., 2011) and 3b-HSD (Miller et al., 2013). Both of these hormones 
can convert androgens (testosterone and androstenedione) into estrogens (E2 and E1). 
Testosterone and androstenedione can be converted into E2 and E1 (Longcope et al., 1969; 
Longcope et al., 1978), respectively, and DHT can be converted into 3b-Adiol, a weak 
estrogenic molecule (Miller et al., 2013). The conversion of androgens into estrogenic 
molecules over 48 hours of cell culture could contribute to the low level of AR bioactivity. 
 
T47D cells express the P450-aromatase enzyme (Sadekova et al., 1994), therefore, androgenic 
precursors could be detected as estrogenic due to intracellular metabolism. In future, the use 
of an aromatase inhibitor in the cell culture media could help to improve the specificity of the 
assay towards estrogen-specific measurement. Furthermore, 17b-HSD is responsible for the 
inter-conversion between E2 and E1. Therefore, it could be postulated that estrogens could 
be converted into a more potent metabolite (E2) or a weaker metabolite (E1) and not 
represent the serum estrogenicity. However, a previous study has demonstrated that the net 
flux through this enzyme in MCF-7 cells is negligible with an approximate 20% flux each way 




The most compelling limitation of this study is the full recruitment of 30 patients was not 
reached within the timeframe of this PhD. Therefore, no conclusions with regards to breast 
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cancer can be obtained from this bioassay data and the clinical relevance with regards to 
prognostic information cannot yet be inferred. However, despite a low sample size, the lack 
of a meaningful relationship between immunoassay and bioactivity results still provides 
impetus to move forward with recruiting and measuring ER- and AR bioactivity of the targeted 
30 patients. It would be of interest to carry out a follow up study in 5-years’ time to help 





Letrozole is a long-term therapy, which is generally prescribed for 5 to 10 years. Letrozole is a 
non-steroidal, reversible, competitive antagonist to the P450-aromatase enzyme. However, 
acquired resistance to aromatase inhibitors occurs in approximately 20% of patients with ER+ 
breast cancer. The predominant site of aromatase expression is within adipose fibrocytes, 
which is the main source of E2 for postmenopausal women. However, breast tumour cells 
express aromatase (Esteban et al., 1992; Lu et al., 1996) in both the stromal (normal 
connective tissue) and carcinoma cells (Miki et al., 2007), which locally synthesises E2 to drive 
cellular proliferation. Upon aromatase blockade, peripheral and breast E2 synthesis ceases  
(Takagi et al., 2013) and this stops the ER-dependent cellular proliferation of tumour cells. 
However, under long term E2 deprivation, letrozole resistance can be acquired. Through 
activation of non-classical ER cell signalling mechanisms, ERs can become autonomously 
activated by ligand-independent mechanisms. These ligand-independent mechanisms involve 
phosphorylation of ER downstream of growth factor receptor signalling pathways to promote 
cell survival (Shin et al., 2006) (Cavazzoni et al., 2012) (refer back to Chapter 1.0, Section 
1.4.3.2, Figure 1.7 for an overview of ligand-independent signalling of ER). Long term E2 
deprivation (mimicking the effects of letrozole) has been shown to lead to 
hyperphosphorylation of Ser118 of ERa, which is capable of activating ERE-induced gene 
transcription (Dowsett et al., 2005). Under these circumstances, the ER bioactivity of the 
serum would likely not be a good predictor of breast cancer relapse since the tumour is able 
to progress independent of ER activation. While seen as a limitation of this study, it is indeed 




Delineating ERa and ERb bioactivity 
 
The endogenous co-expression of both ERa and ERb in T47D-ER cells could be an inherent 
disadvantage to the assay. There are differences in ligand specificity and affinity between both 
ER isoforms and this may be why ERb expression in breast tumours can be translated into 
clinical importance. As described in section 1.4.1 and 1.4.3 of the literature review (Chapter 
1.0), there are differences in receptor structure, cofactor recruitment, affinity for E2 and the 
ERE. Ligands of endogenous, synthetic and phytoestrogen nature bind ERa and ERb with 
differing affinities, which alters the level of gene transcription (Sun et al., 1999; Escande et al., 
2006). These molecular level changes cause in vitro and in vivo changes, whereby ERb 
overexpression in T47D cells (cultured in vitro or implanted as a xenograft in mice) has been 
shown to induce a slower rate of cell proliferation compared with when ERa and ERb are 
equally expressed (Ström et al., 2004; Hartman et al., 2006). A slower rate of cell proliferation 
induced by ERb could manifest clinically as it has been shown that of ERb expression in breast 
carcinoma cells is favourable for improved odds of disease-free survival (Hopp et al., 2004; 
Gruvberger-Saal et al., 2007). Although, it has also been shown that tumour cells that express 
ERb without ERa have a proliferative effect when treated with tamoxifen (anti-estrogen) 
(O’Neill et al., 2004), which could owe to the difference in ligand specificity of each ER isoform. 
The role of ERb in breast carcinogenesis is not fully understood and it is evident that their 
relative expression levels can affect the activity levels of each receptor.  
 
The clinical, in vivo, in vitro and molecular differences between ERa and ERb underpins the 
importance of also using a cell line that can specifically detect ERa or ERb activation in tandem 
with a cell line that co-expresses both ER isoforms. By separating the activity levels of ERa and 
ERb, such differences in bioactivity measures could be more informative for identifying 
patients that have a higher risk of relapse. The next step of this study was to develop a specific 
ERa cell line and then develop an ERb cell line. In chapter 6.0, the methods and results 




In this small, preliminary study, the ER and AR bioactivity of serum from only four post-
menopausal females diagnosed with ER+ positive breast cancer was monitored over a 4 or 12-
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week period. During this time, the patients were placed on routine treatment with an 
aromatase inhibitor, letrozole. Based on the results of four patients, ER bioactivity reduced 
for all patients upon letrozole treatment, whereas AR bioactivity unexpectedly decreased or 
did not change. Overall, bioactivity was measurable through the HEK291-AR and T47D-ER 
bioassays with some intra-patient changes observed. Based on the small number of patient 
samples tested, the bioactivity measurement could provide more read outs than the E2 and 
testosterone immunoassay data alone. However, since only four patients were part of the 
study, these results cannot be extrapolated to indicate clinical significance at this point in 
time. This small study only shows that serum from post-menopausal females is measurable in 
the AR- and ER-bioassays and this provides a promising platform for the continuation of this 
project with the full 30 patients since there may be important clinical information to be 
obtained from ER- and AR-RGBs in reference to breast cancer and letrozole treatment.  
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6.0 The development of a HeLa-ERa 






This chapter details the methods involved with creating our own ERa responsive cell line by 
co-expressing HeLa cells with an ERa expression- and luciferase reporter plasmid (HeLa-
ERa/Luc). The purpose of creating this cell line was to measure net ERa bioactivity of serum 
and plasma to determine if cell-based ERa bioassays can provide additional information for 
clinicians in the context of breast cancer. This assay exploits classical ligand-dependent ERa 
cell signalling to measure the net estrogenicity of test samples (Chapter 1.0, Section 1.4.3.1). 
Thereby, upon treatment of this assay with an estrogenic molecule for 24-48 hours, 
recombinant nuclear ERas are activated. As an overview of classical ER cell signalling, ERas 
dimerise when activated by a ligand to form a transcription factor that functions to induce 
gene expression by binding to EREs located upstream of target genes. In the case of this assay, 
the luciferase gene is located downstream of the ERE on the reporter plasmid. Therefore, 
following treatment with an estrogen, ERas bind to ERE to drive luciferase gene expression. 
After incubation, cells are lysed and treated with luciferin. Luciferin is the substrate for the 
luciferase enzyme, and together with ATP and O2, light is emitted if the luciferase enzyme is 
present (Figure 6.1). The level of light emission is proportional to the amount of luciferase and 




Figure 6.1: The luciferase reaction for light emission in the bioassay. 
 
The cell lysate is exposed to the luciferin substrate and is converted into light in the 
presence of O2 and ATP when the luciferase enzyme is present. The luciferase enzyme is 
only present if ERs have been activated upstream and bind and activate ERE on the reporter 
plasmid to drive gene transcription of luciferase.  
 
The first step involved with creating the HeLa-ERa/Luc cell line was to determine if HeLa cells 
express endogenous sex steroid hormone receptors (ERa, ERβ, progesterone receptor (PR) 
and AR). Endogenous steroid hormone receptor expression raises the potential for cross 
reactivity with the ERE. The implications in the context of the bioassay, means that steroid 
hormone receptors, other than ERa, could bind to the ERE and therefore elicit reporter gene 
expression and be interpreted as ERa bioactivity. ERβ can bind ERE, although with lower 
affinity than ERa (Mosselman et al., 1996). It has also been shown that ERa can form 
heterodimers with AR and such heterodimeric complexes can activate ERE-mediated gene 
transcription (Panet-Raymond et al., 2000). However, the risk of cross reactivity with other 
steroid hormone receptor is low since AR, PR, MR and GR all bind related response elements, 
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which have higher levels of sequence homology (Nelson et al., 1999), whereas, the DNA 
sequence of ERE is distinct (Gruber et al., 2004). However, to eliminate any possibility of any 
potential cross reactivity, the HeLa cells were chosen due to their lack of endogenous SHRs.  
 
Following characterization of steroid hormone receptor expression in HeLa cells, they were 
co-transfected in a two-step process. The ERa-expression plasmid (pESR1-DDK) was first 
transfected into HeLa cells and the clone with the highest ESR1 gene expression was 
transfected with the ERE-luciferase reporter plasmid (pERETATAluc). pESR1-DDK expresses 
the neomycin resistance gene, which renders transfectants resistant to the antibiotic, G418. 
Therefore, G418-resistant cells were selected to stably express this plasmid through G418 
exposure. Stable ERa-expressing HeLa cells were then transfected with pERETATAluc. 
pERETATAluc has 3X ERE and TATA box upstream of the luciferase reporter gene, therefore, 
allowing activated recombinant ERas to stimulate luciferase gene expression in the presence 
of an estrogenic test substance. However, prior to transfection with pERERTATAluc, the 
plasmid was cloned with a puromycin resistance gene (PuroR) to allow for positively 
transfected cells to be selected for by treatment with puromycin.  
 
This cell line did not end up being used to test serum or plasma samples. Despite a significant 
increase in luciferase mRNA after E2 treatment, no luminescence could be detected 
suggesting not enough protein was being made. Future optimisation of this cell line is required 





6.2 Methods and Results 
 
The general cell culture protocol for HeLa cell can be found in General Methods (Chapter 2.0, 
Section 2.6) 
 
6.2.1 Quality control of host HeLa cells  
 
Steroid hormone receptor mRNA was measured in host HeLa cells via real-time-polymerase 
chain reaction (RT-qPCR) to determine the relative endogenous expression levels of AR, PR, 
ESR1 and ESR2 mRNA. This is important to ensure no other steroid hormone receptors are 
expressed by HeLa cells. This is to prevent any potential cross reactions with the ERE on the 
reporter plasmid and therefore, interference with the bioassay. By characterising endogenous 
steroid hormone receptor levels and ensuring there is no, or very low levels of steroid 
hormone receptors, it eliminates the risk of cross reactions in the host HeLa cells. 
 
6.2.1.1 Relative expression levels of ESR1, ESR2, AR and PR mRNA in HeLa cells 
 
HeLa cells showed mRNA expression of AR, PR, ESR1 and ESR2 by RT-qPCR (Table 6.1) (see 
General Methods, Chapter 2.0, Section 2.1.3 for RT-qPCR method). The RT-qPCR results show 
no ESR1, ESR2 or PR mRNA present in HeLa cells due to very high CT (CT greater than 30) or no 
amplification. However, the CT of AR mRNA indicates that there is some level of AR expression 
and this may lead to cross-reactivity.  
 
Table 6.1: Average CT ± SEM for ESR1, ESR2, AR, PR and GAPDH mRNA in 
HeLa cells.  
 
GAPDH is the reference gene since it is stably expressed and is used to compare relative gene 
expression. All values rounded to the nearest 1 decimal place. 
mRNA Average CT ± SEM Number (n) 
ESR1 33.8 ± 3.3 10 
ESR2 34.2 ± 0.9 3 
AR 25.8 ± 0.1 2 
PR No amplification 1 
GAPDH 15.1 ± 0.4 15 
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6.2.1.2 Expression of Human AR protein in native HeLa cells 
 
Due to a low CT value of 25.8 obtained by RT-qPCR for AR mRNA in native HeLa cells (Table 
6.1), a Western Blot analysis was performed to determine if the AR mRNA in HeLa cells is 
translated into protein (refer to General Methods, Chapter 2.0, Section 2.2 for Western Blot 
method). Western Blot analysis showed no human AR (hAR) protein in HeLa proteins extracts 
(expected size of 98 kDa) (Figure 6.2). Purified human AR protein served as a positive control 
and a band was present at 98 kDa. GAPDH served as a reference protein and was present in 
HeLa protein extract lanes only at the expected size of 36 kDa. Western blots were repeated 
on 3 independent days (n=3). Therefore, AR should not be a significant problem for cross 





Figure 6.2: Western Blot for hAR protein in HeLa cells. 
 
Total HeLa protein was extracted and purified hAR protein served as the positive control. A.) B.) and C.) Western blots show no AR protein band 
detected at the expected size of 98 kDa for HeLa protein lanes. AR protein lanes show a band at 98 kDa (positive control). GAPDH was detected just 
above the expected size of 36 kDa in all HeLa protein lanes and not purified hAR protein lanes.  
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6.2.2 Transfection of HeLa cells with pESR1-DDK  
 
Following steroid hormone receptor characterisation of HeLa cells, the cells were next 
transfected with the expression plasmid, pESR1-DDK. 
 
6.2.2.1 Optimisation of G418 concentration 
 
Before HeLa cells could be transfected with pESR1-DDK, the concentration of G418 needed to 
be optimized to enable for the selection of HeLa cells that were positively transfected with 
pESR1-DDK. pESR1-DDK harbours the neomycin resistance gene (NeoR), which confers G418 
resistance. Therefore, when treating cells with a cytotoxic concentration of G418 (as 
determined by G418 kill curve in Figure 6.3), only cells that express NeoR will survive the high 
concentration of G418. Via this method, cells that have been transfected with pESR1-DDK can 
be selected. Therefore, an effective concentration of G418 needed to be established to ensure 
non-transfected HeLa cells were not viable.  
 
HeLa cells were seeded into three 6-well plates at a concentration of 2x105 cells/mL in DMEM 
(supplemented with 10% (v/v) FCS). Once cells reached 95% confluence, HeLa cells were 
treated with 17 serial dilutions of G418, ranging from 100 µg/mL to 1700 µg/mL. A control 
well treated without G418 was also included. HeLa cells were assessed for cell viability for 12 
days and media was changed every second day. The optimal concentration (600 µg/mL) of 
G418 was chosen since HeLa cells started to die after 4 days, steadily died off over the 




Figure 6.3: Kill curve of HeLa cells treated with G418. 
 
HeLa cells were treated with serial dilutions of G418 (100 µg/mL – 1700 µg/mL) and cell viability was recorded daily. The optimal rate of cell death 
was determined to be a concentration of 600 µg/mL of G418 (red line). Representative curve from two independent experiments.  
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6.2.2.2 Transfection of HeLa Cells with pESR1-DDK 
 
HeLa cells were transfected with pESR1-DDK (3X ERE TATA luc, Addgene, Cat #11354 - see 
Figure 6.4 for plasmid map) to induce ERa expression using the Lipofectamine 3000 
transfection kit (Invitrogen Life Technologies, Cat #1718526) as per the following protocol. 
HeLa cells were seeded in two 6-well plates at a concentration of 1.0 x 105 cells/mL and 
transfected with pESR1-DDK once they had reached 95% confluency. One well was not 
transfected and treated with G418 (600 µg/mL) to ensure complete cell death of non-
transfected cells. 
 
Lipofectamine solution:  
Reagent: Volume per plate: 
• DMEM (containing high glucose (4500 mg/L), L-glutamine (584 
mg/L) and sodium pyruvate (110 mg/L)) 
125 μL x 2 
• LipofectamineTM 3000 reagent  3.75 μL and 7.5 μL 
 
The above reagents were multiplied by 4 and the Lipofectamine reagent was diluted in serum-
free DMEM in 1.7 mL Eppendorf tubes. 
 
Diluted DNA Mixture 
Reagent: Volume (2X): 
• DMEM (containing high glucose (4500 mg/L), L-glutamine (584 
mg/L) and sodium pyruvate (110 mg/L)) 
250 μL 
• DNA (pESR1-DDK)  2.5 μg 
• P3000 reagent  10 μL 
 
The diluted DNA mixture was added to Lipofectamine solutions in a 1:1 ratio (125 μL diluted 
DNA and 125 μL Lipofectamine solution) in 1.7 mL Eppendorf tubes. The mixtures were 
incubated for 15 minutes at room temperature. Following incubation, the cells were exposed 
to the DNA-lipid complexes (refer to the next page for a diagram of the plate set up).  
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Cells were incubated for 24 hours at 37°C. The following day, the media was replaced with 
DMEM containing 600 μg/mL G418 to begin the selection process. G418-resistant HeLa cells 
were grown to 100% confluency in each well and labelled clone A-H.  
 
Plate 1: 3.75 μL Lipofectamine 
A 
3.75 μL Lipofectamine 
2.5 μg pESR1-DDK 
+G418 
B 
3.75 μL Lipofectamine 






3.75 μL Lipofectamine 
2.5 μg pESR1-DDK 
+G418 
D 
3.75 μL Lipofectamine 




Plate 2: 7.5 μL Lipofectamine 
E 
7.5 μL Lipofectamine 
2.5 μg pESR1-DDK 
+G418 
F 
7.5 μL Lipofectamine 




7.5 μL Lipofectamine 
2.5 μg pESR1-DDK 
+G418 
H 
7.5 μL Lipofectamine 




All eight clones (A-H) were assessed for ESR1 mRNA expression via RT-qPCR using Taqman 
primers (see General Methods, Chapter 2.0, Section 2.1.3 for RT-qPCR method). All clones 
produced low CT values (average CT = 21.38) compared with HeLa cells (average CT = 33.5). 
Clone B, F and G induced the lowest CT values (Table 6.2, Figure 6.5A) and therefore, the 
highest ESR1 expression. The CT value for ESR1 in Clone G measured on average 21.3, which 
was significantly lower than HeLa cells (CT=33.5) (****p<0.0001, ordinary one-way ANOVA, 
multiple comparisons corrected for with a Sidaks’ test, Figure 6.5 A, page 198), which indicates 
that Clone G has higher ESR1 expression levels. The fold-change in ESR1 expression of Clone 
G compared with native HeLa cells showed a 2294-fold increase (Figure 6.5B, page 198) and 




Figure 6.4: Plasmid map for ERa expression plasmid, pESR1-DDK. 
 
The CMV promoter drives overexpression of the ESR1 gene and the Neo gene encodes for 
G418 resistance. Upon transfection with pESR1-DDK, G418 resistant cells will express ESR1. 
 
Table 6.2: CT of ESR1 in pDDK-ESR1-transfected HeLa clones. 
 
HeLa mRNA (grey) served as the control to show relative changes in ESR1 expression levels. 
Clone G (red) was chosen for subcloning. GAPDH was used as the reference gene since it is 
stably expressed and is used to compare relative gene expression CT = 15. All values rounded 
to the nearest 1 decimal place. 
Clone CT Number (n) 
A 24.1 1 
B 22.4 1 
C 24.4 1 
D 24.6 1 
E 23.7 1 
F 21.8 1 
G 21.3 ± 0.2 3 
H 24.9 1 




6.2.2.3 Subcloning of Clone G 
 
Clone G underwent subcloning for the purposes of ensuring that each subclone had identical 
plasmid copy number and to improve the reliability of the bioassay. The first step of the 
subcloning procedure involved diluting the cells to 90 cells/33 mL in 100 µL of DMEM 
(supplemented with 10% FCS (v/v) and 600 µg/mL G418) for an average of 1 cell every 3 wells 
of a 96-well plate, across 3 plates. Wells were included in the experiment if only one colony 
of cells were growing and discounted if more than one colony was growing in a single well. 
Each subclone was passaged up to a 6-well plate and then assessed for ESR1 expression levels 
via RTqPCR (see General Methods, Chapter 2.0, Section 2.1.3 for RT-qPCR method). ESR1 gene 
expression was measured across 22 subclones and subclone G22 had the lowest CT, therefore, 
the highest ESR1 gene expression (Table 6.3). The CT for ESR1 in clone G22 cells measured on 
average 21.7 and this was significantly lower than HeLa cells (CT=33.5) (****p<0.0001, 
ordinary one-way ANOVA, multiple comparisons corrected for with a Sidaks’ test, Figure 6.5A, 
page 198), which associated with a 3890-fold increase in ESR1 expression (Figure 6.5B, page 




Table 6.3: CT of ESR1 subcloned Clone G cells. 
 
HeLa mRNA (grey) was used as the control to show relative changes in ESR1 expression 
levels. Clone G22 (red) was chosen to move forward with transfection with the reporter 
gene plasmid (pERETATAluc). GAPDH was used as the reference gene since it is stably 
expressed and is used to compare relative gene expression CT = 15. All values rounded to 
the nearest 1 decimal place. 
Subclone G# CT Number (n) 
G1 27.0 1 
G2 27.3 1 
G3 26.3 1 
G4 26.1 1 
G5 28.5 1 
G6 26.5 1 
G7 26.1 1 
G8 27.2 1 
G9 26.5 1 
G10 28.6 1 
G11 27.9 1 
G12 28.1 1 
G13 26.3 1 
G14 27.7 1 
G15 27.6 1 
G16 27.4 1 
G17 26.0 1 
G18 24.5 1 
G19 27.0 1 
G20 25.8 1 
G21 26.3 1 
G22 21.7 ± 0.9 4 




Figure 6.5: Characterizing relative ESR1 expression levels in Clone G AND 
G22. 
 
A. The mean CT ± SEM for ESR1 expression in HeLa cells was significantly lower than Clone 
G and G22, showing that ESR1 was overexpressed (****p<0.0001, ordinary one-way 
ANOVA). CT is the number of cycles of RTqPCR required for the ESR1 (gene of interest) to 
reach threshold. B. The fold change in ESR1 expression relative to HeLa cells equates to 
2294 in Clone G cells and 3900 in Clone G22 cells. The overexpression of ESR1 demonstrates 
the successful transfection of the expression plasmid, pESR1-DDK.  























































6.2.3 Cloning pERETATAluc with puromycin dihydrochloride resistant 
gene 
 
To enable the selection of HeLa cells expressing the reporter plasmid (pERETATAluc), the 
puromycin resistance gene (PuroR) was subcloned from pTRE-T2-ΔmIR-IRES-Puro (addgene, 
Cat #105168) into pERETATAluc (Figure 6.6A for plasmid map). HeLa cells that survived 
puromycin treatment were selected as positive transfectants and propagated. The first step 
required to generate a puromycin resistance gene expressing plasmid was to amplify the gene 
from the donor plasmid, pTRE-T2-ΔmIR-IRES-Puro (Figure 6.6A) and insert the gene into 
pERETATAluc in between the MluI and Acc65I restriction sites (Figure 6.6B). 
 
6.2.3.1 Primer Design for SV40-PuroR amplification from pTRE-T2-ΔmIR-IRES-Puro 
 
The simian vacuolating virus 40 (SV40) promoter and PuroR were amplified from pTRE-T2-
ΔmIR-IRES-Puro. SV40 operates as an enhancer and promoter to drive downstream 
transcription of the puromycin resistance gene. 
 
6.2.3.2 SV40-PuroR sticky end primers 
 
To amplify the SV40 and PuroR gene from pTRE-T2-ΔmIR-IRES-Puro, forward and reverse 
primers were designed to anneal immediately upstream of the SV40 promoter and 
downstream of the PuroR gene, respectively, to amplify this region of DNA (Figure 6.6A). The 
forward (PuroR-F) and reverse (PuroR-R) primers include sticky ends at the 5’ end of the 
primer. The sticky ends do not anneal to the DNA template during PCR since they harbour 
clamp base pairs and the restriction site. The forward primer is the compliment of the bottom 
strand of DNA (running 3’ – 5’). The reverse primer is the reverse compliment of the top strand 
of DNA (running 5’ – 3’).  The clamp base pairs protect the primers from degradation during 
PCR and the restriction sites are specifically recognized by restriction enzymes to cut the PCR 
product at the 5’ ends. The forward primer contains 6 clamp base pairs (attgca – green letting 
in Table 6.4) and Acc65I restriction site (ggtacc – blue lettering in Table 6.4). The reverse 
primer contains 6 clamp base pairs (ttagct - green letting in Table 6.4) and MluI restriction site 
(acgcgt – orange lettering in Table 6.4). Restriction sites, Acc65I and MluI, were chosen from 
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the multiple cloning site (MCS) in pERETATAluc since they were unique to pERETATAluc and 
both exhibit 100% cutting efficiency in NEBuffer 3.1. The primers require a GC ratio of between 
40 – 60% and for this ratio to be of similar value between the two primers. This ensures that 





Figure 6.6: Plasmid map of pTRE-T2-ΔmIR-IRES-Puro (donor plasmid) and pERETATAluc (recipient plasmid). 
 
A. The SV40 promoter and puromycin resistance gene from pTRE-T2-ΔmIR-IRES-Puro was isolated and amplified by PCR using sticky end primers; 
Acc65I PuroR-F and MluI PuroR-R (shown as purple arrows in A). B. MluI and Acc65I restriction sites were cut with restriction enzymes to allow the 
insertion of SV40-PuroR gene from pTRE-T2-ΔmIR-IRES-Puro. Acc65I and MluI restriction sites are shown at base pair numbers 4024 and 4038, 
respectively. The location of the sequencing primer and luciferase forward and reverse primers are shown by the purple arrows.  Screenshot images 














Table 6.4: Sequence of sticky end SV40-PuroR forward and reverse primers.  
 
The sequences and annealing sites for PuroR-F and PuroR-R primers (purple arrows) designed to amplify the SV40 promoter and PuroR gene from 
pTRE-T2-ΔmIR-IRES-Puro are stated below. PuroR-F is shown with reference to the SV40 promoter located downstream and PuroR-R is shown in 
reference to the upstream PuroR gene. Screenshot images from SnapGene. 
Primer Sequence 
PuroR-F 5’- att gca ggt acc ctg tgg aat gtg tgt cag tta ggg tgt 
Position and sequence of 
primer in relation to SV40 
promoter 
 
PuroR-R 5’- tta gct acg cgt ggc tga tta tga tcc tct tga gtc gg 
Position and sequence of 





6.2.3.3 PCR for SV40-PuroR Genes from pTRE-T2-ΔmIR-IRES-Puro 
 
The SV40 promoter and PuroR gene were amplified from pTRE-T2-ΔmIR-IRES-Puro using 
PuroR-F and PuroR-R primers in a PCR reaction as per the following protocol.  
 
PCR master mix 
Reagent: Volume per reaction: 
• KAPA HiFi Hot Start Ready Mix (Kapa Biosystems, Cat 
#KR0370) 
12.5 μL 
• PuroR-F primer  0.75 μL 
• PuroR-R primer  0.75 μL 
• dH2O  10 μL 
 
Mini-prep of pTRE-T2-ΔmIR-IRES-Puro (1 ng/μL) was added to PCR master mix to make volume 
up to 25 μL. Followed kit instructions for Mini-prep (QIAprep®Spin Miniprep kit, Qiagen, Cat 
#27104). 
 
6.2.3.4 PCR run 
 
Initial denaturation was held at 95°C for 3 minutes, followed by 35 cycles at 98°C for 20 
seconds, 68°C for 15 seconds and 72°C for 60 seconds. Final extension was held at 72°C for 5 
minutes. PCR products were electrophoresed on a 1.0% (w/v) agarose gel (see General 
Methods, Chapter 2.0, Section 2.1.4.2 agarose gel protocol) to ensure a single product (band) 
was generated in the PCR (Figure 6.7).  
 
The PCR product harbours MluI and Acc65I restriction sites at the 5’ ends of the PCR product. 
The restriction sites allow for specific digestion at this location in the PCR product. This ensures 
that the PCR product can be ligated (inserted) into the receiving plasmid at the corresponding 





Figure 6.7: DNA gel showing the PCR product amplified from pTRE-T2-
ΔmIR-IRES-Puro. 
 
The expected size of the SV40 promoter and PuroR gene is 1168 bp. 
 
6.2.3.5 Purification of the PCR product 
 
A single product (band) was amplified in the PCR reaction (Figure 6.7), which allowed for direct 
purification of the sample. The DNA product was purified from the PCR reaction using the 
QIAquick PCR purification kit (Qiagen, Cat #28104) by following kit instructions. 
 
6.2.3.6 Double digest of the SV40-PuroR product 
 
The purified PCR product was treated with MluHFI and Acc65I restriction enzymes to digest 
the 5’ ends of the purified PCR product. The following protocol was carried out to digest the 
5’ ends of the purified SV40-PuroR PCR product.  
 
Reagent: Volume:  
• Mlu-HF (New England Biolabs, Cat #R3198S) 2.0 μL 
• Acc65I (New England Biolabs, Cat #R0599S) 2.0 μL 
• 3.1 Buffer (New England Biolabs, Cat #B7203S) 5.0 μL 
  
The above reagents were mixed in a 1.7 mL Eppendorf tube and made up to 50 μL with DEPC-
treated H2O. The sample was incubated at 30°C for 30 min. Digested and non-digested PCR 
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products (of the SC40-PuroR PCR product) were electrophoresed on a 1.5% (w/v) agarose gel 
to compare the size of the bands and thus, ensure the digestion was successful (Figure 6.8A).  
 
6.2.3.7 Purification of the double-digested PCR product 
 
A single product (band) was amplified in the PCR reaction (Figure 6.8B), which allowed for 
direct purification of the sample. The DNA product was purified from the PCR reaction using 






Figure 6.8: DNA gels showing the digested and purified PCR product. 
 
A. Comparison of PCR product amplified with PuroR-F and PuroR-R primers both non-
digested and digested with Acc65I and MluI restriction enzymes (expected size 1168 bp). 
The slightly smaller band for the digested product is due to the removal of some base pairs 
from 5’ ends of the PCR product following restriction enzyme digest. B. Digested PCR 
product following purification (expected band size 1168 bp).  
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6.2.3.8 Double digest and purification of pERETATAluc  
 
The recipient plasmid, pERETATAluc (3X ERE TATA luc, Addgene, plasmid #11354) underwent 
a double digest procedure by ligation of the Acc65I and MluI restriction sites to linearise the 
plasmid. Following double digestion of pERETATAluc, the linearised plasmid harbours MluI and 
Acc65I 5’ sticky ends. These restriction site ends of the linearized plasmid allow for the 
insertion of the double-digested SV40-PuroR PCR product.  
 
MluI-HF and Acc65I restriction enzymes cut pERETATAluc at MluI and Acc65I restriction sites 
in 3.1 buffer as per the following protocol.  
 
Reagent: Volume:  
• Mlu-HF (New England Biolabs, Cat #R3198S) 2.0 μL 
• Acc65I (New England Biolabs, Cat #R0599S) 2.0 μL 
• 3.1 Buffer (New England Biolabs, Cat #B7203S) 5.0 μL 
  
The above reagents were mixed in a 1.7 mL Eppendorf tube and made up to 50 μL with dH2O. 
The double digest sample was incubated at 37°C for 30 min. Following double digestion of the 
plasmid, the linearised pERETATAluc was purified using the QIAquick PCR purification column. 
The digested (linearised) and non-digested (circularised) pERETATAluc were run on a 1.5% 
(w/v) agarose gel to ensure the digestion reaction was successful characterised by a clean 
band (Figure 6.9). 
 
 
Figure 6.9: DNA gel of circularized- and linearized pERETATAluc. 
 
The linearised plasmid travels further as a straight piece of DNA can move more easily 
through the gel. Expected size of pERETATAluc is 5757 bp. 
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6.2.3.9 Dephosphorylation of the 5’ ends of pERETATAluc  
 
To prevent self-ligation of the linearised plasmid (pERETATAluc), it underwent a 




• pERETATAluc  250 ng 
• Cut Smart Buffer (New England Biosystems, Cat #B7204S) 2.0 μL 
• Shrimp Alkaline Phosphatase (rSAP) (New England 
Biosystems, Cat #M0371S) 
0.5 μL 
 
The above reagents were mixed in a 1.7 mL Eppendorf tube and made up to 20 μL dH2O. The 
sample was incubated at 37°C for 30 min. The reaction was stopped by heat shock at 65°C for 
5 minutes. 
 
6.2.3.10 Ligation of pERETATAluc and SV40-PuroR 
 
SV40-PuroR was ligated (inserted) into pERETATAluc at the MluI and Acc65I restriction sites as 
per the following protocol. 
 
Reagent: Amount/volume: 
• Linearised pERETATAluc 40 ng 
• SV40PuroR purified double-digest product   40 ng 
• ANZA T4 DNA ligase master mix (Invitrogen, Cat #IVGN2104) 5 μL 
• dH2O 12.75 μL 
 
The above components were carefully mixed in a 1.7 mL Eppendorf tube and incubated at 






6.2.3.11 Transformation of E.coli competent cells with pERETATAlucSV40PuroR 
 
One Shot Top 10 chemically competent cells (Invitrogen, Cat #C404003) were thawed on ice 
followed by the addition of 5 μL of ligation mixture. Cells and ligation mixture were mixed by 
carefully pipetting up and down and then incubated on ice for 30 minutes. Cells were heat 
shocked at 42°C for exactly 30 seconds followed by a 2 minute incubation on ice. 250 μL SOC 
media (Invitrogen, Cat #15544-034) was added to cells followed by a careful mix. The mixture 
was incubated at 37°C on an orbital shaker (225 rpm) for 1 hour. The competent cells, at two 
volumes of 50 μL and 150 μL were streaked out on LB-ampicillin agar plates and incubated at 
37°C for 18 hours. The following day, distinct small colonies were visible by eye and ready for 
inoculation. 
 
6.2.3.12 Colony PCR 
 
A total of 8 random single isolated colonies were selected from the LB-agar plate to undergo 
colony PCR to determine if the SV40-PuroR gene insert was present in 
pERETATAlucSV40PuroR. Each bacterial colony was streaked onto 1/8th of an agar plate. To 
introduce the DNA from each bacterial colony into the PCR mixture, the spreader tool was 
then dipped directly into the PCR mixture (same PCR set up and PCR run settings as Section 
6.2.3.4). The PCR reaction was electrophoresed on a 1.5% (w/v) agarose gel to visualize the 
presence of a product (band) at an expected size of 1168bp. pTRE-T2-ΔmIR-IRES-Puro 
underwent the same PCR reaction to serve as a positive control and a no template control 
(NTC) (DEPC-treated H2O in replacement of DNA) was electrophoresed concurrently to ensure 
no DNA contamination (Figure 6.10). 
 
The LB-agar plate was incubated overnight for 18 hours at 37°C. Following incubation, a small 
amount of clone 4 was inoculated into a 40mL LB-ampicillin broth and incubated at 37°C, 225 
rpm for 18 hours. The following day, a midi-prep was carried out to isolate 




Figure 6.10: DNA gel of SV40-PuroR gene amplified from colony PCR. 
 
A band is present for all 8 subclones (colonies) at the expected size for the SV40 promoter 
and PuroR gene of 1168 bp. pTRE-T2-ΔmIR-IRES-Puro (pTRE) served as a positive control. 
No band in the NTC lane ensures no DNA contamination of the PCR reaction. 
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6.2.4 Transfection of clone G with pERETATAlucSV40PuroR  
 
6.2.4.1 Optimisation of puromycin concentration 
 
pERETATAlucSV40PuroR expresses PuroR as a selectable marker, which confers resistance to 
puromycin. Therefore, an optimal concentration of puromycin needed to be established to 
ensure non-transfected HeLa cells are not viable under the treatment of puromycin. HeLa cells 
were seeded into two 6-well plates at a concentration of 2.0 x 105 cells/mL in DMEM 
(supplemented with 10% (v/v) FCS). Once cells reached 95% confluence, HeLa cells were 
treated with 11 serial dilutions of puromycin, ranging from 0.2 µg/mL to 2.2 µg/mL. A control 
well containing no puromycin was also included. HeLa cells were assessed for cell viability for 
10 days with daily media changes. The optimal concentration of 1.0 µg/mL puromycin was 
chosen since HeLa cells started dying after 2 days, steadily died off over the following 4 days 
and all cells were dead by day 6, which is within an appropriate time frame (Figure 6.11). 
 
6.2.4.2 Transfection of clone G22 HeLa cells with pERETATAlucSV40PuroR 
 
To develop an ERa-expressing HeLa cell line with an ERE-reporter plasmid, Clone G cells (ESR1 
positive) were transfected with pERETATAlucSV40PuroR using the Lipofectamine 3000 
transfection kit. HeLa cells were seeded in one 6-well plate at a concentration of 1.0 x 105 
cells/mL and transfected at 95% confluency. One well of Clone G cells was not transfected and 




Reagent: Volume per plate: 
• DMEM (containing high glucose (4500 mg/L), L-glutamine (584 
mg/L) and sodium pyruvate (110 mg/L)). 
125 μL x 2 
• LipofectamineTM 3000 reagent 3.75 μL and 7.5 μL 
 
The above reagents were duplicated and the Lipofectamine reagent was diluted in serum-free 
DMEM in 1.7 mL Eppendorf tubes. 
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Figure 6.11: Representative graph of the puromycin kill curve. 
 
HeLa cells were treated with serial dilutions of puromycin (0.2 μg/mL – 2.2 μg/mL) and cell viability was recorded daily. The optimal rate of cell death 
was determined to be a concentration of 1.0 μg/mL of puromycin (red line). Representative curve from two independent experiments. 
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Diluted DNA Mixture 
Reagent: Volume for 2 
Lipofectamine 
Solutions: 
• DMEM (containing high glucose (4500 mg/L), L-glutamine (584 
mg/L) and sodium pyruvate (110 mg/L)). 
250 μL 
• DNA (pERETATAlucSV40PuroR)  1 μg and 5 μg 
• P3000 Reagent  10 μL 
 
In a 1:1 ratio, 1 µg diluted DNA mixture was added to 3.75 µL Lipofectamine solutions and 5 
ug diluted DNA mixture was added to 7.5 µL Lipofectamine solutions in 1.7 mL Eppendorf 
tubes. The mixtures were incubated for 15 minutes at room temperature. Following 
incubation, cells were treated with the DNA-lipid complex. Cells were incubated for 24 hours 
at 37°C.  
The following day, the media was replaced with DMEM (supplemented with 10% FCS (v/v), 
600 µg/mL G418 and 1.0 1.0 µg/mL puromycin) to begin the selection process for puromycin 
resistant cells.  
 
6-well plate set up for transfection: 
I 
3.75 μL Lipofectamine 
2.5 μg pESR1-DDK 
+G418 
II 
3.75 μL Lipofectamine 







3.75 μL Lipofectamine 
2.5 μg pESR1-DDK 
+G418 
IV 
3.75 μL Lipofectamine 




6.2.4.3 Isolating Puromycin resistant colonies 
 
Puromycin and G418 resistant HeLa colonies were isolated using cloning cylinders when 
colonies reached ~100 cells in size. The media was aspirated from the well and cells were 
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washed with 1X PBS. The cloning cylinder was carefully placed over the cell colony using long 
forceps and ensured the cylinder was sealed to the base of the well. To lift the colony of cells, 
50 µL of TrypleETM was pipetted into the cloning cylinder and incubated for ~2 minutes at 
37°C. Trypsin was diluted using DMEM media (containing high glucose (4500 mg/L), L-
glutamine (584 mg/L), sodium pyruvate (110 mg/L) supplemented with 10% FCS, 600 µg/mL 
G418 and 1.0 1.0 µg/mL puromycin) and cells were transferred to a single well in a 24-well 
plate with 500 µL DMEM media (containing high glucose (4500 mg/L), L-glutamine (584 mg/L), 
sodium pyruvate (110 mg/L) supplemented with 10% FCS, 600 µg/mL G418 and 1.0 1.0 µg/mL 
puromycin). Cells were incubated at 37°C, 5% CO2 until cells were ~90% confluent. A total of 
6 colonies (Clones G22.1-6) survived colony isolation and propagation. Cells were propagated 
through increasing sizes wells of plates and culture flasks until they reached 80% confluence 
in two T75 cm2 flasks. One T75 cm2 flask was treated with 37 nM E2 (final concentration 0.01% 
EtOH) for 48 hours. The other was frozen following the cell freezing procedure detailed in 
Chapter 2.0, Section 2.6.3. Total RNA was extracted from the E2-treated cells to assess for 
luciferase mRNA expression by PCR and gel electrophoresis (see General methods Chapter 
2.0, Sections 2.1.1, 2.1.2 and 2.1.4 for protocols). 
 
6.2.4.4 Assessment of Clone G22.1-6 HeLa cells transfected with 
pERETATAlucSV40PuroR for luciferase mRNA 
 
Cells at ~80% confluence in a T75 flask underwent a media change to DMEM F12 media 
(supplemented with 10% charcoal-stripped FCS, 600 µg/ml G418 and 1 µg/mL puromycin). 
Next, cells were treated with 30 nM E2 (0.01% (v/v) ethanol) for 48 hours then RNA was 
harvested (Clones G22.1-6). Luciferase mRNA generated in response to E2 treatment was 
probed for using the primers designed against the plasmid gene DNA sequence. These primers 
were referred to as luciferase-forward (Luc-F) and luciferase-reverse (Luc-R) primers (Table 
6.5, page 216). The presence of luciferase mRNA would ensure the luciferase gene is 





PCR master mix 
Reagent: Volume per reaction: 
• KAPA HiFi Hot Start Ready Mix (Kapa Biosystems, Cat 
#KR0370) 
12.5 μL 
• Luc-F primer  0.75 μL 
• Luc-R primer  0.75 μL 
• dH2O  9 μL 
 
cDNA from Clone G22.1-6 cells, reverse transcription control (2 μL), DNA of pERETATAluc (2 
μL of 1 ng/μL) and pERETATAlucSV40PuroR (2 μL of 1 ng/μL) were individually added to each 
PCR master mix. The volume in the PCR master mix was made up to 25 μL with the cDNA. In 
replacement of DNA, 2 μL of DEPC-treated H2O was added to PCR master mix to serve as a 
NTC.  
 
6.2.4.5 PCR run 
 
PCR samples were placed in the Kyratec SuperCycler for the PCR reaction. Initial denaturation 
was held at 95°C for 3 minutes, followed by 35 cycles of 98°C for 20 seconds, 54°C for 15 
seconds and 72°C for 60 seconds. Final extension was held at 72°C for 5 minutes. PCR products 
were electrophoresed on a 1.5% (w/v) agarose gel (refer to General Methods, Chapter 2.0, 
Section 2.1.4 for protocol) (Figure 6.12A, page 217). 
 
Since clone G22.3 cells tested positive for luciferase mRNA, cells were plated in a 6-well plate 
in DMEM F12 media (supplemented with 10% charcoal-stripped FCS, 600 µg/ml G418 and 1 
µg/mL puromycin) and treated with E2 (30 nM and 1000 nM) and ethanol (0.01% (v/v) final 
ethanol concentration). The RNA extraction, reverse transcription and PCR steps were 





Table 6.5: Sequence of luciferase primers.  
 
The purple coloured primers in the image below shows the sequence of the forward and reverse primers designed to amplify part of the luciferase 
gene from pERETATAluc. The sequence, GC ratio and melting point (Tm) of the forward and reverse primers are listed below.  
 
Primer Sequence 
Forward 5’- ttt cga gtc gtc tta atg ta 
Reverse 5’- gct gta aat tag ata aat cgt att 
Position and sequence of 








Figure 6.12: DNA gel assessing for the expression of luciferase mRNA in E2-
treated clones (G22.1-6). 
 
A. The expected size of 154 bp is observed for the two positive control samples 
(pERETATAluc and pERETATAlucSV40PuroR), Clone G22.3 and G22.4. Clone G22.1, 2, 5 and 
6 were negative for the luciferase gene. NTC and RT control samples were negative, which 
ensures there was no DNA contamination. B. Clone G22.3 (a) used the same cDNA as the 
first gel (A), G22.3 (b) was treated with 1000 nM E2, (c) was treated with 30 nM E2 and (d) 
was treated with ethanol. pERETATAlucSV40PuroR served as the positive control and RT 




6.2.5 Confirmation of Assay Activity in Clone G22.3 and G22.4 
 
Clone G22.3 and G22.4 cells were seeded in clear 96-well plates, treated with a serial dilution 
of E2 (37 nM to 0.007 pM) for 48 hours and the BrightGlo bioassay was carried out to assess 
for luciferase activity of both clones (refer to Appendix 9.1 for protocol). There was no 
measurable luciferase activity from either clone, therefore, further work is required to 




6.3 Conclusion and Future Directions 
 
In this chapter, the methods and corresponding results taken to develop an ERa-RGB is 
detailed. The first step was ensuring the HeLa cell line would serve as an appropriate host with 
limited cross reactivity by measuring the mRNA levels of endogenous SHR. It was determined 
that HeLa cells were a good host as there was little or no SHR mRNA or subsequent protein. 
Subsequently, cells were transfected with pESR1-DDK to increase expression of ERa positive 
transfectants were selected with the G418 antibiotic and subcloned by growing cell colonies 
from 1 cell/well. Clone G22 was chosen to move forward with and a second transfection was 
completed. G22 showed higher ESR1 mRNA levels than HeLa cells. The second plasmid, 
pERETATAluc, containing the ERE upstream of the luciferase reporter gene, was cloned with 
the SV40-PuroR gene from pTRE-T2-ΔmIR-IRES-Puro to allow for the selection of cells with the 
antibiotic, puromycin. Clone G22 cells were transfected with pERETATAluc-SV40PuroR and 
subcloned through the use of cloning cylinders. The subclones G22.1-6 were assessed for 
luciferase mRNA levels following E2 treatment and 2 out of 6 clones tested positive for 
luciferase mRNA. Both clones were assessed for luciferase activity by treating cells with E2, 
however, no light emission was measurable from either clone. Therefore, this cell line is not 
currently functional for measuring ERa-mediated gene transcription and further work is 
required. 
 
A first step to helping to understand the reason for lack of luminescence would involve 
sequencing the pERETATAluc-SV40PuroR plasmid to ensure there are no mutations in the 
plasmid that would affect luciferase transcription. Although luciferase mRNA levels can be 
measured in clones G22.3 and G22.4, this was not quantified and this could be minimal 
promoter activity of the plasmid driving a small amount of luciferase gene expression. Since 
ethanol-treated Clone G22.3 (Figure 6.12B) also produced a band at 150 bp, this would also 
suggest that the luciferase mRNA being produced is a result of minimal promoter activity of 
the plasmid and not induced by ERa. Since the PuroR gene was inserted into the multicloning 
site, which is situated very closely to the location of the ERE, it could be possible that the 
sequence of ERE was disrupted during the cloning procedure. Therefore, the activated 
recombinant ERa was unable to bind effectively to the ERE to induce gene expression of 
luciferase. The level of luciferase mRNA measured by PCR could be very small and therefore 
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not translate to a quantifiable activity of of luciferase once the mRNA was translated into a 
protein. 
 
Another possible reason for lack of luminescence could be due to a translation issue of the 
luciferase mRNA into a functional protein. Interestingly, AR mRNA was quantifiable in HeLa 
cells denoted by the relatively low CT value, but protein was not detected by Western Blot in 
HeLa protein extracts. Therefore, it could be that HeLa cells may have issues translating some 
proteins.  
 
A transient transfection with pERETATAluc into Clone G cells followed by E2 treatment would 
have been a good first step to ensure the plasmid is functional in the cells. This step was not 
taken since the plasmid is commercially available and it was expected that the plasmid would 
be operational. 
 
The cells were still G418 resistant when the mRNA was harvested from Clone G22.3 and G22.4, 
which strongly suggests that pESR1-DDK was still expressed within the cells. However, future 
work would involve ensuring that clone G22.3 and G22.4 still had measurable levels of ESR1 
mRNA.  
 








7.1 Overview of key findings 
 
This study set out to determine if RGBs have clinical utility. AR- and ERa/b-RGBs are novel 
clinical approach to measuring net estrogens and androgens in serum, which could have 
prognostic value. The key finding of this study showed that serum and plasma net 
estrogenicity and androgenicity can be directly measured by the HEK293-AR and T47D-ER 
bioassays. Furthermore, intra-patient changes were also detected. To further support the 
clinical application of RGBs, the current clinical measure for E2 and testosterone 
measurement, immunoassay, failed to detect testosterone and E2 in all samples and no intra-
patient changes were derived. The establishment of our own clinical study provides a 
promising platform for future investigation into the clinical importance and application of 
RGBs in the prognosis of breast cancer patients. Like all good science, major lessons have been 
learnt including the need for good, robust assay development. These lessons will be discussed 
below. 
 
7.2 Key findings from each results chapter 
 
The overarching aim of this study was to determine if RGBs can be used to measure clinically 
relevant samples. The first three results chapters tested the clinical efficacy of AR- and ER-
RGBs by ultimately testing breast cancer plasma and serum samples. Whereas, the final results 
chapter aimed to develop a ERa-specific RGB hosted in HeLa cells. 
 
Chapter 3 tested both equine and human plasma to determine if the HEK293-AR bioassay was 
capable of measuring serum and plasma AR bioactivity. However, prior to testing equine and 
human plasma, the performance of the HEK293-AR and yeast-AR bioassays were directly 
compared to determine if a yeast- or mammalian cell line would be most optimal for 
measuring serum AR bioactivity. It was shown that the yeast-AR bioassay was unable to 
measure physiological concentrations (0.5 - 13 nM) of testosterone in serum and was reliably 
out-performed by the mammalian HEK293-AR bioassay. The HEK293-AR bioassay was 
sensitive enough to measure testosterone-spiked into serum down to low physiological 
concentrations (0.5 nM) as well as bioavailability and sex differences. Throughout this chapter, 
it became apparent that there was a clear serum interference effect occurring due to the 
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observed suppression in the maximal read-out of the assay. Despite serum interference, the 
HEK293-AR bioassay was evidently useful for screening AR bioactivity of a large number of 
thoroughbred racehorse plasma samples. Within the gelding and mare subpopulations, high 
AR bioactivity outlier samples were identified. These samples contained no detectable level 
of testosterone as determined by ELISA. This finding suggests that an alternative androgenic 
molecule other than endogenously synthesised testosterone could be responsible for this 
elevated AR bioactivity. This information could raise awareness for anti-doping agencies for 
further investigation into the utility of an AR bioassay for screening racehorse plasma samples. 
To test the clinical feasibility of the HEK293-AR bioassay, human breast cancer patient plasma 
before- and after chemotherapy was provided to our laboratory (n=9 patients, 2 time-points 
per patient). Once again, AR bioactivity could be detected in all plasma samples and temporal 
changes (before- and after chemotherapy) were also observed for 2 patients. In keeping with 
the equine plasma samples, the AR-RGB results provided more information than the 
immunoassay data alone since only 3 out of 18 samples had a detectable level of testosterone. 
Overall, the HEK293-AR bioassay provided more information for both equine- and human 
breast cancer patient plasma samples than the immunoassay results. 
 
Chapter 4 optimised and applied the T47D-ER bioassay towards measuring the same breast 
cancer patient plasma that was tested in the previous chapter. The ethanol concentration 
used to dissolve E2, the time of treatment with E2, cell seeding density and serum 
concentration within the cell culture media were the optimised parameters of the assay. A 
revised and optimised cell culture protocol for the T47D-ER bioassay can be found in Appendix 
9.1. As with the HEK293-AR bioassay, a prominent serum interference effect was observed in 
the presence of serum. Charcoal-stripped FCS is a common, integral constituent of cell culture 
media. However, FCS alone was capable of inducing up to 60% of assay activation. Upon 
lowering the FCS concentration, the background level of assay activation was also reduced. 
Furthermore, the addition of ethanol under E2-deprived conditions did not augment ER 
bioactivity, which clearly demonstrated that the serum was activating the T47D-ER bioassay. 
The most exciting finding of this chapter was obtaining a readout from the assay for all breast 
cancer patient samples. Interestingly, estrogenic bioactivity did not change for 7 out of 9 
patients following chemotherapy despite a clear decrease in E2 concentration for most 
patients. This observation could be explained by the presence of alternative estrogenic 
molecules in the plasma, which could be responsible for this steady level of ER bioactivity. This 
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finding underpins the reason and premise for the use of RGBs in a clinical context since the 
clinically measured variable (E2 measurement by immunoassay) showed a favourable 
decrease in E2 but the net estrogenicity does not follow the same trend. 
 
Chapter 5 detailed the establishment of a clinical study designed to utilise both HEK293-AR 
and T47D-ER bioassays. The study is not complete and all results in this chapter were derived 
from four patients. In this study, post-menopausal females with ER+ breast cancer were 
recruited to provide blood samples before-, 4-, and 12-weeks after starting aromatase 
inhibitor therapy with letrozole. The results of this study are a subset of what will become a 
full pilot study of 30 patients. Due to time limitation, only 4 patients were screened across 2- 
or 3 time points (blood samples). Furthermore, as a result of the low number of patients in 
this study, only bioassay performance can be commented on. Letrozole blocks the enzyme 
aromatase to prevent the conversion of two androgenic precursors; androstenedione and 
testosterone into estrogens; E1 and E2, respectively. As expected, ER bioactivity dropped 
significantly for all patients upon the onset of letrozole treatment. There was a residual level 
of ER bioactivity for all patients following letrozole treatment despite undetectable levels of 
E2 by immunoassay. AR bioactivity was low, yet measurable and remained steady between 
time points for 3 out 4 patients. One patient decreased in AR bioactivity, however the 
relevance of this finding cannot be determined by this study alone. Interestingly, only one 
sample had a measurable level of testosterone that was on the cusp of the limit of detection 
of the immunoassay. Once again, due to the discordant results between the AR- and ER-RGB 
and immunoassay data, these results show that RGB measurement could have the potential 
to provide companion information to the current clinical standard measure for testosterone 
and E2. 
 
The clinical study that was established as part of this PhD provided the reason to create our 
own ER-RGB that specifically measures only ERa bioactivity, as it may provide different 
information than combined ERa/b bioactivity represented by the T47D-ER bioassay. Unlike 
the T47D cells, which endogenously express both ERa and ERb, HeLa cells were chosen to 
create the ERa-specific bioassay since they do not express endogenous steroid hormone 
receptors. This helps to ensure minimal crosstalk between endogenous steroid hormone 
receptors. The HeLa cell line was cloned across two steps; (1) stable transfection with the ERa 
expression plasmid, followed by (2) stable transfection with an ERE-driven luciferase reporter 
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gene plasmid. The reporter gene plasmid was cloned with a puromycin resistant gene to allow 
for the selection of ERa-expressing HeLa cell clones that also express the reporter gene 
plasmid. Following the establishment of a number of HeLa cell clones that overexpressed ERa 
mRNA and luciferase mRNA, the cell line was unable to produce any measurable light emission 
(luminescence). As a result of the time frame of this PhD, the cell line was not operational for 
testing serum samples in this study. However, future studies will work to optimise the cell line 
for clinical application.  
 




A major finding and advantage of this study is that serum can be directly measured by the 
HEK293-AR and T47D-ER bioassays. However, it was shown that serum interference by 
component(s) of the matrix are a hurdle to overcome for the yeast-AR, HEK293-AR and T47D-
ER bioassays.  
 
Any test that measures serum parameter(s) will encounter the inevitable matrix effects of the 
complicated milieu of components (growth peptide hormones, steroid hormones, steroid 
binding proteins, vitamins, minerals and electrolytes). Our assay was no exception and 
previous studies have shown that measurement of testosterone or E2 by ELISA or RIA can be 
improved following chromatography extraction to remove serum proteins (Stanczyk et al., 
2003). However, since RGBs are measuring the biologically important aspect of androgens and 
estrogens, removing or denaturing the serum proteins would create an artificial measurement 
that is not biologically relevant. This is because the transport of steroid hormones in the blood 
relies on steroid binding proteins and is an important aspect of steroid hormone biology. 
Therefore, the serum interference needs to be incorporated into the understanding of the 
results of the bioassay rather than to try eliminate serum interference all together.  
 
It is yet to be determined whether serum components are interfering with the intracellular 
signalling mechanisms that converge on steroid hormone receptor signalling, or if the matrix 
has extracellular effects that interfere with the bioassay at the point of reporter protein 
measurement. Extracellular effects involve the interaction of components of serum that are 
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buffering or preventing interaction with the applied substrate. In this study it was interesting 
to observe that both aspects could hold true. In the T47D-ER bioassay, it was shown that 
serum (10% charcoal-stripped FCS) was increasing the baseline of the assay, whereas in the 
HEK293-AR bioassay serum was reducing the maximal readout of the bioassay. Therefore, two 
different mechanisms could be inducing these observations. As previously discussed in 
Chapter 4, growth factors and/or SHBG within present in FCS could be activating intracellular 
signalling pathways (via growth factor receptors or GPCRSs) that converge on kinase 
activation. Kinase activation can lead to subsequent receptor phosphorylation and ligand-
independent activation of ER. ER activation in estrogen-deprived conditions by 
phosphorylation could be a mechanism that explains the increased baseline of the assay 
(Rosner et al., 1992; Ignar-Trowbridge et al., 1993; Fissore et al., 1994; Kato et al., 1995b; 
Tremblay et al., 1997; Rosner et al., 1999; Tremblay et al., 1999; Chen et al., 2002). 
Alternatively, in the HEK293-AR bioassay, it is more likely that a component of the serum 
matrix, such as SHBG or albumin, is interacting with and buffering the function of the SEAP 
reporter protein. This is because the induction of the assay is suppressed in the presenece of 
serum and plasma. In the HEK293-AR bioassay, the media, which contains the test serum is in 
direct contact with the applied SEAP substrate, which enables the luminescence read-out. On 
the contrary, the media is aspirated during the assay procedure for the T47D-ER bioassay, 
therefore, the Bright-Glo luciferin substrate does not have a direct interaction with serum. 
This helps to explain why the T47D-ER bioassay did not have a serum-substrate interaction 
occurring that could induce serum interference via the same mechanism as the HEK293-AR 
bioassay. 
 
The two-way serum interference observed in the HEK293-AR and T47D-ER bioassays makes it 
challenging to pinpoint a single component of serum that is responsible for either dampening 
or augmenting the baseline of the assay. Taken together, the serum matrix effects are likely 
to be specific to the RGB being used (ER or AR) and within the context of how the reporter 
gene is quantified. 
 
Interpretation of ER-RGBs 
 
A changing baseline or inducibility of the assay when treated with serum makes it difficult to 
derive a serum measurement from a standard curve. It is common to interpolate standard 
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curves with the value induced by the test serum sample to derive an estradiol-equivalent- 
(EEQ) or testosterone-equivalent concentration (TEQ) value. For the purposes of this 
discussion, EEQ will be focussed on but the points pertain to TEQ as well. Studies have created 
E2 standard curves from each patient serum sample tested (Paris et al., 2002b), or from 
charcoal-stripped pooled serum (Widschwendter et al., 2009) to help overcome the serum 
interference effects for more accurate derivation of EEQ. However, despite this approach to 
obtain an EEQ value from a standard curve, it is common to observe that the EEQ is generally 
lower than the E2 concentration measured by quantitative measures. This means that there 
is poor correlation between E2 concentration and ER bioactivity (Lim et al., 2012), with up to 
a 3-fold difference (Wang et al., 2005). 
 
The advantage of a holistic and non-specific measure  
 
Due to the difficulty deriving an EEQ value, in this study, the units remained arbitrary and are 
expressed as ratio of maximal assay activation. Another reason for the arbitrary nature of the 
units is that the interpretation of the assay is in a manner that upholds the entire purpose of 
the assay. The purpose being that RGBs measure and encapsulate all biologically relevant and 
bioavailable androgens or estrogens in the assay and not just specifically E2 or testosterone. 
RGBs could be considered a measure in their own right without direct comparison to 
quantitative measures.  
 
In breast cancer research, there is a continual drive to increase the precision and specificity of 
biomarkers. By improving the specificity and accuracy of biomarkers, the tumour can be 
characterised more accurately with associated risk of disease-free survival. Furthermore, the 
responsiveness to neoadjuvant treatments such as aromatase inhibitors, tamoxifen and 
chemotherapy can also be predicted with higher accuracy. Current biomarkers include ER, PR, 
HER2, Ki67 (genetic marker of cell proliferation) and tests for genetic markers (Mammaprint, 
Oncotype, DX and Prosigna). In addition to tumour biomarkers, surrogate biomarkers such as 
E2 as routinely measured to ensure E2 levels remain low to prevent ER-induced ER+ breast 
cancer cell proliferation. However, the ability to accurately and reliably measure E2 is 
constantly under scrutiny since current measures are unreliable for low concentrations of E2 
(Stanczyk et al., 2003; Stanczyk et al., 2010; Stanczyk & Clarke, 2014). However, the bioassay 
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approach is a holistic measure, which offers a novel method to approach endocrine 
measurement. 
 
Every cell behaves differently 
 
Every cell type expresses different concentrations (amount of) and expression profiles (type 
of) cofactor proteins, steroid hormone receptors and steroid hormone metabolising enzymes. 
Therefore, each cell type will provide a slightly different interpretation of the net estrogenicity 
or androgencitiy of a serum sample. Therefore, there is no one size fits all approach to cell-
based RGBs. Utilising an ER+ breast cancer cell line (T47D) to assess ER bioactivity from 
patients with ER+ breast cancer would seem a logical first step. However, there are many 
different cell lines that are commercially available that also express ERs. Although many 
different cell types express ERs, the results of the assay in response to the same serum sample 
could vary greatly. An amalgamation of previous studies show that the EC50 of E2 in ERa-RGBs 
can vary 5-fold between ER+ breast cancer cell lines, with reported values measuring 5pM and 
50 pM in T47D (Legler et al., 1999) and MCF-7 (Matthews et al., 2001) cells, respectively. 
However, other studies have reported EC50 values of E2 measuring 5 pM in MCF-7 cells 
(Balaguer et al., 1999), 20 pM in HeLa cells (Jausons-Loffreda et al., 1994) and as high as 60 
nM in yeast-ER bioassays (Wang et al., 2014b). The variability among cell lines for E2, the most 
potent endogenous estrogen, illustrates how the biology of each cell can greatly influence the 
interpretation of the bioactivity of a test sample. 
 
7.4 RGBs have clinical research value 
 
RGBs provide a generalized readout about the level of estrogneicity or androgenicity of a test 
sample. Previous studies have shown that both ERa and ERb bioactivity independently 
associate with the risk of lung cancer (Lim et al., 2014b), breast cancer (Widschwendter et al., 
2009; Fourkala et al., 2011; Lim et al., 2014a) and hip fractures (Lim et al., 2012). This is a 
clinically novel approach to understanding the endocrine measurement since this assay is not 
a direct target for known endocrine molecules, such as E2 or testosterone. This PhD has 
provided a foundation for future investigation into the applicability and clinical relevance of 
such a test in the context of horse racing plasma, human plasma samples and breast cancer 
patients undergoing letrozole treatment.  
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There are still many steps of optimisation required to streamline the protocol, analysis and 
interpretation of results to actualise RGBs in a clinical setting. At this stage, RGBs hold promise 
in a clinical research context, whereby research laboratories can utilise RGBs to help to 
understand the risk of relapse for patients in advance. By strengthening the technique in 
research laboratories, this can help to translate research clinically. Once the research is able 
to convincingly provide novel information to clinicians that can help to improve patient care, 
then steps can be taken towards implementing a standardized protocol to monitor serum 
estrogenicity and/or androgenicity. By building a translational research programme, this 
would help to help foster and improve collaborations and relationships between clinicians and 
researchers for the common goal being improved health outcomes for patients. 
 
7.5 Future directions 
 
To validate the RGB method more accurately, testosterone and E2 concentration within each 
serum sample, the use of LC/MS would be exquisitely more accurate and sensitive compared 
with ELISA.  
 
The projected future of this study involves finishing the creation of the HeLa-ERa cell line 
followed by creating a Hela-ERb cell line. Such RGBs would be utilised to test patient samples 
in the aromatase inhibitor study. The T47D-ER bioassay measured the combined ERa/b 
bioactivity of test samples. The use of a combined ERa/b cell line could be considered 
representative of normal cellular physiology since most cells co-express both receptor 
isoforms (Mosselman et al., 1996; Kuiper et al., 1997). In a system where both receptor 
isoforms are expressed, there are functional interactions between ERa and ERb (Cowley et 
al., 1997). These interactions are of importance in gene regulation since ERa and ERb bind to 
EREs with different affinities (Mosselman et al., 1996; Hyder et al., 1999). ERb has been shown 
to downregulate ERa mRNA, protein expression levels (Trukhacheva et al., 2009) and ERa-
mediated gene transcription. The dominant negative regulation of ERa induced by ERb 
ultimately affects the net estrogenicity of a test sample. For example, E2 binds to ERa with a 
higher affinity than ERb (Mosselman et al., 1996) and activates gene transcription at EREs 
more effectively than ERb alone. Therefore, since ERb dominantly negatively regulates ERa in 
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a co-expressing cell line, the net ER bioactivity of E2 is effectively reduced. Therefore, there is 
good value in continuing to utilise the T47D-ER bioassay for future assessment of serum 
samples. However, single isoform cell lines could provide different information. By comparing 
the ER bioactivity with a single isoform of ER to the bioactivity in a cell line that co-expresses 
both isoforms clinically important information could be obtained. The prognostic, and 
therefore clinically relevant information of the combined or separated ER bioactivity measure 
could only be determined once follow up studies that can track 5- to 10-years after treatment 
are carried out. 
 
Another avenue of research could involve measuring the anti-estrogenicity and -androgenicity 
of each serum sample. By co-treating the ER- and AR-RGBs with an EC50 concentration of E2 
or testosterone, the level of receptor suppression by the test serum is indicative of the anti-
estrogenicity and -androgenicity, respectively. This could also be an informative measure that 
may also help to predict risk of disease-free survival. 
 
Recruiting all 30 patients and testing 3 times points from each patient (0-, 4- and 12-weeks) 
using the HEK293-AR, T47D-ER, HeLa-ERa and HeLa-ERb would complete the study that was 
established in chapter 5. Future avenues of research for this study once fully complete, could 
involve following up each patient in 5- and 10- years to assess if relapse had occurred and if 
there are correlations with AR, combined ERa/b or separate ERa and -b bioactivity. This type 
of study would help to determine if RGBs have prognostic value in the context of letrozole 
resistance and subsequent disease-free survival of breast cancer patients. Due to the obvious 
limitation of only four patients tested in the aromatase inhibitor study (Chapter 5), no clinical 
relevance of the outcome of the study can be inferred. However, this small study of four 
patients does provide exciting impetus to further explore the relationships between E2, 




AR- and ER-RGBs are novel cell-based tools that have been used to assess the net estrogenicity 
and androgenicity of clinically relevant samples. Although serum interference was a common 
hurdle across both assays, more information was derived from the bioassay measurement 
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compared with the immunoassay test for E2 or testosterone alone. Therefore, RGBs have the 
potential to accompany current clinical quantitative measures of E2 and testosterone. The 
clinical importance of this additional information cannot currently be determined but this 
study provides a platform for future investigation into how ER- and AR bioactivity could be 
useful in the prognosis of patients. RGBs are not yet ready for implementation in clinical 
laboratories for routine screening, however, they have earnt their place in research 
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9.1 Optimised protocol for T47D-ER cell bioassay 
 
Seeding of T47D-ER cells 
 
T47D-ER cells were seeded at the time of passaging into clear 96-well plate(s) in phenol-red 
free F-12 media, supplemented with: 
o Charcoal-stripped FCS        2% (v/v) 
o G418          75 µg/mL 
 
T47D-ER cells seeded at a concentration of 5.0 x 105 cells/mL in 100 µL. Cells were counted 
using the trypan blue staining method (for protocol refer to General Methods, Chapter 2.0, 
Section 2.4.2). 
 
Treatment of T47D-ER cells 
 
Estradiol dose response curve 
 
E2 was dissolved and diluted in ethanol to a final concentration of 0.01% (v/v). For a final 
ethanol concentration of 0.01%, 1 µL of E2 (37 µM) was added to 1 mL phenol-red free DMEM 
F12 supplemented with charcoal-stripped FCS and G418. Next, the E2-spiked media was mixed 
well and 15 µL was transferred to 135 µL media on top of cells, in duplicate, to further dilute 
the ethanol/E2 concentration 10-fold. The final concentration of ethanol was 0.1% (v/v) and 
E2 was 37 nM. Once the E2 was added to the starting duplicate wells of the 96-well plate, the 
E2-containing media was mixed well. Next, 50 µL of media was transferred to the wells below 
containing 100 µL media (1:3 dilution). This serial dilution procedure was repeated over 15-
17 steps.  
 
As a vehicle control, 10 µL or 1 µL of 100% ethanol was spiked into 1 mL DMEM F12 
supplemented with charcoal-stripped FCS (10%) and G418 (75 ug/mL) (1:1000 dilution) and 
10 µL was added to 90 µL media (1:10 dilution) on cells in duplicate for a final ethanol 
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concentration of 0.1% (v/v) and  0.01% (v/v), respectively. Cells were incubated at 37°C, 5% 
CO2 for 48 hours. The luminescence induced by the E2 dose response curve was normalised 
to the luminescence produced by the ethanol vehicle control. 
 
Treatment of cells with serum and plasma 
 
T47D-ER cells were treated with test serum or plasma for a final concentration of 2% (v/v). To 
achieve a 2% (v/v) concentration, the media on top of cells was aspirated and replaced with 
98 µL of DMEM F12 supplemented G418 (75 ug/mL) without FCS and 2 µL of test serum or 
plasma was added to each well. Cells were incubated at 37°C, 5% CO2 for 48 hours. 
 
Bright Glo assay 
 
The 96-well plate containing the seeded T47D-ER cells were removed from the 37°C incubator. 
The media upon the cells was aspirated and 100 µL of Bright Glo reagent (Promega, Cat 
#E2610) was added to each well to lyse the cells and introduce luciferin to initiate a light 
emission in the presence of luciferase. Following 2 minutes of incubation at room 
temperature, the 100 µL of cell lysate was transferred to a 96-well white opaque plate. The 
white opaque 96-well plate was inserted into the plate reader (Molecular Devices, Spectra 
Max i3x) and each well measured for read for end-point luminescence using SoftMax Pro 
(version 7.0.2) software. 
 
 
Figure 9.1: Overview of the optimised steps of the T47D-ER cell bioassay. 
 
 On day 1, 100 µL of cells at a concentration of 5 x 105 cells/mL are seeded into a clear 69-
well plate in phenol red-free media. On day 2, the T47D-ER cells are treated with E2 
(ethanol concentration not exceeding 0.01% (v/v)) or the test sample (serum/plasma) at a 
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concentration of 2%(v/v). On day 4 following 48 hours incubation with the test sample(s), 
the assay is performed. Bright Glo reagent is added to the cells and the plates are read using 





EC50  of estradiol 
 
The luminescence values obtained from the plate reader data were directly transferred to 
GraphPad Prism Version 8.0. The duplicate values were imported into side-by-side columns 
and the data was transformed, normalised and fitted to a non-linear regression sigmoidal 
curve. The EC50 value for E2 was derived from the sigmoidal curve generated for each dose 
response curve.  
 
Analysis of serum ER bioactivity 
 
The raw luminescence values obtained from serum samples were averaged across for 
duplicate. All luminescence values were reported as a ratio to maximal luminescence induced 
by the E2 dose response curve, which is a measure of maximal assay performance. The 
luminescence values were then divided by the luminescence induced by the top three points 
of the E2 dose response curve for each assay performed by following the following equation:  
 
!"#$%	#%	'"($'")	*2 = -.'$/0120/20	%3	104.'/6)"1'"-.'$/0120/20	%3	'"($'")	*2  
 
The ratios for each independent experiment were imported into a column graph in GraphPad 
Prism (Version 8.0) and the experiment was repeated a minimum of three times. Outliers were 
removed by the ROUT method.  
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9.2 Patient information sheet and consent form for 
Letrozole Study 
 
Study title: Screening serum estrogen receptor α and –β bioactivity in 
women on aromatase inhibitor therapy  
Principal investigator: Name Professor Alison Heather 
Department Physiology 
Position Professor 
Contact phone number: 
(03) 479 7399 
 
Introduction 
Thank you for showing an interest in this project.  Please read this information sheet 
carefully. Take time to consider and, if you wish, talk with relatives or friends, before 
deciding whether or not to participate.  
If you decide to participate we thank you.  If you decide not to take part there will be no 
disadvantage to you and we thank you for considering our request.   
 
What is the aim of this research project? 
The main sex hormone in females is estradiol. Higher levels of blood estradiol in 
postmenopausal women is associated with a risk for developing breast cancer.  In the body, 
estradiol enters cells and activates biological pathways by binding to the aptly named 
estrogen receptor or ER. Abnormal signaling by estradiol and ER is known to cause breast 
cancer.  
To treat breast cancer, drugs called aromatase inhibitors are used to decrease estradiol 
levels in blood. The decrease in estradiol levels should lead to lower activity of ER. However, 
ER may be activated by other compounds in blood such as other estrogens or 
phytoestrogens. 
We want to see if ER activity decreases with aromatase inhibitor therapy. If it does not, then 
the results will better inform scientists to understand possible causes of relapsing breast 
cancer.  
 
Who is funding this project? 
This project is co-funded by the Division of Health Sciences and the School of Biomedical 
Sciences, University of Otago. 
 
Who are we seeking to participate in the project? 
We are seeking newly diagnosed postmenopausal women with ER positive breast cancer 
that will be starting aromatase inhibitor therapy as part of their adjuvant therapy.  
The inclusion criteria is postmenopausal status, an ER positive status of the tumour, and the 
clincian’s decision to treat with an aromatase inhibitor. The exclusion criteria are 
premenopausal, estrogen insensitive tumours, or the decision to not treat with an 




If you participate, what will you be asked to do? 
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It is completely your decision to participate in this study. If you do choose to participate, we 
will require one blood sample (20 mL) prior to starting aromatase inhibitor therapy and then 
another blood sample (20 mL) at 4-weeks and then another blood sample at 12-weeks after 
starting aromatase inhibitor therapy. 
 
Is there any risk of discomfort or harm from participation? 
There is very little risk of discomfort or harm from participating. It will involve a routine 
blood sampling procedure.  
 
What specimens, data or information will be collected, and how will they be used?  
Blood samples will be collected at 3 times (before aromatase inhibitor therapy and then 4- 
and 12- weeks after aromatase inhibitor therapy is initiated).  
All blood samples will be processed to obtain plasma and this plasma will be  used to 
measure estradiol concentrations and ER bioactivity. The information collected will be only 
these two measurements. The data collected will be used to generate a scientific manuscript 
and for inclusion in a PhD thesis.  
The plasma samples will be used completely. There will be no long term storage and no 
materials will be retained beyond the completion of the study.  
 
What about anonymity and confidentiality? 
Each blood sample will be identified by a unique code and the patients details provided will 
only be known to the Principal Investigator, Prof. Alison Heather. 
 
If you agree to participate, can you withdraw later? 
You may withdraw from participation in the project at any time and without any 
disadvantage to yourself.  
 
Any questions? 
If you have any questions now or in the future, please feel free to contact either: 
Name Professor Alison Heather 
Position Principal Investigator 
Department Physiology 
Contact phone number: 
(03) 479 7399 
Name Rachel Lund 
Position PhD student 
Department Physiology 
Contact phone number: 
(03) 479 4211 
 
This study has been approved by the University of Otago Human Ethics Committee (Health). 
If you have any concerns about the ethical conduct of the research you may contact the 
Committee through the Human Ethics Committee Administrator (phone +64 3 479 8256 or 
email gary.witte@otago.ac.nz). Any issues you raise will be treated in confidence and 




Screening serum estrogen receptor α and –β bioactivity in women on aromatase inhibitor 
therapy 
 
Principal Investigator: Professor Alison Heather 
email: alison.heather@otago.ac.nz 
Phone: (03) 479 7399 
 
CONSENT FORM FOR PARTICIPANTS 
Following signature and return to the research team this form will be stored in a secure place for ten 
years. 
Name of participant:………………………………………….. 
I have read the Information Sheet concerning this study and understand the aims of this 
research project. 
I have had sufficient time to talk with other people of my choice about participating in the 
study.   
I confirm that I meet the criteria for participation which are explained in the Information 
Sheet. 
All my questions about the project have been answered to my satisfaction, and I understand 
that I am free to request further information at any stage.  
I know that my participation in the project is entirely voluntary, and that I am free to withdraw 
from the project at any time without disadvantage. 
I know that as a participant I will... 
Provide age, menopausal status, estrogen receptor status of tumour 
Donate 3 blood samples as listed in the information sheet 
I understand the nature and size of the risks of discomfort or harm which are explained in the 
Information Sheet. 
I know that when the project is completed all personal identifying information will be removed 
from the paper records and electronic files which represent the data from the project, and 
that these will be placed in secure storage and kept for at least ten years.  
I understand that the results of the project may be published and be available in the University 
of Otago Library, but that either (i) I agree that any personal identifying information will 
remain confidential between myself and the researchers during the study, and will not appear 
in any spoken or written report of the study . 
I know that there is no remuneration offered for this study, and that no commercial use will be 
made of the data.  
I understand that the blood samples will be used to test for estradiol concentrations and 
estrogen receptor activity. The samples will be used in their entirety during the study and 
there will be no long term storage of samples.  
 
Signature of participant:  Date: 
   
   
 
Name of person taking consent:  Date: 
   
 
